

# **Prof. Gregor K. Wenning, MD PhD MSc**

Neurologist

Chair, Division of Clinical Neurobiology

Department of Neurology

Medical University Innsbruck



## **CURRICULUM VITAE**

**Name:** Gregor Karl WENNING

**DOB:** 21. March 1964 in Horstmar GERMANY

**Parents:** Karl-Heinz and Elisabeth Wenning

**Married to:** Prof. Roberta Granata, 2 sons  
(Maximilian 24 and Marco 22)

Important Publications <i>(Citations &gt; 200)</i>	<ul style="list-style-type: none"><li>Wenning et al. Brain 1994;117:835-845 (<b>845</b>)</li><li>Wenning et al. Mov Disord 1997; 12:133-47 (<b>759</b>)</li><li>Stefanova et al. Trends Neurosci 2005; 28:501-6</li><li>Wenning et al. Ann Neurol 2008; 64:239-46 (<b>261</b>)</li><li>Gilman et al. Neurol 2008; 71:670-6 (<b>1896</b>)</li><li>Wenning et al. Lancet Neurol 2013;12:264-74 (<b>302</b>)</li><li>Facciulli &amp; Wenning et al. NEJM 2015; 372:249-63 (<b>289</b>)</li><li>Wenning et al. Ann Neurol 2018; 83: 10-12</li><li>Refolo et al. Acta Neuropathol Commun. 2018; 6:2</li><li>Heras Garvin et al. Mov Disord 2019; 34:255-263</li></ul>
Positions	Full Professor and Chair, Division of Clinical Neurobiology, Department of Neurology, Medical University Innsbruck (MUI) Director, Dysautonomia Center, MUI Principal Investigator, Parkinson and Movement Disorder Centre, Department of Neurology, MUI Member, Senate, MUI Coordinator, European MSA (EMSA) Study Group Chair, Movement Disorder Society MSA (MODIMSA) Study Group President, Bishop Golser Foundation for Research on Atypical Parkinsonism Board Member, European Federation of Autonomic Societies Associate Editor, Clinical Autonomic Research
Awards	<ul style="list-style-type: none"><li>German National Scholarship Foundation, 1983-1990</li><li>UK PD Society Research Fellow, 1992-1994</li><li>Austrian Parkinson Society Award, 1998 (First recipient)</li><li>Oppenheimer MSA Award, 2004 (First recipient)</li><li>JP Schouuppe MSA Award, 2014</li></ul>

	<ul style="list-style-type: none"> <li>• Inaugural Steven Myers Lecture, Baltimore 2016</li> <li>• Plenary MSA Lecture, AAS Newport Beach, CA, USA, 2017</li> <li>• Dr Johannes Tuba Award, Tyrolean Medical Chamber 2017</li> <li>• JP Schouuppe Lifetime Achievement in MSA Award, 2020</li> <li>• Wittgenstein Award Nominee, 2020</li> </ul>
Areas of Research	<ul style="list-style-type: none"> <li>• Multiple system atrophy and related atypical parkinsonian disorders</li> <li>• Autonomic function testing</li> <li>• Advanced MRI in neurodegenerative disorders</li> <li>• Therapeutic interventions in MSA (animal modeling, drug screening, phase 2/3 trials)</li> </ul>

<b>1. School</b>	
1970-1983	Primary School (St. Gertrudis, Horstmar/Westfalia) and Grammar School (Gymnasium Arnoldinum, Burgsteinfurt/Westfalia)
08.06.1983	A-Level (Average mark 1,2)
<b>2. Medical career</b>	
1983-1990	Medical Student at Westfalian Wilhelm University, Münster/GER (preclinical (“Physikum”) and clinical exam („ärztliche Prüfung“) each with total mark 2)
1983-1990	Fellow of the German National Scholarship Foundation
1989-1990	Final year at University Hospital Münster (Internal Medicine and Surgery) and at National Hospital for Nervous Diseases, Queen Square, London (Neurology, Prof. I. McDonald)
01.01.1991	Residency, Department of Neurology, University Hospital, Tübingen GER (Head Prof. Dr. J. Dichgans)
17.12.1991	Doctorate („summa cum laude“) at Westfalian Wilhelm University, Münster/Westfalia GER (Topic: Investigations of long ascending and descending pathways in motor system degenerations (supervisor: Prof.Dr. A. Ludolph)
10.07.1992	Practitioner Status, Physicians’Council, Münster, Westfalia GER
06.03.1995	Resident, Department of Neurology, University Hospital, Innsbruck (Prof. W. Poewe)
01/1996	PhD, University of London (Multiple system atrophy)
1997/98	Residency at the University Department of Psychiatry, Innsbruck (Head: Prof. Dr. H. Hinterhuber)
1998/99	Residency at the University Department of Internal Medicine, Innsbruck (Head: Prof. Dr. J. Patsch)

01/1999	Together with Prof. Werner Poewe founding Coordinator of the European MSA Study Group (EMSA-SG; <a href="http://www.emsa-sg.org">www.emsa-sg.org</a> ) with 24 European partner sites (Objective: Registry, Scale Development, Natural History Study, Genetics, Experimental Studies, Intervention trials such as Growth Hormone (SERONO, Phase II), Minocycline MEMSA (Phase II) and Rasagiline (TEVA, Phase IIb); 5FP EC Support)
01.07.1999	Habilitation at the Medical Faculty of Innsbruck University (Topic: MSA: clinical and experimental findings)
24.08.1999	Associate Professor of Neurology, Medical Faculty, University of Innsbruck
31.08.1999	Board certified Neurologist and Psychiatrist (Austrian Chamber of Physicians)

Since 09/1999	Coordination of a novel Research Program of the Federal Ministry of Science (Progression of striatonigral Degeneration in MSA) (Objective: natural history of MSA-P as determined by rating scales and neuroimaging indices incl. diffusion-weighted imaging, MR volumetry, and SPM based analysis of $\beta$ -CIT/IBZM SPECT; progression markers in MSA animal models)
since 1999	Consultant Neurologist with the following assignments in general neurology: intensive care unit, emergency room, ward rounds, outpatient service. PI at the Parkinson and Movement Disorder Centre (Focus on academically driven MSA drug trials at the clinical trial centre KKS)
2001	EEG Diploma and Member, Austrian Society for Clinical Neurophysiology Austrian Clinical Trial Diploma
10/2002	Rejection of a Full Professorship at the Department of Neurology, Ulm, GER

Since 2002	<p>Founder and Head, Autonomic Function Unit, Department of Neurology, Medical University Innsbruck (MUI) <u>Objectives</u>:</p> <ol style="list-style-type: none"> <li>1. state-of-the-art diagnosis and management of OH, POTS, and syncope,</li> <li>2. academic studies focusing on cardiovascular autonomic failure in degenerative parkinsonism;</li> <li>3. initiation &amp; participation in clinical trials (MSA, PD-OH);</li> </ol> <p><u>Facilities</u>:</p> <ol style="list-style-type: none"> <li>1. tilt table test (TTT) laboratory –Taskforce Monitor®, catecholamine assays and EEG recordings available, 400 TTTs p.a.;</li> <li>2. outpatient service at the Movement Disorder Unit (MSA/PD patients) and at the general neurology clinic (POTS, syncope, secondary dysautonomias);</li> <li>3. inpatient admission for dysautonomia patients;</li> <li>4. interdisciplinary case management with cardiologists, gastroenterologists, pediatricians, and psychiatrists as required</li> <li>5. neurophysiological work-up of dysautonomia (sympathetic skin response, heart rate variability, sudomotor testing, skin &amp; nerve biopsy)</li> </ol> <p><u>Current AFU team</u> (excluding in/outpatient service):</p> <p>1 assistant professor, 2 consultant neurologists, 3 resident neurologists, 1 bioengineer, 3 nurses, 2 MD PhD students and 2 undergraduate MD students)</p>
05/2006	<p>Full Professor and Chair, Division of Clinical Neurobiology at the Department of Neurology, MUI), administrative DCN staff: 1 part-time academic secretary, 1 part-time clinical secretary, 2 DCN Sections:</p> <p>Autonomic Function Unit – as above - and</p> <p>Experimental Neurodegeneration Research Laboratory <u>Objectives</u>:</p> <ol style="list-style-type: none"> <li>1. to elucidate the pathogenesis of MSA</li> <li>2. to identify novel therapeutic targets in MSA models</li> <li>3. to screen candidate neuroprotective agents</li> </ol> <p><u>Facilities</u>:</p> <ol style="list-style-type: none"> <li>1. Neuroscience research laboratory (behavioural phenotyping unit, cell culture, immunohistochemistry, stereology)</li> <li>2. MUI animal core facility (breeding and housing)</li> <li>3. additional facilities as required at MUI campus</li> </ol>
	<p><u>Current team:</u></p> <p>1 associate professor (Nadia Stefanova MD PhD, section head), 2 postdocs, 2 PhD neuroscience students, 1 MSc student in molecular medicine, 1 technician</p>
Since 2007	Founding Co-PI, Neuroscience PhD Excellence Programme “Signal Processing in Neurons” (SPIN, <a href="http://www.neurospin.at">www.neurospin.at</a> ) at MUI, co-funded by Austrian Science Foundation (FWF) and MUI
12/2007	MSC (Master of Health Economics), Private University for Health Science, Medical Information Technology and Engineering (UMIT), Hall i.T., Austria
2008-2014	Chair, Austrian Autonomic Society
Since 2008	Executive Board, Department of Neurology, MUI

Since 2010	Deputy Member of Senate, MUI
Since 2011	Deputy Speaker (2011-2014), Associate PI (since 2015) Project Centre Grant SFB-F44 Calcium signaling in chronic CNS diseases ( <a href="http://www.uibk.ac.at/pharmazie/pharmakologie/sfb-f44/">http://www.uibk.ac.at/pharmazie/pharmakologie/sfb-f44/</a> ), co-funded by Austrian Science Foundation and MUI
2012	<i>Tertio loco</i> , Chief of Division of Neurology, Department of Medicine, University of Ottawa, Canada
Since 2012	Deputy Treasurer, European Federation of Autonomic Societies (EFAS)
Since 2012	Chair, International Movement Disorder Society MSA (MODIMSA) Study Group ( <a href="http://www.movementdisorders.org/MDS/About/Committees-Other-Groups/Study-Groups/Multiple-System-Atrophy.htm">http://www.movementdisorders.org/MDS/About/Committees-Other-Groups/Study-Groups/Multiple-System-Atrophy.htm</a> )
Since 2014	Associate Editor, Clinical Autonomic Research
Since 2015	President, Bishop Golser Foundation (Italy) for Research on Atypical Parkinsonism ( <a href="http://www.bz-bx.net/home_deu/startseite/00032691_BischofDrKarlGolserStiftung.html">http://www.bz-bx.net/home_deu/startseite/00032691_BischofDrKarlGolserStiftung.html</a> )
Since 2016	Member of Habilitation Committee, MUI
Since 2019	Member of Senate, MUI

<b>3. Memberships in scientific associations</b>	
AAN	American Academy of Neurology Section on Autonomic Nervous System Section on Movement Disorders Section on History
AAS	American Autonomic Society
ABN	Association of British Neurologists
ANA	Austrian Neuroscience Association
BSS	Brain Stem Society
DGN	German Neurology Society
DGN AG-ANS	German ANS Society
DPG	German Parkinson Society
EFAS	European Federation of Autonomic Societies
EHDN	European Huntington's Disease Network
EMSA-SG	European MSA Study Group
MDS	Movement Disorder Society Task-Force on Diagnostic Criteria for PD and related disorders Task-Force on Rating Scales in Parkinson's disease
	UPDRS Revision Task-Force MSA (MODIMSA) Study Group
MDS-ES	Movement Disorder Society European Section
NECTAR	Network for European Intracerebral Transplantation and Restoration

ÖAG	Austrian Alzheimer Society
ÖGN	Austrian Neurology Society
ÖGN AG ANS	Austrian Autonomic Society
ÖPG	Austrian Parkinson Society

<b>4. Fellowships and stays abroad</b>	
<b>Fellowships</b>	
1983-1990	German National Scholarship Foundation
1992-1994	UK PD Society Fellow (Topic: clinicopathological studies of MSA, Institute of Neurology, London (Professor Marsden, Professor Quinn) (grant: € 119.550,-)
<b>Stays abroad</b>	
1986-1987	First clinical year at King's College School of Medicine, London, England
1990	Final clinical year at National Hospital for Nervous Diseases, Queen Square, London (Prof. I. McDonald, Prof. C.D. Marsden)
01.01.1992-31.12.1994	Clinical Research Fellow, Honorary Clinical Assistant and PhD Student, Department of Clinical Neurology, Movement Disorders Group, Institute of Neurology, Queen Square, London (Prof. C.D. Marsden, Dr. N. Quinn)
01.01.1993-30.06.1994	Research Fellow at Department of Pharmacology, King's College London (Prof. P. Jenner)
01.11.1993-30.06.1994	Honorary Clinical Assistant (Professor I. McDonald) at Moorfields Eye Hospital, London, England
01.12.1994-31.12.1994	Honorary Registrar (Dr Quinn) at the Department of Clinical Neurology, Institute of Neurology, Queen Square, London, England
06/1996	Research Fellow, Neuroepidemiology Branch, National Institutes of Health, Bethesda, Washington, USA (Dr I Litvan)
04-06/2000	Visiting Professor, Autonomic Function Unit, National Hospital for Neurology and Neurosurgery, Queen Square, London, England (Prof. Dr. C. Mathias)
07/2004	Visiting Professor, Brain Repair Group, School of Biosciences, Cardiff University, Wales (Prof. S. Dunnett)
04/2005	Visiting Professor, Wallenberg Neuroscience Centre, Section of Restorative Neurology, Lund (Prof. A. Björklund)
07/2008	Visiting Professor, Western General Hospital, Toronto (Prof. A. E. Lang)

<b>5. Awards and prizes</b>	
1983–1990	Fellow of the German National Scholarship Foundation
1992–1994	Fellow of the UK Parkinson's Disease Society
1998	Austrian Parkinson Society Award (First recipient)
2004	Oppenheimer MSA Award (First recipient)
2014	JP Schouppé MSA Award
2016	Inaugural Stephen Myers Lecture, Baltimore, USA
2017	Plenary MSA Lecture, AAS Newport Beach, CA, USA
2017	Dr Johannes Tuba Award, Tyrolean Medical Chamber

<b>6. Board Activities</b>	
since 1999	EMSA-SG Board (Coordinator)
2001-2002	International Executive Committee of the Movement Disorder Society – European Section (MDS-ES)
2001-2004	Chair, MDS Membership Committee
2002-2006	Member, Editorial Board Movement Disorders Journal
2003-2010	Treasurer, Austrian Parkinson Society
since 2004	Member, Editorial Board Journal of Neural Transmission
2005-2007	Member, MDS Bylaws Committee
2005-2010	Board Member NECTAR (=Network for European Intracerebral Transplantation and Restoration)
2008-2014	Chair, Austrian Autonomic Society
since 2008	Council Member, EFAS (European Federation of Autonomic Societies)
since 2010	Austrian Representative for Guidelines on Syncope of the German Neurology Society
2012-2019	Scientific Advisory Board, US MSA Coalition
since 2012	Scientific Advisory Board, Joseph G. Fortier Defeat MSA Foundation
since 2012	Chair, Movement Disorder Society MSA (MODIMSA) Study Group
2012-2019	Deputy Treasurer, EFAS
since 2015	Scientific Advisory Board, Global MSA Taskforce
since 2015	Scientific Advisory Board, UK MSA Trust
since 2015	President, Bishop Golser Foundation for Research on Atypical Parkinsonism
since 2017	Austrian Autonomic Society
since 2018	MDS MSA Criteria Revision Taskforce
since 2019	President, Scientific Advisory Board, US MSA Coalition

<b>7. Congress Organization</b>	
10/1995	International Workshop Neurotransplantation, Innsbruck
01/1999	1 <sup>st</sup> EMSA-SG Conference, Innsbruck
12/1999	International Organising Committee der 10. NECTAR Annual Meeting, Amsterdam
06/2000	2 <sup>nd</sup> EMSA-SG Conference, Barcelona
09/2000	International Organising Committee, Alpine Basal Ganglia Club, Lubljana
03/2001	Alpine Basal Ganglia Club, Innsbruck
05/2001	3 <sup>rd</sup> EMSA-SG Conference, London
05/2002	4 <sup>th</sup> EMSA-SG Conference, Innsbruck
09/2002	Austrian Parkinson Society (ÖPG) Symposium Atypical Parkinsonism, Pörtschach
02/2003	International MDS Symposium „Atypical parkinsonism: from protein dysfunction to therapeutic intervention“, Innsbruck
07/2003	5 <sup>th</sup> EMSA-SG Conference, Barcelona
05/2004	ÖPG Annual Conference, Klagenfurt
06/2004	2nd International MSA Congress (IMSAC-2), Rome
12/2004	6 <sup>th</sup> EMSA-SG Conference, Innsbruck
09/2005	Alpine Basal Ganglia Club, Graz
10/2006	International MSA Symposium, Kyoto
01/2007	7 <sup>th</sup> EMSA-SG Conference, Innsbruck
01/2007	IMSAC-3, Innsbruck
11/2007	ÖPG Annual Conference, Innsbruck
12/2007	NECTAR Annual Meeting, Lund
02/2008	ÖPG Annual Conference, Innsbruck
02/2008	8 <sup>th</sup> EMSA-SG Conference, Neapel
06/2009	9 <sup>th</sup> EMSA-SG Conference, Paris
06/2010	10 <sup>th</sup> EMSA-SG Conference, Buenos Aires
09/2010	Focused Workshop on APDs, Geneva
06/2011	11 <sup>th</sup> EMSA-SG Conference, Toronto
09/2011	Focused Workshop on MSA, Budapest
06/2012	12 <sup>th</sup> EMSA-SG Conference, Dublin
06/2013	1 <sup>st</sup> MDS MSA (MODIMSA) Study Group Meeting, Sydney

06/2014	2 <sup>nd</sup> MODIMSA-SG Meeting, Stockholm, 02/2015 MDS Synuclein Symposium, Innsbruck
06/2015	ANS Symposium, 1 <sup>st</sup> EAN (European Neurology Academy) Meeting, Berlin
06/2015	3 <sup>rd</sup> MODIMSA-SG Meeting, San Diego
09/2015	ANS Symposium, ISAN/AAS/EFAS Meeting, Stresa
06/2016	4 <sup>th</sup> MODIMSA-SG Meeting, Berlin
02/2017	17th EFAS Congress, Innsbruck
06/2017	5 <sup>th</sup> MODIMSA-SG Meeting, Vancouver
06/2018	6 <sup>th</sup> MODIMSA-SG Meeting, Hong Kong
06/2019	7 <sup>th</sup> MODIMSA-SG Meeting, Nice

<b>8. Referee</b>
<b>a) Scientific journals</b>
Acta Neuropathologica
Annals of Neurology
Annals of Otology, Rhinology and Laryngology
Archives of General Psychiatry
Brain
Brain Stimulation
Cell Transplantation
Chemical Senses
Clinical Autonomic Research
Clinical Neurophysiology
Drugs and Ageing
European Journal of Neurology
European Neurology
Experimental Biology and Medicine
Gerontology
Journal of Neural Transmission
Journal of Neurology
Journal of Neurology, Neurosurgery and Psychiatry
Journal of Neuroscience and Behavioural Health
Journal of Nuclear Medicine
Lancet
Lancet Neurology

Movement Disorders Journal
Nature Clinical Practice Neurology
Neural Regeneration Research
Neurobiology of Disease
NeuroImage
Neurology
Parkinsonism and Related Disorders
Science Translational
Therapeutic Advances in Neurological Disorders
F1000
<b>b) Advisory and Editorial Activities, Ad-hoc Reviews</b>
Editor Parkinson-News (2003 - 2010)
Associate Editor "Clinical Autonomic Research"
Editorial Board "Cerebellum and Ataxias"
Editorial Board "Frontiers in Movement Disorders"
Editorial Board "Journal of Neural Transmission"
Editorial Board "Movement Disorders Journal" (2002-2006)
Editorial Board "Synapse" (2006-2012)
Editorial Board "The Open Toxinology Journal"
Supplement Guest Editor "Current Opinion in Neurology"
Supplement Guest Editor "Journal of Neurology"
Supplement Guest Editor "Movement Disorder Journal"
Referee, Era Net Neuron
Referee, Cochrane Library
Referee, Medical Research Council, United Kingdom
Referee, PPP Healthcare Medical Trust
Referee, Prinses Beatrix Fonds
Referee, Wellcome Trust
International Advisory Board Alpine Basal Ganglia Club
International Advisory Board CONy
Scientific Advisory Board German PSP Society
Scientific Advisory Board Kompetenz-Netz Parkinson (KNP) (2000-2008)
Scientific Advisory Board Multiple System Atrophy Coalition USA
Scientific Advisory Panel "Multiple System Atrophy Trust UK"
Scientific Advisory Board ÖPG (Austrian Parkinson Society)

## **9. Mentoring of dissertations and diploma theses**

Martin Karl Gollner, 1997 <b>Progression des idiopathischen Parkinson-Syndroms und psychosoziales Outcome</b> (Dissertation)
Elisabeth Luginger, 1997 <b>Die Häufigkeitsverteilung von Parkinson-Syndromen in einer neurologischen Praxis</b> (Dissertation)
Regina Waldner, 1999 <b>A novel neural transplantation model of striatonigral degeneration using 3-nitropropionic acid</b> (MD, dissertation)
Christoph Scherfler, 1999 <b>Characterization of a MSA-P rat model</b> (MD, dissertation)
Leila Badry, 1999 <b>Balance regulation in patients with cervical dystonia using dynamic posturography</b> (MD, dissertation)
Sigrid Lutz, 2000 <b>Nosography of DLB versus PDD</b> (MD, dissertation)
Katja Dierkes, 2001 <b>In vivo imaging of dopamine transporter function in rat striatum using pinhole SPECT and 123I-beta-CIT: coregistered with small animal MRI</b> (MD, dissertation)
Almut Koehler, 2001 <b>L-Dopa monotherapy in patients with Parkinson's disease</b> (MD, dissertation)
Jan Kricek, 2001 <b>MRI-based volumetry in multiple system atrophy (MSA) and Parkinson's disease</b> (MD, dissertation)
Markus Warscher, 2001 <b>MR-based volumetry in differential diagnosis of Parkinson's disease and progressive supranuclear palsy (PSP)</b> (MD, dissertation)
Hannes Joachim Meier, 2002 <b>Routine MRI in the differential diagnosis of MSA and PD</b> (MD, dissertation)
Doris Burtscher, 2002 <b>Development and Validation of a Teaching Tape for the Motor Section of the Unified Multiple System Atrophy Rating Scale (UMSARS)</b> (MD, dissertation)
Anja Diem, 2003 <b>Mortality in patients with Parkinson's disease: A Tyrolean cohort study</b> (MD, dissertation)
Laura Mantoan, 2003 <b>Effects of caspase inhibition in the double lesion SND rat model</b> (MD, dissertation)
Monika Mitschnigg, 2003 <b>Effects of minocycline in a MSA double lesion rat model</b> (MD, dissertation)
Karl Egger, 2003 <b>Brain atrophy in DLB versus AD using voxel-based volumetry</b> (MD, dissertation)
Sonja Scholz, 2004 <b>Evaluation of striatal D2 receptor in rats by iodine 123-IBZM-pinholeSPECT</b> (MD, dissertation)
Katherina Mair, 2004 <b>Diffusion-weighted imaging (DWI) in patients with the Parkinson variant of Multiple System Atrophy: A study using the Trace of Diffusion Tensor</b> (MD, dissertation)
Kathrin Premschütz-Schützenau, 2004 <b>Topography and temporal profile of putaminal degeneration in MSA-P. A prospective MRI study using DWI</b> (MD, dissertation)

Caroline Frick, 2004 <b>UMSARS rates of progression in MSA: a prospective natural history study</b> (MD, dissertation)
M. Köllensperger, 2004 <b>Dysautonomia in MSA: a prospective natural history study</b> (MD, dissertation)
K. Leibenger, 2004 <b>Cardiovascular autonomic function testing in a Tyrolean healthy cohort</b> (MD, dissertation)

Claudia Liener, 2005 <b>Differential diagnosis of parkinsonian syndromes: MIBG SPECT versus DWI MRT</b> (MD, dissertation)
Violeta Staeva, 2007 <b>L-Dopa toxicity in a SND rat model</b> (MD, diploma thesis)
Duerr Susanne, 2007 <b>Spectral analysis of heart rate and blood pressure in PD versus MSA-P</b> (MD, diploma thesis)
Mayerhofer Christoph, 2008 <b>Comparison of Schellong and tilt table testing in the assessment of orthostatic hypotension in patients with parkinsonism</b> (MD, diploma thesis)
Anton Pallua, 2009 <b>Generation of a tightly regulated and inducible mouse model for oligodendroglial <math>\alpha</math>-synucleopathy</b> (Neuroscience, PhD)
Köllensperger Martin, 2009 <b>Neuroregenerative strategies in a double lesion rat model of Multiple System Atrophy</b> (Neuroscience, PhD)
Patrice Grether, 2009 <b>SPM analysis of brain DWI in asymptomatic and symptomatic Huntington's disease</b> (MD, diploma thesis)
Kofler Miriam, 2009 <b>Regenerating L-Dopa response in MSA by neuronal stemcells: experimental evidence</b> (Biology, MSc)
Barbara Pichler, 2009 <b>Immunohistochemical characterization of neural Transplants in the double lesion MSA rat model</b> (Biology, MSc)
Viertler Margot, 2009 <b>Phenotyping of dopaminergic neurotransmission of MSA-P versus MSA-C using <math>\beta</math> [beta]-CIT SPECT and SPM analysis</b> (MD, diploma thesis)
Florian Krismer, 2009 <b>Neuroprotective effects of erythropoietin in a transgenic mouse model of multiple system atrophy</b> (MD, diploma thesis)
Bücke Philipp, 2009 <b>Progress in MSA research: an update</b> (MD, diploma thesis)
Stefan Pittl, 2009 <b>Time course and predictors of tilt-induced syncope</b> (MD, diploma thesis)
Undine Hauser, 2010 <b>Neuroprotection in the tg PLP MSA mouse model</b> (Biology, MSc)
Lucas Mangard, 2010 <b>L-Dopa induced dyskinesias in a PD animal model</b> (Biology, MSc)
Sylvia Stemberger, 2011 <b>Mesenchymal stem cells for neurotransplantation in MSA: experimental rationale</b> (Neuroscience, PhD)
Christine Kleemann, 2011 <b>Characterization of 6-OHDA lesions in the tg PLP MSA mouse model</b> (MD, diploma thesis)
Julia Kuen, 2011 <b>Characterization of progressive motor impairment in the tg PLP mouse model</b> (MD, diploma thesis)

Philipp Fuchs, 2011 <b>Neurogenesis in a tg MSA mouse model</b> (Neuroscience, PhD)
Manuela Metzler, 2011 <b>Neurogenic OH: an update</b> (MD, diploma thesis)
Kathrin Karner, 2011 <b>Delayed OH in MSA</b> (MD, diploma thesis)
Lisa Pohl, 2011 <b>A discordant monozygotic twin pair in MSA: Implications for genetic factors</b> (MD, diploma thesis)
Sonya Neto, 2012 <b>Cell Fate Analysis of Embryonal and Adult Stem Cell-Derived Grafts in the 6-OHDA Model of Parkinson's Disease</b> (Neuroscience, PhD)
Lisa Fellner, 2012 <b>Neuroinflammation in <math>\alpha</math>-Synucleinopathies</b> (Neuroscience, PhD)
Daniela Kuzdas, 2013 <b>Characterization of an inducible transgenic mouse model of MSA</b> (Neuroscience, PhD)
Christine Mantinger, 2014 <b>PNS pathology in a tg MSA mouse model</b> (MD, diploma thesis)
Melanie Kraus, 2014 <b>Pacemaker therapy for cardioinhibitory syncope with asystole: a review</b> (MD, diploma thesis)
Sabine Eschlböck, 2014 <b>Therapies for non-motor features in MSA and PD: a review</b> (MD, diploma thesis)
Patrick Sommer, 2014 <b>Neuroinflammation in the tg PLP MSA mouse model</b> (Biology, MSc)
Clara Wimmer, 2015 <b>Cognitive impairment in MSA</b> (MD, diploma thesis)
Alessandra Fanciulli, 2015 <b>Cardiovascular autonomic failure in MSA and PD</b> (Neuroscience, PhD)
Christian Dallinger, 2015 <b>Stürze und orthostatische Hypotonie bei Morbus Parkinson</b> (MD, diploma thesis)
Turkhan Mehdiyev, 2015 <b>Multiple system atrophy: a Review</b> (MD, diploma thesis)
Sabine Krendl, 2015 <b>Outcome of patients with tilt-table induced cardio- inhibitory syncope with asystole: a retrospective study</b> (MD, diploma thesis)
Dominik Brück, 2015 <b>Alpha synuclein endocytosis via Rab5</b> (Molecular biology, MSc)
Florian Krismer, 2015 <b>Clinical and experimental studies in MSA</b> (Neuroscience, PhD)
Edith Sturm, 2016 <b>Histone modifications as a therapeutic target in multiple system atrophy: experimental evidence</b> (Neuroscience, PhD)
Serena Venezia, 2017 <b>Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal <math>\alpha</math>synucleinopathy</b> (Neuroscience, PhD)
Kallab Martin, 2018 <b>Region-Specific Effects of Immunotherapy With Antibodies Targeting <math>\alpha</math>-synuclein in a Transgenic Model of Synucleinopathy.</b> (MD, diploma thesis)
Violetta Refolo, 2018 <b>Microglial activation in the tg PLP MSA mouse model</b> (Neuroscience, PhD)
Christine Kaindlstorfer, 2018 <b>MPO inhibition and neuroprotection the tg PLP MSA mouse model</b> (Neuroscience, PhD)
Lorenz Härtner, 2019 <b>Characterization of REM sleep behavior disorder and related features in a mouse model for multiple system atrophy</b> (Neuroscience, PhD)

Marcos Herrera Vaquero, 2019 <b>Towards an iPSCs based model for MSA</b> (Neuroscience, PhD)
--

Miguel Lemos, <b>Targeting alpha-synuclein for disease modification in MSA</b> (PhD, ongoing)
---

<b>10. Teaching</b>
---------------------

1	General neurology	Bedside teaching, Department of Neurology, MUI, since 1995.
2	Autonomic neurology and neuroscience	Lecture and seminars, MUI, since 2006
3	Movement disorders	Videobased seminars, lectures, bedside and outpatient teaching, since 1999
4	Neurobiology of neurodegeneration	Seminars and lectures (Founding Co-PI at Neuroscience excellence graduate programme “signal processing in neurons”=SPIN, MUI, since 2006)

<b>11. Invited international Talks</b>
--

1	12.03.1993	Institute of Neurology, <b>London</b> . The natural history of multiple system atrophy.
2	05.04.1993	Hospital General de Santo Antonio, <b>Oporto</b> . The natural history of multiple system atrophy.

3	27.08.1993	Parkinson's Disease Society Brain Bank, <b>London</b> . Clinicopathological correlations in multiple system atrophy.
4	22.11.1993	Parkinson's Disease Society Brain Bank, <b>London</b> . The cerebellar pathology of multiple system atrophy.
5	29.03.1994	11 <sup>th</sup> International Symposium on Parkinson's disease, <b>Rome</b> . Multiple system atrophy
6	28.04.1994	Institute of Neurology, <b>London</b> . Olivopontocerebellar pathology in multiple system atrophy.
7	11.05.1994	UK Parkinson's Disease Society, <b>London</b> . Parkinsonism plus syndromes.
8	18.05.1994	Institute of Neurology, <b>London</b> . Advanced Short course in movement disorders: multiple system atrophy.
9	25.05.1994	Istituto di Neurologia. Universita Cattolica del Sacro Cuore, Policlinico Gemelli, <b>Rome</b> . Survival studies in multiple system atrophy.
10	21.06.1994	Universitätsklinikum Rudolf-Virchow, Freie Universität, <b>Berlin</b> . Clinical and experimental studies on MSA.
11	20.09.1994	Institute of Neurology, <b>London</b> . Short course for Norwegian neurologists: Multiple system atrophy - what is it?

12	20.10.1994	Institute of Neurology, <b>London</b> . Experimental studies of neural transplantation in a rat model of striatonigral degeneration.
13	15.05.1996	Scientific Colloquium, University <b>Tübingen</b> . MSA - an atypical Parkinsonian disorder.
14	28.08.1996	Colloquium Neurologie, <b>Hamburg</b> . Atypical Parkinson-Syndromes.
15	03.09.1996	Asian Oceanina Congress of Neurology, <b>Seoul</b> . The pathology of multiple system atrophy.
16	08.06.1997	Basal Ganglia Club Meeting of the Austrian, Italian and Slovenian Basal Ganglia Clubs, <b>Tarvisio</b> . Current status of fetal mesencephalic transplantation in Parkinson's disease
17	02.07.1998	III International Congress of Pathophysiology, <b>Lahti</b> . Natural history of Parkinson's disease – assessment, methods and therapeutic interventions.
18	05.03.1999	1. Congress of the German Parkinson-Society e.V., <b>Würzburg</b> . Multiple system atrophy.
19	05.05.1999	Colloquium, Medical University <b>Hannover</b> . MSA Update.
20	15.05.1999	Basal Ganglia Club Italy, <b>Rome</b> . Symptomatic therapy in early Parkinson's disease.
21	02.06.1999	Basal Ganglia Club Switzerland, <b>Bern</b> . Molecular Neurobiology of MSA.
22	18.06.1999	Neurological hospital for movement disorders/Parkinson, <b>Berlin</b> . Differentialdiagnose des Parkinsonsyndroms.
23	01.- 03.09.1999	International workshop on PSP/CBD and MSA, <b>Stowe</b> , UK. Clinical aspects of MSA.
24	21.10.1999	Parkinson-Symposium, University hospital, <b>Basel</b> . Multiple system atrophy.
25	23.10.1999	Parkinson-Symposium, University hospital <b>Mannheim</b> . Clinical relevance of entacapone in PD.
26	23.10.1999	Parkinson-Symposium, University hospital <b>Frankfurt</b> . Differentialdiagnosis of Parkinsonism.
27	05.11.1999	Parkinson-Symposium, annual meeting of the greek neurological society, <b>Athens</b> . The clinical experience with entacapone: results from clinical trials.
28	15.06.2000	6 <sup>th</sup> International Congress of Parkinson's Disease and Movement Disorders, <b>Barcelona</b> . Multiple system atrophy.
29	01.07.2000	2. Baden Württembergic Symposium about neurological movement disorders, <b>Rottweil-Rottenmünster</b> . Parkinson Update
30	13.09.2000	Alpine Basal Ganglia Club, <b>Ljubljana</b> . Diagnosis of atypical parkinsonism.
31	28.09.2000	Annual meeting of german neurologic society, <b>Baden Baden</b> . Morbus Parkinson- Neuroprotektion: Utopie oder Wirklichkeit?
32	15.10.2000	Annual meeting EFNS, <b>Copenhagen</b> . Multiple system atrophy.

33	25.10.2000	Colloquium University hospital, <b>Heidelberg</b> . MSA.
34	28.11.2000	Colloquium University hospital, <b>Dresden</b> . MSA.
35	10.01.2001	Colloquium University hospital, <b>Freiburg</b> . MSA.
36	05.02.2001	Colloquium, Charite, Humbold University, <b>Berlin</b> . Update on MSA: diagnostic and therapeutic aspects.
37	19.02.2001	University Hospital Clinic I Provincial, <b>Barcelona</b> . Experimental models of MSA.
38	10.03.2001	2. German Parkinson Congress, <b>Bochum</b> . MSA, PSP and other APDs.
39	26.05.2001	University Brain Bank, <b>Barcelona</b> . Diagnostic accuracy in Lewy body dementia.
40	07.06.2001	XVI Helsinki University Congress of Drug Research, <b>Helsinki</b> . Current and future perspectives of dopamine receptor agonists in the treatment of Parkinson's disease.
41	14.06.2001	2. Parkinson-Symposium, <b>Zihlschacht, CH</b> . Diagnosis and therapy of MSA.
42	16.06.2001	II. Parkinson-Symposium, <b>Ruegen</b> . Differentialdiagnosis of parkinsonism.
43	27.07.- 01.08.2001	XIV International Congress on Parkinson's Disease, <b>Helsinki</b> . Routine cardiovascular autonomic function testing differentiates multiple system atrophy from Parkinson's disease.
44	12.09.2001	10 <sup>th</sup> Congress of the International Psychogeriatric Association, <b>Nizza</b> . The clinical diagnosis of dementia with Lewy bodies.
45	27.09.2001	International Parkinson-Symposium, <b>Milano</b> . The parkinsonisms.
46	07.12.2001	8emes Journees Therapeutique et Neurologie, <b>Paris</b> . Multiple system atrophy.
47	05.- 08.03.2002	3. German Parkinson Congress, <b>Dresden</b> . Differentialdiagnosis of parkinsonian disorders.
48	13.- 16.06.2002	International Colloquium, Parkinson aktuell, <b>Chateau de Taulane</b> , France
49	06.07.2002	Parkinson-Symposium, <b>Erlangen</b> . MSA Update.
50	25.- 29.09.2002	75. Congress of the German Neurology Society, <b>Mannheim</b> . Corticobasal Degeneration.
51	24.10.2002	Satellite Symposium LIMPE' Board, <b>Lecce</b> . Efficacy and safety of entacapone in PD patients with suboptimal levodopa response: a six month randomised placebo-controlled double-blind study in Germany and Austria (CELOMEN).
52	27.10.2002	NNIPPS-Investigator Meeting, <b>Reisensburg</b> . MSA – clinical features.
53	09.- 14.11.2002	7 <sup>th</sup> International Meeting The Movement Disorder Society, <b>Miami</b> . PSP, MSA, CBGD: Clinical update.
54	20.- 22.11.2002	International Psychogeriatric Association (IPA) Expert Conference, <b>Budapest</b> . Motor symptoms of DLB.

55	06.12.2002	Parkinson-Symposium, <b>Copenhagen</b> . The role of imaging in the differentiation between Parkinson's disease and Parkinson plus diseases.
56	05.- 08.03.2003	3 <sup>rd</sup> German Parkinson-Congress, <b>Dresden</b> . Differentialdiagnosis of Parkinsonism
57	25.03.2003	EuMeCom training, <b>Ziegelsee</b> . Diagnosis and Differentialdiagnosis of IPD.
58	10.05.2003	Neurology-Update, University <b>Halle</b> . What,s new in Parkinson,s disease.
59	17.05.2003	3 <sup>rd</sup> German-Scandinavian Meeting on Movement Disorders, <b>Gothenburg-Kiel</b> . Imaging in Movement Disorders/The role of MRT for the differential diagnosis of parkinsonism.
60	23.05.2003	5 <sup>th</sup> Meeting of the European Federation of Autonomic Societies (EFAS), <b>Toulouse</b> . Neuropathology of parkinsonian syndrome perhaps focusing on MSA.
61	24.06.2003	Neuro-Colloquium, <b>Munich</b> . MSA: an atypical Parkinsonian syndrome?
62	06.09.2003	German Neurology Congress, <b>Hamburg</b> . MSA and PSP.
63	13.09.2003	35 <sup>th</sup> Danube Neurological Symposium, <b>Belgrade</b> . Mini-symposium: What is new in movement disorders? MSA – red flags: an update.
64	17.10.2003	14 <sup>th</sup> Conference of the South-East European Society for Neurology and Psychiatry, <b>Thessaloniki</b> . Cognitive function in Parkinson's disease.
65	18.10.2003	University <b>Bochum</b> . Psychiatric complications in PD.
66	05.12.2003	Annual Meeting Danish Movement Disorder Society (DANMODIS), <b>Copenhagen</b> . Multiple system atrophy: clinical features, evaluation and treatment.
67	10.03.2004	Ludwig Maximilians University <b>Munich</b> . Clinicopathological features and pathogenesis of MSA.
68	26.04.2004	University Hospital <b>Ulm</b> . Central autonomic failure and neurodegeneration.
69	29.04.2004	Ludwig Maximilians University <b>Munich</b> . Parkinson-Dementia and Dementia with Lewy-Bodies: two names, one disease?
70	16.06.2004	8 <sup>th</sup> International Meeting of The Movement Disorder Society, Palazzo dei Congressi, <b>Rome</b> . MSA: clinical update.
71	27.06.2004	ENS 2004, <b>Barcelona</b> . ENS course on Parkinson's Disease. The role of imaging in the differential diagnosis of parkinsonian syndromes.
72	12.07.2004	University of <b>Cardiff</b> . Neurotransplantation in MSA.
73	04.- 07.09.2004	8 <sup>th</sup> Congress of the EFNS, <b>Paris</b> . The therapeutic options for atypical parkinsonian syndromes.
74	05.10.2004	University <b>Leipzig</b> . MSA-Animal models.
75	06.- 09.10.2004	Annual Meeting German Neurology Society, <b>Dusseldorf</b> . Differentialdiagnosis of Parkinsonian syndromes.
76	03.11.2004	EuMeCom teaching, <b>Hannover</b> . Parkinson – Aspekt der Diagnostik.

77	06.11.2004	University <b>Erlangen</b> . Deep brain stimulation in PD.
78	27.11.2004	University <b>Ulm</b> . Role of MRI in the differential diagnosis of parkinsonism.
79	08.03.2005	9 <sup>th</sup> International MDS Congress, <b>New Orleans</b> . Etiology and pathogenesis of MSA.

80	15.04.2005	Wallenberg Center, University <b>Lund</b> . Animal models of MSA.
81	19.05.2005	7 <sup>th</sup> EFAS Meeting, <b>Bled</b> . Dysautonomia progression in MSA.
82	06.06.2005	16 <sup>th</sup> ICPD, <b>Berlin</b> . MSA-P.
83	19.06.2005	ENS Meeting, <b>Vienna</b> . Dysautonomia in Parkinson's syndromes: diagnosis and management.
84	03.07.2005	Parkinson Symposium, La Sapienza, <b>Rome</b> . Clinical neurobiology of alpha-synucleinopathies.
85	01.10.2005	Update Neurology 2005, <b>Dusseldorf</b> . Therapeutic strategies in PD.
86	14.10.2005	Alpine Basal Ganglia Club, <b>Graz</b> . Update on atypical parkinsonian syndromes.
87	22.10.2005	Milano Parkinson 2005, <b>Milano</b> . Synucleinopathies: the clinical and biological spectrum.
88	05.11.2005	Specialists Registrar Training Day, <b>Naas</b> . Response fluctuations in PD – clinical signs, mechanisms and treatment.
89	19.11.2005	14 <sup>th</sup> Symposium on the treatment of Parkinson's disease, <b>Tokyo</b> . The Diagnosis of MSA.
90	21.11.2005	<b>Koichi</b> Medical University. MSA – State of the Art.
91	29.11.2005	Parkinson Symposium, <b>Steinfurt</b> . Recognition and therapy of atypical parkinsonian disorders.
92	04.02.2006	Parkinson Expert Meeting, <b>Munich</b> . Diagnosis of Parkinsonism.
93	03.03.2006	15 <sup>th</sup> Parkinson Symposium, <b>Frankfurt</b> . MSA and PSP animal models.
94	25.05.2006	8 <sup>th</sup> EFAS Meeting, <b>Lisbon</b> . The role of MRI in the diagnosis of multiple system atrophy.
95	22.09.2006	79 <sup>th</sup> annual Meeting of the German Society of Neurology, <b>Mannheim</b> . Differential diagnosis and therapy in atypical parkinson syndromes (MSA, PSP).
96	23.09.2006	79 <sup>th</sup> annual Meeting of the German Society of Neurology, <b>Mannheim</b> . Video seminar on movement disorders „MSA and other atypical parkinson syndromes“
97	30.10.2006	10 <sup>th</sup> Internatinal Congress of Parkinson's Disease and Movement Disorders, <b>Kyoto</b> . Staging of MSA.
98	02.12.2006	NECTAR Meeting, <b>Freiburg</b> . News on MSA.
99	03.03.2007	Neurology Symposium, <b>Augsburg</b> . Update on Clinic and Diagnostic of atypical Parkinson Syndromes.
100	09.03.2007	5 <sup>th</sup> German Parkinson Meeting, <b>Ulm</b> . The role of DWI and VBM in atypical Parkinson Syndromes.

101	21.- 25.3.2007	51 <sup>th</sup> Annual Meeting German Society for Clinical Neurophysiology, <b>Munich</b> . Neurophysiological Diagnostics for Differential Diagnosis of Parkinson Syndromes: What is useful?
102	27.06.2007	The PSP International Medical Workshop, <b>Northamptonshire</b> . A Critical Review of Symptomatic Drug Therapies for PSP including Amantadine.
103	06.07.2007	Prof. Niall Quinn Festschrift, <b>London</b> . Modelling MSA.
104	25.08.2007	11 <sup>th</sup> Congress of the European Federation of Neurological Societies, <b>Brussels</b> . Update on PSP and MSA.
105	12.09.2007	80 <sup>th</sup> Meeting of the German Society of Neurology, <b>Berlin</b> . The Natural History of MSA – The EMSA Study.
106	08.12.2007	Nectar Meeting, <b>Lund</b> . Cell therapy for MSA: from Bench to Bedside.
107	08.03.2008	16 <sup>th</sup> Parkinson-Symposium, <b>Marburg</b> . MSA Update.

108	28- 29.03.2008	EMSA-SG Annual Meeting, <b>Naples</b> . 1. EMSA Registry – Final Analysis. 2. UMSARS Tape Validation.
109	24.06.2008	12 <sup>th</sup> International Congress of Parkinson's Disease and Movement Disorders, <b>Chicago</b> . Atypical Parkinsonism.
110	25.08.2008	12 <sup>th</sup> Congress of the European Federation of Neurological Societies, <b>Madrid</b> . Second Consensus Statement on the Diagnosis of MSA.
111	28.06.2008	3 <sup>rd</sup> PD Workshop, <b>Munich</b> . Continuous dopaminergic stimulation in IPD.
112	11.09.2008	10 <sup>th</sup> International Conference on Neural Transplantation and Repair, <b>Freiburg</b> . Towards neurotransplantation in MSA: preclinical evidence.
113	13.09.2008	81 <sup>st</sup> Congress of the German Neurology Society, <b>Hamburg</b> . Translational research in multiple system atrophy: from bench to bedside. Second consensus statement on the diagnosis of multiple system atrophy.
114	17.09.2008	Colloquium Neurologie – Atypical parkinsonism, <b>Jena</b> . MSA Update.
115	17.10.2008	6 <sup>th</sup> International Congress on mental dysfunction & other non-motor feauturs in PD and related disorders, <b>Dresden</b> . Neuropsychiatric changes in MSA.
116	25.10.2008	3 <sup>rd</sup> Parkinson-Symposium, <b>Cologne</b> . Can MSA be diagnosed? Is it treatable?
117	19.02.2009	International Workshop on Multiple System Atrophy, <b>Tokyo</b> . Natural History of MSA-P.
118	27.02.2009	9 <sup>th</sup> Forum on Neurology and Neurogeriatrics, <b>Recklinghausen</b> . Update on therapies for MSA and APDs.
119	07.03.2009	6 <sup>th</sup> German Parkinson Congress, <b>Marburg</b> . Synucleinopathies: DLB, PAF and MSA.
120	13.03.2009	Bologna Parkinson 2009, <b>Bologna</b> . Multiple system atrophy: from bench to bedside.

121	19.- 22.05.2009	50 <sup>th</sup> Annual Meeting of the Japanese Society of Neurology, <b>Sendai</b> . 1. Recent insight into pathophysiology or pathogenesis of MSA. 2. Up-to-date skills and key points in differential diagnosis of MSA. 3. Perspectives of treatment for MSA. 4. Prospect in the research on MSA: for proper diagnosis and treatment.
122	27.- 29.05.2009	1 <sup>st</sup> International Forum of Neurological diseases and Rehabilitation: MSA, <b>Sao Paulo</b> . Clinical diagnosis of MSA.
123	08.- 10.06.2009	13 <sup>th</sup> International Congress of Parkinson's Disease and Movement Disorders, <b>Paris</b> . Advances in the etiopathogenesis of MSA: Oligodendrocytes, genes and environment. What's new in MSA?
124	07.07.2009	The PSP Association International Medical Workshop, <b>London</b> . Amantadine in PSP: From symptomatic to disease modifying treatment.
125	22.07.2009	University hospital, <b>Erlangen</b> . Differentialdiagnosis in early parkinsonism.
126	21.10.2009	Neuro-Colloquium, Neurocenter <b>Freiburg</b> . Update on atypical Parkinsonian syndromes.
127	02.12.2009	Parkinson Workshop, <b>Frankfurt</b> . Trial methodology in MSA – where are we?

128	06.03.2010	17 <sup>th</sup> Parkinson Symposium <b>Marburg</b> . Update MSA (Genetics, Subtypes, Diagnosis, Therapeutic strategies).
129	30.03.2010	Medical University <b>Hannover</b> . Video-based differential diagnosis of movement disorders.
130	14.05.2010	12 <sup>th</sup> Congress of the European Federation of Autonomic Society, <b>Taormina</b> . MSA etiopathogenesis: lessons from genomic studies and transgenic models.
131	23.06.2010	Training clinic <b>Munich</b> . Neues zu atypischen Parkinson-Syndromen.
132	23.- 28.09.2010	14 <sup>th</sup> EFNS Congress, <b>Geneva</b> . What non-motor symptoms may be precursors of Parkinson's Disease?
133	08.10.2010	Journées Internationales de la SNF, <b>Paris</b> . New diagnosis criteria for multiple system atrophy and supranuclear palsy.
134	16.10.2010	5 <sup>th</sup> Workshop Morbus Parkinson, <b>Munich</b> . Diagnosis and therapy of autonomic disorders in IPD.
135	19.11.2010	Parkinson Symposium <b>Biberach</b> . Disease modification in MSA: relevance for Parkinson's disease
136	26.11.2010	20 <sup>th</sup> Annual Meeting of NECTAR, <b>Freiburg</b> . Multiple system atrophy: Current status in experimental and clinical studies.
137	10.12.2010	International Neurological-Pathological Symposium on Neurodegenerative Diseases, <b>Olomouc</b> . Multiple system atrophy.
138	12.03.2011	AD/PD 2011, <b>Barcelona</b> . Genetic and neuropathological role of alphaSynuclein in PD and related disorders.

139	18.03.2011	ScanModis Meeting, <b>Stockholm</b> . MSA: Overview and update.
140	16.05.2011	I Seminari di Neurologia della Sapienza, <b>Rome</b> . How to diagnose Atypical Parkinsonism – a bedside approach.
141	07.06.2011	15 <sup>th</sup> International Congress of Parkinson's Disease and Movement Disorders, <b>Toronto</b> . Current management of MSA, PSP and FTDP and future targets of therapeutic intervention.
142	17.06.2011	EFAS Summer School, <b>Lisbon</b> . ANS and movement disorders: Diagnosis and follow-up.
143	01.07.2011	4 <sup>th</sup> MDS European Summer School for Young Neurologists, <b>Naples</b> . MSA, PCP, CBD.
144	13.09.2011	15 <sup>th</sup> Congress of the European Federation of Neurological Societies, EFNS, <b>Budapest</b> . Update on multiple system atrophy.
145	30.09.2011	Annual meeting of the German Neurology Society, <b>Wiesbaden</b> . Central autonomic failure – Key to pathophysiology and differential diagnosis of common neurological disorders.
146	07.10.2011	Symposium on Movement disorders, <b>Leuven</b> , Update on Multiple System Atrophy
147	14.10.2011	13 <sup>th</sup> Annual Meeting of the European Federation of Autonomic Societies EFAS, <b>Bern</b> . Autonomic Failure in MSA: an update.
148	04.11.2011	1 <sup>st</sup> UK MSA Research Meeting, <b>London</b> . MSA animal models.
149	19.03.2012	4 <sup>th</sup> International Congress on Multiple System Atrophy, <b>Toulouse</b> . Update on the EMSA cohort.
150	03.03.2013	International Conference on “Alpha-Synuclein in Parkinson’s Disease and Related Neurodegenerative Diseases, <b>Dubai</b> . Non-Neuronal AS Pathology.
151	08.03.2013	13 <sup>th</sup> Scandinavian Meeting on Parkinson’s Disease and Related Disorders, <b>Stockholm</b> . What is new in MSA?

152	13.03.2013	8 <sup>th</sup> German Parkinson Congress, <b>Würzburg</b> . Atypical Parkinsonian Syndromes.
153	17.04.2013	Parkinson Symposium, <b>Lund</b> . MSA - a wolf in sheep's clothing?
154	10.06.2013	ENS, <b>Barcelona</b> . Parkinson plus syndromes: advances in diagnostics and management.
155	16.- 20.06.2013	International Parkinson and movement disorder congress, <b>Sydney</b> . MSA: molecular pathogenesis and animal models.
156	31.07.2013	ISAN/EFAS Meeting, <b>Giessen</b> . Recent phase 2 and 3 trials in MSA.
157	23.08.2013	DPV, <b>Steinfurt, GER</b> . MSA: a Wolfe in sheep clothing.
158	20.09.2013	MEFOPA/ NeuraSync Meeting, <b>Rome</b> . Therapeutic approaches in MSA animal models.
159	27.11.2013	AMASA Symposium, <b>Erlangen</b> . Baseline data of the EMSA PIGD study.
160	05.12.2013	Institute of Clinical Pharmacology, <b>Hannover</b> . MSA: a wolf in sheep clothing.

161	09.12.2013	WFN PD Congress, <b>Geneva</b> . MSA Update.
162	27.02.2014	2 <sup>nd</sup> UK MSA research meeting. MSA research and clinical interest, <b>London</b> . Animals models of MSA.
163	14.03.2014	14 <sup>th</sup> Scandinavian Meeting on Parkinson's Disease and Related Disorders, <b>Copenhagen</b> . Atypical Parkinson syndromes, differential diagnosis.
164	19.03.2014	6 <sup>th</sup> International Meeting of the BrainStem Society, <b>Berlin</b> . Brainstem in multiple system atrophy.
165	23.04.2014	Interdisciplinary Study Group Movement Disorders, <b>Hannover</b> . MSA – new aspects.
166	01.06.2014	EFNS – ENS, <b>Istanbul</b> . Multiple System Atrophy - clinical variations and autonomic problems.
167	06.08.2014	Universita' degli Studi "G. D'Annunzio" – <b>Chieti</b> . Atypical Parkinsonism.
168	16.- 18.04.2015	German Parkinson Congress, <b>Berlin</b> . Update MSA.
169	15.06.2015	MDS-Kongress, <b>San Diego</b> . Outcome of clinical trials in MSA.
170	06.12.2015	XXI. World Congress on Parkinson's Disease and Related Disorders IAPR, <b>Milan</b> . MSA.
171	08.12.2015	XXI. World Congress on Parkinson's Disease and Related Disorders IAPR, <b>Milan</b> . MSA vs PD.
172	08.- 09.04.16	Dr. Lars Timmermann, <b>Köln</b> . Atypische Parkinsonsyndrome.
173	21.- 23.04.2016	MSA Congress, <b>Salerno</b> . MDS MSA Study group.
174	19.- 23.06.16	MDS, <b>Berlin</b> . MDS PSP study group meeting.
175	03.- 06.10.16	The inaugural Stephen K. Myers Memorial Symposium for patients and caregivers of Multiple System Atrophy and other Parkinsonian Disorders, <b>Baltimore</b> . Vortrag: Atypical Parkinsonism: Are we ready to tame the beast? Department of Health & Human Service, Dr. Sonja Scholz, <b>Washington</b> . Vortrag: Multiple System Atrophy: an update.
176	02.- 03.11.16	MultySyn Meeting, <b>Lund</b> . Opportunities and bottlenecks for interventions in Multiple System Atrophy with Parkinsonism.
177	24.11.2016	EURAC research, <b>Bozen</b> .
178	25.- 26.11.16	Südtiroler Parkinson Gesellschaft, <b>Bozen</b> . Atypische Parkinsonsyndrome, Vorsitz: Die Rolle der Rehabilitation.
179	26.– 27.01.17	ASAP SynTau Workshop, <b>Köln</b> .
180	23.– 25.02.2017	Basal Ganglia Seminar, <b>Warschau</b> . Atypical parkinsonian disorders: an update.
181	24.– 25.03.2017	Scandinavian meeting on PD and related disorders, <b>Kopenhagen</b> . News on MSA.

182	04.– 06.05.2017	10. dt. Kongress für Parkinson und andere Bewegungsstörungen, <b>Baden-Baden</b> . Multisystematrophie.
183	18.05.2017	RSM Meeting, <b>London</b> .
184	04.– 08.06.2017	MDS Congress, <b>Vancouver</b> . MSA study group meeting.
185	07.– 10.09.2017	20 years of alpha-synuclein in Parkinson's Disease and related synucleinopathies: from the bedside to the bench and back to the patient, <b>Athen</b> . The natural history of MSA.
186	20.– 23.09.2017	DGN, <b>Leipzig</b> . Multisystematrophie.
187	06.– 07.10.2017	Consensus conference "Diagnosis and treatment of nocturnal stridor and dysphagia in multiple system atrophy", <b>Bologna</b> .
188	24.05.2018	Annual Meeting of the Japanese Society of Neurology, <b>Sapporo, Japan</b> . Multiple system atrophy.
189	15.06.2018	EAN Congress, <b>Lissabon, Portugal</b> . 2 Talks. 1) Preclinical target discovery in MSA: pitfalls and how we can avoid them. 2) Hypotension and dysautonomia.
190	08.10.2018	MDS Congress, <b>Hongkong</b> . MSA Criteria Revision Task Force Meeting.
191	26.10.2018	American Autonomic Society, <b>Newport Beach, California, USA</b> . MSA Plenary Lecture.
192	23.- 26.05.2020	6th EAN Congress Paris, Abstract & Review, Lecture, <b>Paris</b> . Virtual Meeting; Lecture at Symposium 06"EAN/EFAS: Highlights in Expanding arena of autonomic disorders
193	17.06.2020	Lundbeck Expert Meeting, <b>Virtual Meeting</b> . EU and US Workshops
194	25.- 27.06.2020	MSA TASK FORCE, <b>Virtual Meeting</b> . International Parkinson and Movement Disorder Society
195	01.09.2020	MoDIMSA Annual Meeting, <b>Virtual Meeting</b> . Accompany the International Parkinson's disease & Movement Disorders Society Meeting
196	12.- 16.09.2020	MDS Congress USA_Philadelphia, <b>Virtual Meeting</b> .
197	28.09.2020	MSA Criteria Revision Task Force Meeting, <b>Virtual Meeting</b> .
198	03.10.2020	MSA Symposium and Award Ceremony, <b>Virtual Meeting</b> . Belgium, Antwerpen, Brüssels_Symposium
199	06.10.2020	Award Bischof Dr. Karl Golser Stiftung, <b>Virtual Meeting</b> . Verleihung des Bischof Dr. Karl Golser Preises 2020
200	30.03.2021	11. Stiftungsratssitzung Bischof Dr. Karl Golser Stiffrung, <b>Virtual Meeting</b> , Abschluss Jahr 2020
201	27.04.2021	International MSA Congress IMSAC, <b>Virtual Meeting</b> , Discuss IMSAC, Pam Bower

202	30.04-01.05.2021	MDS MSA Criteria Consensus Conference, <b><i>Virtual Meeting</i></b> , Iva Stankovic, Werner Poewe, Seppi K, Krismer Fl., Fanciulli A,
203	10.05.2021	MSA Trial (c-abl) Inhibikase, <b><i>Virtual Meeting</i></b> , Roy Freeman, Milton H Werner
204	11.05.2021	Biohaven Pharmatics MSA- Diagnosekriterien, <b><i>Virtual Meeting</i></b> , Irfan Qureshi
205	19.06.-22.06.2021	7th EAN Congress 2021, 7 <sup>th</sup> Congress of the European Academy of Neurology, <b><i>Virtual Meeting</i></b> ,
206	22.06.2021	Task Force on UMARS Revision, MDS, <b><i>virtual Meeting</i></b> , S Videmsky
207	01.07.2021	Biohaven Study, <b><i>Virtual Meeting</i></b> Bill Schwiermann, Cameron Gottlieb
208	20.07.2021	Vaxxinity aSyn asset introduction an consulting request, <b><i>virtual Meeting</i></b> , Jennifer Vaxxinity

12. Invited national Talks		
1	23.03.1995	Univ.-Klinik für Neurologie, <b><i>Innsbruck</i></b> . Ein Neurotransplantationsmodell der Multisystematrophie.
2	20.05.1995	Univ.-Klinik für Neurologie, <b><i>Innsbruck</i></b> . Symposium Morbus Parkinson: Atypische Parkinson-Syndrome.
3	09.06.1995	ÖPG Jahrestagung, <b><i>Graz</i></b> . Differentialdiagnose der atypischen Parkinson-Syndrome.
4	02.03.1996	ÖPG Symposium, <b><i>Seefeld</i></b> . Multisystematrophie.
5	30.01.1997	LKH <b><i>St. Pölten</i></b> . Atypischer Parkinson: Aktuelle klinische und therapeutische Aspekte.
6	25.05.1997	ÖPG Jahrestagung, <b><i>Wiener Neustadt</i></b> . Progression des idiopathischen Parkinsonsyndroms mit sozioökonomischem und psychosozialem Outcome.
7	26.03.1998	ÖPG Jahrestagung, <b><i>Wien</i></b> . Differentialdiagnose des Parkinsonsyndroms
8	01.10.1998	1. Jahrestagung der österreichischen, deutschen und schweizerischen Gesellschaften für Neurorehabilitation, <b><i>Innsbruck</i></b> .

		Krankheitsprogression und –behinderung beim idiopathischen Parkinsonsyndrom.
9	26.03.1999	ÖPG Jahrestagung, <b><i>Graz</i></b> . Epidemiologie des Parkinsonsyndroms.
10	18.11.1999	33. Jahrestagung der ÖGTM, <b><i>Innsbruck</i></b> . Neurotoxine in der dritten Welt am Beispiel „Sugar cane poisoning“ und Mangan-induziertes Parkinsonsyndrom.
11	18.11.1999	33. Jahrestagung der ÖGMT, <b><i>Innsbruck</i></b> . Epidemiologie der Parkinsonsyndrome in den Tropen.

12	10.11.2000	4. Internationale EPDA Konferenz, <b>Wien</b> . Management of sexual dysfunction in Parkinson's Disease.
13	13.01.2001	Symposium City Club, <b>Wien</b> . Amantadin in der Behandlung L-Dopainduzierter Dyskinesien.
14	16.05.2001	Universität <b>Graz</b> . Multisystematrophie.
15	06.07.2001	ÖGN Seminar, <b>Innsbruck</b> . Parkinsonsyndrome, Gangstörungen und Stürze.
16	07.07.2001	1. Neuroimaging-Workshop, <b>Bad Tatzmannsdorf</b> . Differentialdiagnostik der Parkinson-Syndrome – Klinische Probleme.
17	03.09.2001	7. ANA Jahrestagung, <b>Schloss Seggau</b> . Multisystematrophie.
18	08.11.2001	Universität Graz, MSA Update."
19	01.12.2001	ÖÄK Diplom, <b>Innsbruck</b> . Extrapyramidal-motorische Erkrankungen im Alter.
20	12.03.2002	Christian Doppler Klinik <b>Salzburg</b> . Morbus Huntington.
21	10.- 11.09.2002	3. Treffen ArGe APS ÖPG, <b>Pörtschach</b> . Management atypischer Parkinson-Syndrome.
22	27.- 28.10.2002	EFNS <b>Wien</b> . Recent advances in Movement disorders. Update on multiple system atrophy.
23	29.- 30.11.2002	4. Neurologie Update, <b>Wien</b> . Praktische Diagnostik der Parkinsonsyndrome.
24	19.- 22.03.2003	1. ÖGN Jahrestagung, <b>Innsbruck</b> . Videoseminar Bewegungsstörungen. Pathogenese der Parkinson-Krankheit: Ansätze für neue Therapiestrategien.
25	05.06.2003	ÖPG Jahrestagung, <b>Linz</b> . Neurotransplantation bei Mb. Parkinson. UMSARS.
26	05.07.2003	IWOP Interaktiver Workshop, <b>Seefeld</b> . Diagnostik beim Mb. Parkinson und Abgrenzung von verwandten Syndromen.
27	04.10.2003	ÖGNR Jahrestagung, <b>Hochzirl</b> , MSA Update
28	15.11.2003	ÖGKN Jahrestagung, <b>Wien</b> . Dysautonomie bei MSA und anderen atypischen Parkinson-Syndromen.
29	20.11.2003	Institut für Neurowissenschaften, <b>Innsbruck</b> . Neurodegenerative diseases.
30	18.12.2003	Institut für Pharmakologie, <b>Innsbruck</b> . Basics of MSA.
31	22.04.2004	ÖGN Seminar, <b>Innsbruck</b> . Parkinsonsyndrome, Gangstörungen und Stürze.
32	06.05.- 08.05.2004	ÖPG Jahrestagung, <b>Pörtschach</b> . Basalganglienclub.
33	22.- 23.10.2004	Parkinson Symposium, <b>Salzburg</b> . 1. Kognitive Dysfunktion bei M. Parkinson. 2. Amantadin bei der MSA.
34	13.01.2005	Konsensus-Meeting „Parkinson-Demenz“, <b>Wien</b> . Parkinson-Demenz versus Demenz mit Lewy Körperchen.

35	22.04.2005	ÖGN Jahrestagung, <b>Graz</b> . Videoseminar Bewegungsstörungen.
36	09.09.2005	Wagner Jauregg KH <b>Linz</b> . Neuroanatomie und Pathophysiologie von Bewegungsstörungen.
37	13.01.2006	Parkinson Konsensus Meeting, <b>Wien</b> . Management der Wearing Off Symptomatik.
38	17.03.2006	ÖGN Jahrestagung, <b>Wien</b> . Videoseminar für Bewegungsstörungen.
39	16.06.2006	2 <sup>nd</sup> International Symposium on Parkinson's Disease and Movement Disorders, <b>Innsbruck</b> . Interaktive Fallpräsentation.
40	12.01.2007	3 <sup>rd</sup> International Congress on Multiple System Atrophy, Innsbruck. Natural history and phenotypic variation of MSA.
41	03.02.2007	Symposium on Neuroimaging in PD, <b>Igls</b> . Assessing progression with MRI - the MSA experience.
42	17.03.2007	8 <sup>th</sup> International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2007), <b>Salzburg</b> . PD, LBD and MSA: Animal Models and their Use in Therapeutic Strategies.
43	22.05.2007	BrainDays, <b>Rust</b> . Update: Lewy-Body-Demenz.
44	23.10.2007	Christian Doppler LKH, <b>Salzburg</b> . Therapie-Update Mb. Parkinson: Rolle der kontinuierlichen dopaminergen Stimulation.
45	26.11.2007	Universitätsklinik für Neurologie, <b>Innsbruck</b> . Diagnosing atypical parkinsonism - MSA,PSP,CBD.
46	06.02.2008	ÖGN Annual Meeting, <b>Innsbruck</b> . Ist Rasagilin neuroprotektiv? Präklinische Daten.
47	26.02.2008	ÖGN Seminar, <b>Innsbruck</b> . Compliance in der Parkinsonbehandlung.
48	29.02.2008	DAT Imaging Workshop, <b>Innsbruck</b> . Diagnostic pitfalls in PD (clinical case presentation).
49	15.04.2008	LKH <b>Linz</b> . Compliance in der Parkinsontherapie.
50	17.04.2008	Advanced Education "Kunst als Brücke zur Welt", <b>Wien</b> . MSA – eine behandelbare Erkrankung?
51	08.05.2008	BrainDays, <b>Rust</b> . Orthostatische Dysregulation - eine behandelbare Sturzursache. Parkinson Plus Syndrome.
52	14.05.2008	Teaching Course, <b>Innsbruck</b> . Diagnostik und Therapie des Mb. Parkinson – Interaktives Fallseminar.
53	16.05.2008	8. Grazer Parkinsonday, <b>Graz</b> . Therapie des L – Dopa Langzeit – Syndroms: Krankheitsmodifikation.
54	29.05.2008	ÖGN Seminar, <b>Linz</b> . Autonome Erkrankungen in der Neurologie: Neurodegenerative Erkrankungen und Erkrankungen des peripheren Nervensystems.
55	04.09.2008	ÖGN Seminar, <b>Innsbruck</b> . Diagnose und Behandlung der Alzheimer Demenz.
56	19.09.2008	ÖAG Jahrestagung, <b>Wien</b> . Leitsymptom-orientierte Demenzdiagnostik: Leitsymptom Hypo-, Hyperkinesie.
57	23.09.2008	ÖGN Seminar, <b>Innsbruck</b> . Parkinson Demenz – Was gibt es Neues?

58	15.10.2008	Universitätsklinik für Neurologie, <b>Innsbruck</b> "Synkopen und orthostatische Dysregulationen: Eine interdisziplinäre Herausforderung", Innsbruck. Neurogene Synkopen.
59	12.11.2008	ÖGN Seminar, <b>Innsbruck</b> . Parkinsonsyndrome, Gangstörungen und Stürze.
60	14.11.2008	ÖPG Jahrestagung, <b>Linz</b> . Dopaminagonisten und kontinuierliche Plasmaspiegel: Wie wichtig ist die Dosierungsfrequenz?

61	14.01.2009	LKH, <b>Kufstein</b> . Neue Therapiemöglichkeiten der Parkinsonerkrankung.
62	24.- 25.03.2009	ÖGN Jahrestagung, <b>Villach</b> . AG ANS Meeting.
63	14.01.2009	BKH <b>Kufstein</b> . Neue Therapiemöglichkeiten der Parkinsonerkrankung.
64	16.06.2009	LKH <b>Wiener Neustadt</b> . Früherkennung und Frühtherapie bei Mb. Parkinson.
65	20.06.2009	BKH <b>Saalfelden</b> . Grundlagen der Neuroprotektion.
66	25.08.2009	Wagner Jauregg LKH, <b>Linz</b> . Kontinuierliche dopaminerige Stimulation in der Parkinson-Behandlung – Aktuelles aus der Stride-PD-Studie.
67	15.01.2010	<b>Innsbrucker</b> Neurologie Fortbildung. Atypische Parkinson-Syndrome – klinische Hinweiszeichen und sinnvoller Einsatz von Zusatzdiagnostik bei Verdacht auf MSA, PSP oder CBD. Management der nichtmotorischen Symptome des Morbus Parkinson.
68	25.02.2010	ÖGN Jahrestagung, <b>Linz</b> . Diagnostik und Therapie autonomer Störungen bei neurodegenerativen Erkrankungen.
69	03.03.2010	Demenz-Update, <b>Innsbruck</b> . Aktuelles zur Diagnose der Alzheimer Demenz.
70	11.03.2010	27. ÖDG Jahrestagung, <b>Wien</b> . Appetitregulationsstörungen in der Neurologie.
71	23.03.2010	ÖGN Seminar, <b>Innsbruck</b> . Demenztherapie 2010 – Stellenwert von Memantine
72	12.06.2010	4. Waldviertler Neurologie Frühling, <b>Horn</b> . Neuroprotektion bei Morbus Parkinson: Realität?
73	26.06.2010	<b>Klagenfurt</b> , Fortbildung, Universitätsklinik für Neurologie, M. Parkinson: Theorie und Praxis.
74	14.10.2010	BKH <b>Lienz</b> . Krankheitsmodifikation: eine innovative neurologische Therapie-Strategie.
75	15.09.2010	Fortbildung, <b>Wolfurt</b> . Neue Arzneimittel in der Parkinson-Therapie: Wirkungen und Studienergebnisse.
76	21.10.2010	ÖPG Jahrestagung, <b>Wien</b> . Therapieansätze bei atypischen ParkinsonErkrankungen.
77	27.01.2011	PKH <b>Hall</b> . Lewy Body Demenz – Diagnose und Therapie.
78	11.05.2011	Wagner-Jauregg LKH, <b>Linz</b> . Demenztherapie 2011 – Stellenwert von Memantin.

79	04.07.2011	AKH, <b>Linz</b> . DLB Update.
80	17.09.2011	ÖAG Jahrestagung, <b>Rosenburg</b> . Neue Daten zur experimentellen Parkinson Demenz.
81	19.10.2011	Fortbildung, <b>Wolfurt</b> . Parkinson-Therapie: Update.
82	24.02.2012	MDS-ES Winter School, <b>Innsbruck</b> . Clinical presentation of atypical parkinsonism.
83	10.03.2012	6 <sup>th</sup> World Congress on Controversies in Neurology, <b>Wien</b> . Are MSA and PD distinct clinical entities?
84	04.11.2013	Syncope Symposium, <b>Hall in Tirol</b> . Synkopen: Eine wichtige Sturzursache bei Mb. Parkinson
85	07.11.2013	ÖPG Jahrestagung, <b>Bad Ischl</b> . Die Bedeutung der MAO-B-Hemmer für die Behandlung von motorischen und nicht-motorischen Fluktuationen.
86	08.11.2013	ÖPG Jahrestagung, <b>Bad Ischl</b> . Translationale Therapieansätze bei Multisystematrophie und progressiver supranukleärer Parese.
87	23.11.2013	ÖDG Jahrestagung, <b>Salzburg</b> . Parkinson.
88	16.01.2014	Vortragsreihe Gender Medizin, <b>Innsbruck</b> . Gender Aspekte bei Alzheimer und Parkinson.
89	30.01.2014	SINBAR Meeting, <b>Innsbruck</b> . Sleep in MSA.
90	21.03.2014	SFB-F44, <b>Innsbruck</b> . Functional read-outs and novel interventional targets in a transgenic MSA model.
91	26.06.2014	Neurological Kolloquium, <b>Innsbruck</b> . Orthostatische Syndrome: Diagnostik und praktisches Management.
92	16.- 18.10.2014	ÖPG Jahrestagung, <b>Baden</b> . Management autonomer Funktionsstörungen.
93	23.- 25.10.2014	ÖGN Seminar, <b>Innsbruck</b> . Parkinsonsyndrome, Gangstörungen und Stürze.
94	11.- 13.02.2015	Convenor “Alpha-Synuclein: The Gateway to Parkinsonism” Meeting, <b>Innsbruck</b> . Pre-motor aspects of PD: Autonomic failure.
95	15.- 17.10.2015	ÖPG Jahrestagung, <b>Wien</b> . Aktuelles zur Pathogenese der MSA.
96	16.03.2016	ÖGN Jahrestagung, <b>Innsbruck</b> . Aktuelle Entwicklungen bei atypischen Parkinsonsyndromen.
97	21.- 25.03.16	IPOKRATES, <b>Innsbruck</b> .
98	20.- 22.10.16	ÖPG Jahrestagung, <b>Graz</b> . Vortrag: Update MSA.
99	17.11.2016	3. Innsbrucker Synkopenworkshop, <b>Innsbruck</b> .
100	29.- 30.11.2016	SFB f44 Annual meeting, <b>Innsbruck</b> .
101	06.12.2016	Extra jour fixe seminar, Christoph Schwarzer, <b>Innsbruck</b> . Vortrag: MSA: How to tame the beast.

102	22.04.2017	AKVÖ Kongress, <b>Salzburg</b> . Grenzen der Schweigepflicht bei eingeschränkter Fahrtauglichkeit.
103	12. – 14.10.2017	ÖPG, <b>Innsbruck</b> .
104	22.03.2018	Österreichische Gesellschaft für Neurologie, <b>Linz</b> . Therapie der NOH.
105	07.07.2018	EFAS Congress, <b>Wien</b> . PAF-MSA-Parkinson: similarities and differences.
106	07.11.2018	ÖPG Jahrestagung, <b>Linz</b> . MSA – Pathophysiologie, typische und atypische Präsentationen.
107	16.- 19.02.2020	Norcliffe-Lucy Kaufmann, <b>Innsbruck</b> . Familial Dysautonomia and other disorders with afferent baroreflex failure
108	22.02.2020	OLG Synkopen Workshop, <b>Innsbruck</b> . Otto Loewi Gesellschaft zur Forschung der Erkrankungen des autonomen Nervensystems
109	20.09.2020	ÖGN Jahrestagung, <b>Virtual Meeting</b> . MSA-Biomarker & neue Therapiesätze
110	23.10.2020	ÖGN Jahrestagung, <b>Virtual Meeting</b> . Fortbildung Neurologie
111	19.02.2021	Biographie Prof. Gerstenbrand, <b>WIEN</b> . Meeting mit Dr. Ruth Koblizek
112	22.02.2021	Habilitätskommission MUI, <b>Virtual Meeting Innsbruck</b> . 11. Sitzung MUI
113	06.05.2021	MUI Habilitationskolloquium, <b>Meeting Innsbruck</b>
114	30.06.2021	MUI Senatssitzung, im großen Hörsaal MZA, <b>Meeting Innsbruck</b>
115	02.07.2021	ÖGN Klasurtagung, <b>Meeting Hotel Loisum, Langenlois</b> ,
116	07.07.2021	ÖPG Vorstandssitzung, <b>virtual Meeting</b> , Wien

13. Grants		
1992-1994	UK PD Society Research Fellowship, Institute of Neurology, Queens Square, London	<b>119,550 €</b>
1994-1997	Neurotransplantation model of MSA, FWF Project P11748 MED	<b>142,440 €</b>

1995-1996	Clinical investigations of nicotine in Parkinson's disease, VERUM-Stiftung, BRD	<b>45,780 €</b>
1997	Wirksamkeit und Verträglichkeit eines Nikotin-Pflasters bei M. Parkinson: eine doppelblinde Cross-Over Studie (VERUM Stiftung)	<b>50,000 €</b>

1997-1998	Parkinson animal models, Research Grant of the Austrian Parkinson Society	<b>5,090 €</b>
1999	Anti-dyskinetic effects of amantadine in PD: a double-blind cross-over study (Kolassa-Merz)	<b>2,000 €</b>
1999	Safety and efficacy of riluzole in Huntington's disease (AVENTIS Deutschland)	<b>4,000 €</b>
1999-2000	Experimental neuroregeneration and protection in an animal model of MSA, ONB Projekt 8298	<b>43,240 €</b>
1999-2003	Progression of striatonigral Degeneration in MSA, Federal research programme, BMWV 70038/2-Pr4/98	<b>170,420 €</b>
2000-2005	European MSA Study Group, EU Projekt QLRT-2000-00661	<b>543,363 €</b>
2002-2004	Neuroprotection in MSA rat models, FWF Project P14633-PHA	<b>150,070 €</b>
2003	Amantadine trial in MSA (Kolassa-Merz)	<b>5,000 €</b>
2003	Neuroprotective effects of Riluzole in MSA-P rat models (AVENTIS Deutschland)	<b>5,000 €</b>
2003	International Conference on Atypical Parkinsonian Disorders (MOVEMENT DISORDERS SOCIETY, AMERSHAM)	<b>60,000 €</b>
2003-2006	The role of alpha-synuclein in glial cells, FWF Project P16128B01	<b>189,992 €</b>
2005-2006	L-Dopa response in MSA-P rat models, MFF Project	<b>9,780 €</b>
2006	Neuroprotection in MSA models: effects of rasagiline (TEVA)	<b>60,000 €</b>
2005-2008	MSA Neurotransplantation, FWF Project P17905-B05	<b>216,772 €</b>
2007	Autonomic failure in a MSA mouse model, TWF Project	<b>4,000 €</b>
2007	MSA consensus criteria, NIH Project	<b>35,000 €</b>
2007-2011	Brain Repair in MSA, FWF Project DK-C34-B05	<b>135,000 €</b>
2007-2010	MSA and Neuroinflammation, FWF Project P19989-B05	<b>241,752 €</b>
2008	The role of dopaminergic stimulation on striatal graft survival and function in the MSA rat model, MFI Project 9441	<b>65,000 €</b>
2008-2010	Cell Fate Analysis of Embryonal and Adult Stem Cell-Derived Grafts in PD and MSA Models, IFTZ Project	<b>285,960 €</b>
2008	EMSA-SG Conference Napoli 02/2008 (Multiple sponsors)	<b>35,000 €</b>
2009	Neuroprotection in MSA models: effects of MPO inhibitors (AstraZeneca)	<b>75,000 €</b>
2010	Neuroprotection in a mouse model of MSA: AZD (AstraZeneca)	<b>142,500 €</b>

2011-2012	Effects of neurotransplantation in MSA rat models, TWF Project, GZ 29487	<b>16,600 €</b>
2010-2011	Natural history of MSA, ÖNB 13946	<b>28,000 €</b>
2011-2014	Functional read-outs and novel interventional targets in a transgenic MSA model, FWF SFB F44	<b>364,790 €</b>
Since 2012	Alpha-Synuclein und Oligodendroglia in der MSA Pathogenese, FWF P25161	<b>302,773 €</b>
Since 2013	Cardiac Magnetic Resonance Spectroscopic Correlates of Cardiac Sympathetic Denervation in Parkinson's disease: A Comparison with MSA-P and Healthy Controls, KLI380	<b>109,620 €</b>
Since 2013	MultiSyn: Multimodal Imaging of rare Synucleinopathies, HEALTH-F5-2013-602646	<b>537,410 €</b>
Since 2013	Progression of microglial activation in a mouse model of MSA. FWF W1206-08	<b>150.000 €</b>
Since 2014	Autonomic dysfunction in MSA, Parkinson's and Movement Disorder Foundation, USA	<b>10,000 €</b>
Since 2014	Cardiovascular phenotyping of a transgenic mouse model of multiple system atrophy, MUI-Start 2014-05-005	<b>15,071 €</b>
Since 2014	The role of autophagy inhibition in oligodendroglial cytoplasmic inclusion formation in multiple system atrophy, TWF UNI-0404/1660	<b>23,455 €</b>
02/2015	Alpha synuclein conference. Funded by Movement Disorder Society.	<b>47,000 €</b>
Since 2014	GLOMSAR	
Since 2015	GLOMSAR	
Since 2015	Targeting alpha synuclein for treating MSA (ARTEMIS), E-Rare2 JTC	<b>308,500 €</b>
Since 2015	Alpha-synuclein: a pathogenic trigger and interventional target in MSA, SFB Grant F4414	<b>479,955 €</b>
Since 2015	Targeting $\alpha$ -synuclein pathology with the molecular tweezer CLR01 in MSA, MSA Coalition	<b>46,500 €</b>
Since 2015	Defining diagnostic brain MRI markers in early MSA with a novel toolbox: the MINY* study, MSA Coalition	<b>46,500 €</b>
2016-2017	ASAP Tau, JPND Research	<b>49,900 €</b>
2017-2018	Global MSA Registry & Natural History Study, MSA Coalition	<b>44,117 €</b>
2017-2018	Inside the gait – a new era on the horizon for atypical parkinsonian disorders, MSA Coalition	<b>44,117 €</b>
2017-2018	Targeting alpha-synuclein pathology with the molecular tweezer CLR01 in MSA: optimization of drug delivery and biochemical analysis, MSA Coalition	<b>44,117 €</b>
2019	Fit for Science, Land Tyrol	<b>47,000 €</b>

2019	The lions tail family – clinical characterization and genetic analysis of a Bavarian multiplex pedigree with autosomal dominant Parkinsonism, Austrian Parkinson Fund	<b>49,444 €</b>
2019-2021	MSA Revision Taskforce, MDS	<b>29,450 €</b>
2020	Differences in sudomotor dysfunction in neuromyelitis optica spectrum disorder and multiple sclerosis, ÖAD	<b>7,883 €</b>
2020	Abdominal binders for orthostatic hypotension in MSA: a RCT, MSA Coalition	<b>42,072 €</b>
2020	Pyhsiotherapy RCT in MSA-P, FWF Dach Projekt, I 4795	<b>1.156.000 €</b>
	<b>TOTAL</b>	<b>Ausrechnen 6.841.983 €</b>

#### 14. Publications

##### Original work

1	Wenning G. Die Illuminationslehre Augustins. <i>Augustiniana</i> . 1989; 39(1-2):99-118.
2	Ludolph AC, Wenning GK, Masur H, Furatsch N, Elger CE. Die elektromagnetische Stimulation des Nervensystems. I. Normwerte im zentralen Nervensystem und Vergleich mit der elektrischen Stimulation. <i>EEG EMG Z Elektroenzephalogr Elektromyoogr Verwandte Geb</i> . 1989 Sep; 20(3):153-8.
3	Wenning G. Der Einfluß des Manichäismus und des Ambrosius auf die Hermeneutik Augustins. <i>Revue des Etudes Augustiniennes</i> . 1990; 36:80-90.
4	Wenning GK, Shephard B, Magalhaes M, Hawkes CH, Quinn NP. Olfactory function in multiple system atrophy. <i>Neurodegeneration</i> . 1993; 2:169-71.
5	Wenning GK, Quinn N, Magalhaes M, Mathias C, Daniel SE. "Minimal change" multiple system atrophy. <i>Mov Disord</i> . 1994 Mar; 9(2):161-6.
6	Wenning GK, Wietholter H, Schnauder G, Muller PH, Kanduth S, Renn W. Recovery of the hypothalamic-pituitary-adrenal axis from suppression by short-term, high-dose intravenous prednisolone therapy in patients with MS. <i>Acta Neurol Scand</i> . 1994 Apr; 89(4):270-3.

7	Wenning GK, Jager R, Kendall B, Kingsley D, Daniel SE, Quinn NP. Is cranial computerized tomography useful in the diagnosis of multiple system atrophy? <i>Mov Disord</i> . 1994 May; 9(3):333-6.
8	Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. <i>Brain</i> . 1994 Aug; 117 ( Pt 4):835-45.
9	Klein C, Wenning GK, Quinn NP. Pseudotransitorische ischämische Attacke als Erstsymptom bei Multisystematrophie. <i>Nervenarzt</i> . 1995 Feb; 66(2):133-5.
10	Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. <i>J Neurol Neurosurg Psychiatry</i> . 1995 Feb; 58(2):160-6.

11	Davie CA, Wenning GK, Barker GJ, Tofts PS, Kendall BE, Quinn NP, McDonald WI, Marsden CD, Miller DH. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. <i>Ann Neurol.</i> 1995 Feb; 37(2):204-10.
12	Magalhaes M, Wenning GK, Daniel SE, Quinn NP. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease-a retrospective comparison. <i>Acta Neurol Scand.</i> 1995 Feb; 91(2):98-102.
13	Wenning GK, Shephard B, Hawkes C, Petrukevitch A, Lees A, Quinn NP. Olfactory function in atypical parkinsonian syndromes. <i>Acta Neurol Scand.</i> 1995 Apr; 91(4):247-50.
14	Plante-Bordeneuve V, Bandmann O, Wenning GK, Quinn NP, Daniel SE, Harding AE. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy. <i>Mov Disord.</i> 1995 May; 10(3):277-8.
15	Pramstaller PP, Wenning GK, Smith SJ, Beck RO, Quinn NP, Fowler CJ. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. <i>J Neurol Neurosurg Psychiatry.</i> 1995 May; 58(5):618-21.
16	Wenning GK, O'Connell MT, Patsalos PN, Quinn NP. A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease. <i>Mov Disord.</i> 1995 Sep; 10(5):664-7.
17	Garratt H, Wenning G, Quinn N. Dysarthria in multiple system atrophy. <i>Int J Lang Commun Disord.</i> 1995 Oct; 30(S1):415-7.
18	Granata R, Wenning GK, Jolkkonen J, Jenner P, Marsden CD. Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion. <i>J Neural Transm.</i> 1996; 103(3):249-60.
19	Tison F, Wenning GK, Volonte MA, Poewe WR, Henry P, Quinn NP. Pain in multiple system atrophy. <i>J Neurol.</i> 1996 Feb; 243(2):153-6.
20	Wenning GK, Tison F, Elliott L, Quinn NP, Daniel SE. Olivopontocerebellar pathology in multiple system atrophy. <i>Mov Disord.</i> 1996 Mar; 11(2):157-62.
21	Klein C, Wenning GK, Quinn NP, Marsden CD. Ataxia without telangiectasia masquerading as benign hereditary chorea. <i>Mov Disord.</i> 1996 Mar; 11(2):217-20.
22	Litvan I, Agid Y, Jankovic J, Goetz CG, Brandel JP, Lai EC, Wenning G, D'Olhaberriague L, Verny M, Chaudhuri KR, McKee A, Jellinger K, Bartko JJ, Mangone CA, Pearce RK. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (SteeleRichardson-Olszewski syndrome). <i>Neurology.</i> 1996 Apr; 46(4):922-30.
23	Wenning GK, Granata R, Laboyrie PM, Quinn NP, Jenner P, Marsden CD. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. <i>Mov Disord.</i> 1996 Sep; 11(5):522-32.
24	Wenning GK, Kraft E, Beck R, Fowler CJ, Mathias CJ, Quinn NP, Harding AE. Cerebellar presentation of multiple system atrophy. <i>Mov Disord.</i> 1997 Jan; 12(1):115-7.

25	Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandell JP, Lai EC, Verny M, RayChaudhuri K, McKee A, Jellinger K, Pearce RK, Bartko JJ. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. <i>Neurology</i> . 1997 Jan;48(1):119-25.
26	Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. <i>Neurology</i> . 1997 Feb; 48(2):384-93.
27	Wenning GK, Jellinger K, Litvan I. Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism. <i>J Neural Transm</i> . 1997; 104(8-9):845-65.
28	Donnemiller E, Heilmann J, Wenning GK, Berger W, Decristoforo C, Moncayo R, Poewe W, Ransmayr G. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. <i>Eur J Nucl Med</i> . 1997 Mar; 24(3):320-5.
29	Gu M, Gash MT, Cooper JM, Wenning GK, Daniel SE, Quinn NP, Marsden CD, Schapira AH. Mitochondrial respiratory chain function in multiple system atrophy. <i>Mov Disord</i> . 1997 May; 12(3):418-22.
30	Wenning GK, Smith SJ. Magnetic brain stimulation in multiple system atrophy. <i>Mov Disord</i> . 1997 May; 12(3):452-69.
31	Litvan I, Agid Y, Sastry N, Jankovic J, Wenning GK, Goetz CG, Verny M, Brandel JP, Jellinger K, Chaudhuri KR, McKee A, Lai EC, Pearce RK, Bartko JJ. What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. <i>Neurology</i> . 1997 Jul; 49(1):62-9. Erratum in: <i>Neurology</i> 1997 Dec; 49(6):1755.
32	Klein C, Brown R, Wenning G, Quinn N. The "cold hands sign" in multiple system atrophy. <i>Mov Disord</i> . 1997 Jul; 12(4):514-8.
33	Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, Rothwell JC, Brown R, Gustavii B, Hagell P, Jahanshahi M, Sawle G, Björklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. <i>Ann Neurol</i> . 1997 Jul; 42(1):95-107.
34	Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ, McKee A, Jellinger K, Lai EC, Brandel JP, Verny M, Chaudhuri KR, Pearce RK, Agid Y. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. <i>Arch Neurol</i> . 1997 Aug; 54(8):937-44.
35	Bandmann O, Sweeney MG, Daniel SE, Wenning GK, Quinn N, Marsden CD, Wood NW. Multiple-system atrophy is genetically distinct from identified inherited causes of spinocerebellar degeneration. <i>Neurology</i> . 1997 Dec; 49(6):1598-604.
36	Litvan I, Booth V, Wenning GK, Bartko JJ, Goetz CG, McKee A , Jankovic J, Jellinger K, Lai EC, Brandel JP, Verny M, Chaudhuri KR, Pearce RK, Agid Y. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. <i>J Neural Transm</i> . 1998; 105(2-3):217-27.
37	Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, Poewe W, Jellinger K, Chaudhuri KR, D'Olhaberriague L, Pearce RK. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. <i>J Neurol Neurosurg Psychiatry</i> . 1998 Feb; 64(2):184-9.

38	Kofler M, Wenning GK, Poewe W. Cortical and brain stem hyperexcitability in striatonigral degeneration. <i>Mov Disord.</i> 1998 May;13(3):602-7.
39	Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. <i>Mov Disord.</i> 1998 May; 13(3):438-45.
40	Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J, McKee A, Brandel JP, Chaudhuri KR, Lai EC, D'Olhaberriague L, Pearce RK, Agid Y. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. <i>Arch Neurol.</i> 1998 Jul; 55(7):969-78.
41	Litvan I, Jankovic J, Goetz CG, Wenning GK, Sastry N, Jellinger K, McKee A, Lai EC, Brandel JP, Verny M, Chaudhuri KR, Pearce RK, Bartko JJ, Agid Y. Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. <i>Eur J Neurol.</i> 1998 Sep; 5(5):451-7.
42	Klockgether T, Bürk K, Wüllner U, Wenning G, Schulz JB, Döller G, Wessel K, Huss P, Krämer A, Lüdtke R. Risk factors for idiopathic cerebellar ataxia of late onset. <i>J Neurol Sci.</i> 1998 Oct 8; 160(2):171-4.
43	Kronenberg MF, Menzel HJ, Ebersbach G, Wenning GK, Luginger E, Gollner M, Ransmayr G, Utermann G, Poewe W, Kronenberg F. Dopamine D4 receptor polymorphism and idiopathic Parkinson's disease. <i>Eur J Hum Genet.</i> 1999 Apr; 7(3):397-400.
44	Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, Widner H, Brundin P, Rothwell JC, Odin P, Wenning GK, Morrish P, Gustavii B, Björklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. <i>Brain.</i> 1999 Jun; 122( Pt 6):1121-32.
45	Defer GL, Widner H, Marie RM, Remy P, Levivier M, and the Conference Participants. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). <i>Mov Disord.</i> 1999 Jul; 14(4):572-84.
46	Bonifati V, Joosse M, Nicholl DJ, Vanacore N, Bennett P, Rizzu P, Fabbrini G, Marconi R, Colosimo C, Locuratolo N, Stocchi F, Bonuccelli U, de Mari M, Wenning G, Vieregge P, Oostra B, Meco G, Heutink P. The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. <i>Neurosci Lett.</i> 1999 Oct; 274(1):61-5.
47	Wenning GK, Ebersbach G, Verny M, Chaudhuri KR, Jellinger K, McKee A, Poewe W, Litvan I. Progression of falls in postmortem-confirmed parkinsonian disorders. <i>Mov Disord.</i> 1999 Nov; 14(6):947-50.
48	Ebersbach G, Stöck M, Müller J, Wenning G, Wissel J, Poewe W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. <i>Mov Disord.</i> 1999 Nov; 14(6):1011-3.

49	Wenning GK, Scherfler C, Granata R, Bösch S, Verny M, Chaudhuri KR, Jellinger K, Poewe W, Litvan I. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. <i>J Neurol Neurosurg Psychiatry.</i> 1999 Nov; 67(5):620-3.
50	Puschban Z, Scherfler C, Granata R, Laboyrie P, Quinn NP, Jenner P, Poewe W, Wenning GK. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts. <i>Neuroscience.</i> 2000; 95(2):37788.
51	Scherfler C, Puschban Z, Ghorayeb I, Goebel GP, Tison F, Jellinger K, Poewe W, Wenning GK. Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). <i>Neuroscience.</i> 2000; 99(1):4354.
52	Wenning GK, Jellinger KJ, Quinn NP, Poewe WH. An early report of striatonigral degeneration. <i>Mov Disord.</i> 2000 Jan; 15(1):159-62.
53	Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? <i>J Neurol Neurosurg Psychiatry.</i> 2000 Apr; 68(4):434-40.
54	Ghorayeb I, Fernagut PO, Aubert I, Bezard E, Poewe W, Wenning GK, Tison F. Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. <i>Mov Disord.</i> 2000 May; 15(3):531-6.
55	Puschban Z, Waldner R, Seppi K, Stefanova N, Humpel C, Scherfler C, Levivier M, Poewe W, Wenning GK. Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy). <i>Exp Neurol.</i> 2000 Jul; 164(1):166-75.
56	Schocke MF, Waldner R, Puschban Z, Kolbitsch C, Seppi K, Scherfler C, Kremser C, Zschiegner F, Felber S, Poewe W, Wenning GK. In vivo magnetic resonance imaging of embryonic neural grafts in a rat model of striatonigral degeneration (multiple system atrophy). <i>Neuroimage.</i> 2000 Aug; 12(2):209-18.
57	Luginger E, Wenning GK, Bösch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. <i>Mov Disord.</i> 2000 Sep; 15(5):873-8.
58	Donnemiller E, Brenneis C, Wissel J, Scherfler C, Poewe W, Riccabona G, Wenning GK. Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using <sup>123</sup> I-beta-CIT and <sup>123</sup> I-IBZM. <i>Eur J Nucl Med.</i> 2000 Sep; 27(9):1410-4.
59	Müller J, Wenning GK, Jellinger K, McKee A, Poewe W, Litvan I. Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. <i>Neurology.</i> 2000 Sep; 55(6):888-91.
60	Kofler M, Müller J, Reggiani L, Wenning GK. Somatosensory evoked potentials in progressive supranuclear palsy. <i>J Neurol Sci.</i> 2000 Oct; 179(S 1-2):85-91.

61	Waldner R, Puschban Z, Scherfler C, Seppi K, Jellinger K, Poewe W, Wenning GK. No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). <i>Neuroscience</i> . 2001; 102(3):581-92.
62	Kofler M, Müller J, Wenning GK, Reggiani L, Hollosi P, Bösch S, Ransmayr G, Valls-Sole J, Poewe W. The auditory startle reaction in parkinsonian disorders. <i>Mov Disord</i> . 2001 Jan; 16(1):62-71.
63	Ghorayeb I, Puschban Z, Fernagut PO, Scherfler C, Rouland R, Wenning GK, Tison F. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. <i>Exp Neurol</i> . 2001 Jan; 167(1):133-47.
64	Müller J, Wenning GK, Verny M, McKee A, Chaudhuri KR; Jellinger K, Poewe W, Litvan I. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. <i>Arch Neurol</i> . 2001 Feb; 58(2):259-64.
65	Marras C, Lang AE, Ang LC, Zijlmans JCM, Wenning GK. Clinical Grand Rounds. 69-yearold man with gait disturbance and Parkinsonism. <i>Mov Disord</i> . 2001 May; 16(3):548-61.
66	Müller J, Wissel J, Masuhr F, Ebersbach G, Wenning GK, Poewe W. Clinical characteristics of the geste antagoniste in cervical dystonia. <i>J Neurol</i> . 2001 Jun; 248(6):478-82.

67	Stefanova N, Klimaszewski L, Poewe W, Wenning GK, Reindl M. Glial cell death induced by overexpression of alpha-synuclein. <i>J Neurosci Res</i> . 2001 Sep; 65(5):432-8.
68	Seppi K, Mueller J, Bodner T, Brandauer E, Benke T, Weirich-Schaiger H, Poewe W, Wenning GK. Riluzole in Huntington's disease (HD): an open label study with one year follow up. <i>J Neurol</i> . 2001 Oct; 248(10):866-9.
69	Ransmayr G, Seppi K, Donnemiller E, Luginger E, Marksteiner J, Riccabona G, Poewe W, Wenning GK. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease. <i>Eur J Nucl Med</i> . 2001 Oct; 28(10):1523-8.
70	Högl B, Seppi K, Brandauer E, Wenning G, Poewe W. Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): placebocontrolled, polysomnographic case report. <i>Mov Disord</i> . 2001 Nov; 16(6):1177-9.
71	Fernagut PO, Diguet E, Stefanova N, Biran M, Wenning GK, Canioni P, Bioulac B, Tison F. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. <i>Neuroscience</i> . 2002; 114(4):1005-17.
72	Müller J, Wenning GK, Wissel J, Baldauf A, Seppi K, Brenneis C, Poewe W. Riluzole therapy in cervical dystonia. <i>Mov Disord</i> . 2002 Jan; 17(1):198-200.
73	Ebersbach G, Sojer M, Müller J, Ransmayr G, Wenning G, Poewe W. Gleichgewichtsstörungen bei idiopathischer Parkinson-Erkrankung. Der Einfluss zerebrovaskulärer Komorbidität. <i>Nervenarzt</i> . 2002 Feb; 73(2):162-5.
74	Schocke MF, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W, Wenning GK. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. <i>Neurology</i> . 2002 Feb; 58(4):575-80.

75	Bösch SM, Wenning GK, Ransmayr G, Poewe W. Dystonia in multiple system atrophy. <i>J Neurol Neurosurg Psychiatry.</i> 2002 Mar; 72(3):300-3.
76	Müller J, Wenning GK, Wissel J, Seppi K, Poewe W. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. <i>J Neurol.</i> 2002 Mar; 249(3):300-4.
77	Wenning GK, Seppi K, Tison F, Jellinger K. A novel grading scale for striatonigral degeneration (multiple system atrophy). <i>J Neural Transm.</i> 2002 Mar; 109(3):307-20.
78	Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. <i>J Neural Transm.</i> 2002 Mar; 109(3):329-39.
79	Stefanova N, Emgard M, Klimaschewski L, Wenning GK, Reindl M. Ultrastructure of alpha-synuclein-positive aggregations in U373 astrocytoma and rat primary glial cells. <i>Neurosci Lett.</i> 2002 Apr; 19;323(1):37-40.
80	Tison F, Yekhlef F, Chrysostome V, Balestre E, Quinn NP, Poewe W, Wenning GK. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease. <i>Mov Disord.</i> 2002 Jul; 17(4):701-9.
81	Müller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W; Austrian Botulinum Toxin and Dystonia Study Group. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. <i>J Neurol.</i> 2002 Jul; 249(7):842-6.
82	Scherfler C, Donnemiller E, Schocke M, Dierkes K, Decristoforo C, Oberladstätter M, Kolbitsch C, Zschiegner F, Riccabona G, Poewe W, Wenning G. Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT. <i>Neuroimage.</i> 2002 Sep; 17(1):128-41.
83	Müller J, Seppi K, Stefanova N, Poewe W, Litvan I, Wenning GK. Freezing of gait in postmortem-confirmed atypical parkinsonism. <i>Mov Disord.</i> 2002 Sep; 17(5):1041-5.
84	Müller J, Kiechl S, Wenning GK, Seppi K, Willeit J, Gasperi A, Wissel J, Gasser T, Poewe W. The prevalence of primary dystonia in the general community. <i>Neurology.</i> 2002 Sep; 59(6):941-3.
85	Tison F, Yekhlef F, Balestre E, Chrysostome V, Quinn N, Wenning GK, Poewe W. Application of the International Cooperative Ataxia Scale rating in multiple system atrophy. <i>Mov Disord.</i> 2002 Nov; 17(6):1248-54.
86	Osaki Y, Ben-Shlomo Y, Wenning GK, Daniel SE, Hughes A, Lees AJ, Mathias CJ, Quinn N. Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? <i>Neurology.</i> 2002 Nov; 59(10):1486-91.
87	Högl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K, Ulmer H, Wenning G, Poewe W. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. <i>Sleep.</i> 2002 Dec; 25(8):62-6.

88	Ghorayeb I, Fernagut PO, Stefanova N, Wenning GK, Bioulac B, Tison F. Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. <i>Neurosci Lett. 2002 Dec; 335(1):34-8.</i>
89	Högl B, Seppi K, Brandauer E, Glatzl S, Frauscher B, Niedermüller U, Wenning G, Poewe W. Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. <i>Mov Disord. 2003 Mar; 18(3):319-23.</i>
90	Kofler M, Müller J, Seppi K, Wenning GK. Exaggerated auditory startle responses in multiple system atrophy: a comparative study of parkinson and cerebellar subtypes. <i>Clin Neurophysiol. 2003 Mar; 114(3):541-7.</i>
91	Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Müller J, Bösch S, Jaschke W, Poewe W, Wenning GK. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. <i>Neurology. 2003 Mar; 60(6):922-7.</i>
92	Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, Quinn N, Sethi KD, Shults C, Wenning GK; Movement Disorders Society Scientific Issues Committee. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. <i>Mov Disord. 2003 May; 18(5):467-86.</i>
93	Stefanova N, Schanda K, Klimaschewski L, Poewe W, Wenning GK, Reindl M. Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein. <i>J Neurosci Res. 2003 Aug; 73(3):334-40.</i>
94	Stefanova N, Puschban Z, Fernagut PO, Brouillet E, Tison F, Reindl M, Jellinger KA, Poewe W, Wenning GK. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). <i>Acta Neuropathol (Berl). 2003 Aug; 106(2):157-66.</i>
95	Brenneis C, Seppi K, Schocke MF, Müller J, Luginger E, Bösch S, Löscher WN, Büchel C, Poewe W, Wenning GK. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. <i>Mov Disord. 2003 Oct; 18(10):1132-8.</i>
96	Brenneis C, Bösch SM, Schocke M, Wenning GK, Poewe W. Atrophy pattern in SCA2 determined by voxel-based morphometry. <i>Neuroreport. 2003 Oct; 14(14):1799-802.</i>
97	Müller J, Kofler M, Wenning GK, Seppi K, Valls-Sole J, Poewe W. Auditory startle response in cervical dystonia. <i>Mov Disord. 2003 Dec; 18(12):1522-6.</i>
98	Alesch F, Auff E, Brücke T, Eisner W, Müller J, Ott E, Pinter M, Poewe W, Ransmayr G, Schnizer M, Volc D, Wenning G, Wolf E. Konsensusrichtlinien der Österreichischen Parkinson Gesellschaft zur tiefen Gehirnstimulation bei Morbus Parkinson. <i>P-aktuell. 2003; Sonderausgabe 2:1-8.</i>
99	Osaki Y, Ben-Shlomo Y, Lees AJ, Daniel SE, Colosimo C, Wenning G, Quinn N. Accuracy of clinical diagnosis of progressive supranuclear palsy. <i>Mov Disord. 2004 Feb; 19(2):181-9.</i>

100	Brenneis C, Seppi K, Schocke M, Benke T, Wenning GK, Poewe W. Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. <i>J Neurol Neurosurg Psychiatry.</i> 2004 Feb; 75(2):246-9.
101	Schocke MF, Seppi K, Esterhammer R, Kremser C, Mair KJ, Czermak BV, Jaschke W, Poewe W, Wenning GK. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. <i>Neuroimage.</i> 2004 Apr; 21(4):1443-51.
102	Stefanova N, Lundblad M, Tison F, Poewe W, Cenci MA, Wenning GK. Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). <i>Neurobiol Dis.</i> 2004 Apr; 15(3):630-9.
103	Müller J, Wissel J, Kemmler G, Voller B, Bodner T, Schneider A, Wenning GK, Poewe W. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. <i>J Neurol Neurosurg Psychiatry.</i> 2004 May; 75(5):749-53.
104	Kiechl S, Schett G, Wenning G, Redlich K, Oberholzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. <i>Circulation.</i> 2004 May; 109(18):2175-80.
105	Frauscher B, Högl B, Maret S, Wolf E, Bransauer E, Wenning GK, Kronenberg MF, Kronenberg F, Tafti M, Poewe W. Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease: a pilot study. <i>Sleep.</i> 2004 Jun; 27(4):733-6.
106	Brenneis C, Wenning GK, Egger KE, Schocke M, Trieb T, Seppi K, Marksteiner J, Ransmayr G, Benke T, Poewe W. Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. <i>Neuroreport.</i> 2004 Aug; 15(11):1711-4.
107	Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. <i>Mov Disord.</i> 2004 Sep; 19(9):1020-8.
108	Stefanova N, Mitschnigg M, Ghorayeb I, Diguet E, Geser F, Tison F, Poewe W, Wenning GK. Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. <i>J Neurosci Res.</i> 2004 Oct; 78(1):87-91.
109	Peralta C, Werner P, Holl B, Kiechl S, Willeit J, Seppi K, Wenning G, Poewe W. Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort. <i>J Neural Transm.</i> 2004 Oct; 111(10-11):1473-83.
110	Bösch SM, Donnemiller E, Müller J, Seppi K, Weirich-Schwaiger H, Poewe W, Wenning GK. Abnormalities of dopaminergic neurotransmission in SCA2: a combined <sup>123</sup> IbetaCIT and <sup>123</sup> I-IBZM SPECT study. <i>Mov Disord.</i> 2004 Nov; 19(11):1320-5.
111	Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhlef F, Ghorayeb I, Ory F, Galitzky M, Scaravilli T, Bozi M, Colosimo C, Gilman S, Shults CW, Quinn NP, Rascol O, Poewe W; Multiple System Atrophy Study Group. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). <i>Mov Disord.</i> 2004 Dec; 19(12):1391-402.

112	Seppi K, Schocke MF, Donnemiller E, Esterhammer R, Kremser C, Scherfler C, Diem A, Jaschke W, Wenning GK, Poewe W. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. <i>Mov Disord.</i> 2004 Dec; 19(12):1438-45.
113	Stampfer-Kountchev M, Poewe W, Wenning GK. Das posturale Tachykardiesyndrom (POTS). <i>Aktuelle Neurologie.</i> 2005; 32(8):472-6.
114	Pirker W, Scherfler C, Brücke T, Poewe W, Auff E, Katzenschlager R, Ott E, Schnider P, Ransmayr G, Wenning G. Klinische Indikationen für SPECT-Untersuchungen bei Bewegungsstörungen. <i>P-aktuell.</i> 2005; 3:2-11.
115	Seppi K, Yekhlef F, Diem A, Luginger-Wolf E, Müller J, Tison F, Quinn NP, Poewe W, Wenning GK. Progression of parkinsonism in multiple system atrophy. <i>J Neurol.</i> 2005 Jan; 252(1):91-6.
116	Scherfler C, Scholz SW, Donnemiller E, Decristoforo C, Oberladstätter M, Stefanova N, Diederer E, Virgolini I, Poewe W, Wenning GK. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats. <i>Neuroimage.</i> 2005 Feb; 24(3):822-31.
117	Mantoan L, Stefanova N, Egger KE, Jellinger KA, Poewe W, Wenning GK. Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple system atrophy). <i>Acta Neuropathol (Berl).</i> 2005 Feb; 109(2):191-7.
118	Stefanova N, Reindl M, Neumann M, Haass C, Poewe W, Kahle PJ, Wenning GK. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. <i>Am J Pathol.</i> 2005 Mar; 166(3):869-76.
119	Poewe W, Asenbaum-Hanke S, Auff, E, Brücke T, Dal-Bianco P, Fischer P, Gerschlager W, Grossmann J, Hochschorner G, Jellinger K, Katzenschlager R, Koppi S, Ladurner G, Marksteiner J, Ott E, Pinter M, Pirker W, Ransmayr G, Schautzer F, Schmidbauer M, Schmidt R, Schnider P, Soukop W, Volc D, Wenning G. Konsensus-Statement ParinsonDemenz. <i>CliniCum - Sonderausgabe.</i> 2005 Apr;3-8.
120	Diguet E, Fernagut PO, Scherfler C, Wenning G, Tison F. Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice. <i>J Neural Transm.</i> 2005 May; 112(5):613-31.
121	Högl B, Kiechl S, Willeit J, Saletu M, Frauscher B, Seppi K, Müller J, Rungger G, Gasperi A, Wenning G, Poewe W. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. <i>Neurology.</i> 2005 Jun; 64(11):1920-4.
122	Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I, Wenning GK, Poewe W. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. <i>Brain.</i> 2005 Jul; 128(Pt 7):1605-12.
123	Jellinger KA, Seppi K, Wenning GK. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. <i>Mov Disord.</i> 2005 Aug; 20(Suppl 12):S29-36.
124	Stefanova N, Reindl M, Poewe W, Wenning GK. In vitro models of multiple system atrophy. <i>Mov Disord.</i> 2005 Aug; 20(Suppl 12):S53-6.

125	Scherfler C, Sather T, Diguet E, Stefanova N, Puschban Z, Tison F, Poewe W, Wenning GK. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). <i>J Neural Transm.</i> 2005 Aug; 112(8):1025-33.
126	Kamm C, Healy DG, Quinn NP, Wullner U, Moller JC, Schols L, Geser F, Burk K, Borglum AD, Pellecchia MT, Tolosa E, del Sorbo F, Nilsson C, Bandmann O, Sharma M, Mayer P,
	Gasteiger M, Haworth A, Ozawa T, Lees AJ, Short J, Giunti P, Holinski-Feder E, Illig T, Wichmann HE, Wenning GK, Wood NW, Gasser T; European Multiple System Atrophy Study Group. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. <i>Brain.</i> 2005 Aug; 128(Pt 8):1855-60.
127	Wenning GK; Working Group on Atypical Parkinsonism of the Austrian Parkinson's Society. Placebo-controlled trial of amantadine in multiple-system atrophy. <i>Clin Neuropharmacol.</i> 2005 Sep-Oct; 28(5):225-7.
128	Schmidauer C, Sojer M, Seppi K, Stockner H, Högl B, Biedermann B, Brandauer E, Peralta CM, Wenning GK, Poewe W. Transcranial ultrasound shows nigral hypoechoicity in restless legs syndrome. <i>Ann Neurol.</i> 2005 Oct; 58(4):630-4.
129	Muller UJ, Frick B, Winkler C, Fuchs D, Wenning GK, Poewe W, Müller J. Homocysteine and serum markers of immune activation in primary dystonia. <i>Mov Disord.</i> 2005 Dec; 20(12):1663-7.
130	Wenning GK, Kiechl S, Seppi K, Müller J, Högl B, Saletu M, Rungger G, Gasperi A, Willeit J, Poewe W. Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. <i>Lancet Neurol.</i> 2005 Dec; 4(12):815-20.
131	Puschban Z, Stefanova N, Petersen A, Winkler C, Brundin P, Poewe W, Wenning GK. Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy. <i>Brain Res Bull.</i> 2005 Dec 15; 68(1-2):54-8.
132	Brenneis C, Boesch SM, Egger KE, Seppi K, Scherfler C, Schocke M, Wenning GK, Poewe W. Cortical atrophy in the cerebellar variant of multiple system atrophy: a voxel-based morphometry study. <i>Mov Disord.</i> 2006 Feb; 21(2):159-65.
133	Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires M, Frick C, Ndayisaba JP, Ulmer H, Pellecchia MT, Barone P, Kim HT, Hooker J, Quinn NP, Cardozo A, Tolosa E, Abele M, Klockgether T, Ostergaard K, Dupont E, Schimke N, Eggert KM, Oertel W, Djaldetti R, Poewe W; the European MSA Study Group. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). <i>Mov Disord.</i> 2006 Feb; 21(2):179-86.
134	Scherfler C, Schocke MF, Seppi K, Esterhammer R, Brenneis C, Jaschke W, Wenning GK, Poewe W. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. <i>Brain.</i> 2006 Feb; 129(Pt 2):538-42.

135	Metzger S, Bauer P, Tomiuk J, Laccone F, Didonato S, Gellera C, Soliveri P, Lange HW, Weirich-Schwaiger H, Wenning GK, Melegh B, Havasi V, Baliko L, Wieczorek S, Arning L, Zaremba J, Sulek A, Hoffman-Zacharska D, Basak AN, Ersoy N, Zidovska J, Kebrdlova V, Pandolfo M, Ribai P, Kadasi L, Kvasnicova M, Weber BH, Kreuz F, Dose M, Stuhrmann M, Riess O. The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease. <i>Neurogenetics</i> . 2006 Mar; 7(1):27-30.
136	Ozawa T, Healy DG, Abou-Sleiman PM, Ahmadi KR, Quinn N, Lees AJ, Shaw K, Wullner U, Berciano J, Moller JC, Kamm C, Burk K, Josephs KA, Barone P, Tolosa E, Goldstein DB, Wenning G, Geser F, Holton JL, Gasser T, Revesz T, Wood NW; European MSA Study Group. The alpha-synuclein gene in multiple system atrophy. <i>J Neurol Neurosurg Psychiatry</i> . 2006 Apr; 77(4):464-7.
137	Seppi K, Schocke MF, Mair KJ, Esterhammer R, Scherfler C, Geser F, Kremser C, Boesch S, Jaschke W, Poewe W, Wenning GK. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. <i>Neuroimage</i> . 2006 May 15; 31(1):240-5.
138	Schrag A, Geser F, Stampfer-Kountchev M, Seppi K, Sawires M, Kollensperger M, Scherfler C, Quinn N, Pellecchia MT, Barone P, del Sorbo F, Albanese A, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Nilsson CF, Widner H, Lindvall O, Giladi N, Gurevich T, Daniels C, Deuschl G, Coelho M, Sampaio C, Abele M, Klockgether T, Schimke N, Eggert KM, Oertel W, Djaldetti R, Colosimo C, Meco G, Poewe W, Wenning GK. Healthrelated quality of life in multiple system atrophy. <i>Mov Disord</i> . 2006 Jun; 21(6):809-15.
139	Seppi K, Schocke MF, Prennsschuetz-Schuetzenau K, Mair KJ, Esterhammer R, Kremser C, Muigg A, Scherfler C, Jaschke W, Wenning GK, Poewe W. Topography of putaminal degeneration in multiple system atrophy: A diffusion magnetic resonance study. <i>Mov Disord</i> . 2006 Jun; 21(6):847-52.
140	Seppi K, Schocke MF, Mair KJ, Esterhammer R, Weirich-Schwaiger H, Utermann B, Egger K, Brenneis C, Granata R, Boesch S, Poewe W, Wenning GK. Diffusion-weighted imaging in Huntington's disease. <i>Mov Disord</i> . 2006 Jul; 21(7):1043-7.
141	Peralta C, Wolf E, Alber H, Seppi K, Muller S, Bösch S, Wenning GK, Pachinger O, Poewe W. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. <i>Mov Disord</i> . 2006 Aug; 21(8):1109-13.
142	Seppi K, Högl B, Diem A, Peralta C, Wenning GK, Poewe W. Levodopa-induced sleepiness in the Parkinson variant of multiple system atrophy. <i>Mov Disord</i> . 2006 Aug; 21(8):1281-3.
143	Geser F, Wenning GK. The diagnosis of multiple system atrophy. <i>J Neurol</i> . 2006 Aug; 253 Suppl 3:iii2-iii15.
144	Seppi K, Scherfler C, Donnemiller E, Virgolini I, Schocke MF, Goebel G, Mair KJ, Boesch S, Brenneis C, Wenning GK, Poewe W. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. <i>Arch Neurol</i> . 2006 Aug; 63(8):1154-60.
145	Boesch SM, Frauscher B, Brandauer E, Wenning GK, Poewe W, Hogl B. Restless legs syndrome and motor activity during sleep in spinocerebellar ataxia type 6. <i>Sleep Med</i> . 2006 Sep; 7(6):529-32.

146	Metzger S, Bauer P, Tomiuk J, Laccone F, Didonato S, Gellera C, Mariotti C, Lange HW, Weirich-Schwaiger H, Wenning GK, Seppi K, Melegh B, Havasi V, Baliko L, Wieczorek S, Zaremba J, Hoffman-Zacharska D, Sulek A, Basak AN, Soydan E, Zidovska J, Kebrdlova V, Pandolfo M, Ribai P, Kadasi L, Kvasnicova M, Weber BH, Kreuz F, Dose M, Stuhrmann M, Riess O. Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease. <i>Hum Genet.</i> 2006 Sep; 120(2):285-92.
147	Scherfler C, Boesch SM, Donnemiller E, Seppi K, Weirich-Schwaiger H, Goebel G, Virgolini I, Wenning GK, Poewe W. Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [(123)I]beta-CIT SPECT analysis. <i>Eur J Nucl Med Mol Imaging.</i> 2006 Sep; 33(9):1084-90.
148	Boesch SM, Frauscher B, Brandauer E, Wenning GK, Hogl B, Poewe W. Disturbance of rapid eye movement sleep in spinocerebellar ataxia type 2. <i>Mov Disord.</i> 2006 Oct; 21(10):1751-4.
149	Rinnerthaler M, Mueller J, Weichbold V, Wenning GK, Poewe W. Social stigmatization in patients with cranial and cervical dystonia. <i>Mov Disord.</i> 2006 Oct; 21(10):1636-40.
150	Seppi K, Peralta C, Diem-Zangerl A, Puschban Z, Mueller J, Poewe W, Wenning GK. Placebo-controlled trial of riluzole in multiple system atrophy. <i>Eur J Neurol.</i> 2006 Oct; 13(10):1146-8.
151	Hauser RA, Russ H, Haeger DA, Brugiere-Fontenille M, Muller T, Wenning GK. Patient Evaluation of a Home Diary to Assess Duration and Severity of Dyskinesia in Parkinson Disease. <i>Clin Neuropharmacol.</i> 2006 November/December; 29(6):322-30.

152	Wenning GK, Köllensperger M. Therapie des Morbus Parkinson. <i>MedMix.</i> 2006; 10:37-8.
153	Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with Lewy bodies and Parkinson dementia. <i>Neurodegener Dis.</i> 2007; 4(6):428-30.
154	Peralta C, Stampfer-Kountchev M, Karner E, Kollensperger M, Geser F, Wolf E, Seppi K, Benke T, Poewe W, Wenning GK. Orthostatic hypotension and attention in Parkinson's disease with and without dementia. <i>J Neural Transm.</i> 2007; 114(5):585-8.
155	Köllensperger M, Stampfer-Kountchev M, Seppi K, Geser F, Frick C, Del Sorbo F, Albanese A, Gurevich T, Giladi N, Djaldetti R, Schrag A, Low PA, Mathias CJ, Poewe W, Wenning GK. Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. <i>Eur J Neurol.</i> 2007 Jan; 14(1):66-72.
156	Löscher WN, Stampfer-Kountchev M, Sawires M, Seppi K, Mueller J, Szubski C, Hirnsperger K, Brenneis C, Poewe W, Wenning GK. Abnormal responses to repetitive transcranial magnetic stimulation in multiple system atrophy. <i>Mov Disord.</i> 2007 Jan 15; 22(2):174-8.
157	Brenneis C, Egger K, Scherfler C, Seppi K, Schocke M, Poewe W, Wenning GK. Progression of brain atrophy in multiple system atrophy: A longitudinal VBM study. <i>J Neurol.</i> 2007 Feb; 254(2):191-6.
158	Köllensperger M, Stefanova N, Reindl M, Poewe W, Wenning GK. Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy. <i>Mov Disord.</i> 2007 Feb; 22(3):353-8.

159	Stockner H, Sojer M, K KS, Mueller J, Wenning GK, Schmidauer C, Poewe W. Midbrain sonography in patients with essential tremor. <i>Mov Disord.</i> 2007 Feb; 22(3):414-7.
160	Boesch SM, Wolf C, Seppi K, Felber S, Wenning GK, Schocke M. Differentiation of SCA2 from MSA-C using proton magnetic resonance spectroscopic imaging. <i>J Magn Reson Imaging.</i> 2007 Mar; 25(3):564-9.
161	Holmberg B, Johansson JO, Poewe W, Wenning G, Quinn NP, Mathias C, Tolosa E, Cardozo A, Dizdar N, Rascol O, Slaoui T; Growth-Hormone MSA Study GroupMembers of the Growth-Hormone MSA Study Group and the European MSA Study Group are listed as an Appendix; European MSA Study Group (EMSA-SG). Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebocontrolled study. <i>Mov Disord.</i> 2007 Apr 27; 22(8):1138-1144.
162	Boesch SM, Mueller J, Wenning GK, Poewe W. Cervical dystonia in spinocerebellar ataxia type 2: Clinical and polymyographic findings. <i>J Neurol Neurosurg Psychiatry.</i> 2007 May; 78(5):520-2.
163	Stefanova N, Köllensperger M, Hainzer M, Cenci A, Poewe W, Wenning GK. High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence. <i>Mov Disord.</i> 2007 May 15; 22(7):969-73.
164	Hering S, Wenning GK, Seppi K, Poewe W, Mueller J. An open trial of levetiracetam for segmental and generalized dystonia. <i>Mov Disord.</i> 2007 Aug 15; 22(11):1649-51.
165	Egger K, Mueller J, Schocke M, Brenneis C, Rinnerthaler M, Seppi K, Trieb T, Wenning GK, Hallett M, Poewe W. Voxel based morphometry reveals specific gray matter changes in primary dystonia. <i>Mov Disord.</i> 2007 Aug 15; 22(11):1538-42.
166	Köllensperger M, Seppi K, Liener C, Boesch S, Heute D, Mair KJ, Mueller J, Sawires M, Scherfler C, Schocke MF, Donnemilier E, Virgolini I, Wenning GK, Poewe W. Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. <i>Mov Disord.</i> 2007 Sep 15; 22(12):1771-6.
167	Martinez-Rodriguez JE, Seppi K, Cardozo A, Iranzo A, Stampfer-Kountchev M, Wenning G, Tolosa E, Hogl B, Santamaria J, Poewe W; SINBAR (Sleep Innsbruck Barcelona)

	group. Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy. <i>Mov Disord.</i> 2007 Sep 15; 22(12):1822-4.
168	Stefanova N, Reindl M, Neumann M, Kahle PJ, Poewe W, Wenning GK. Microglial activation mediates neurodegeneration related to oligodendroglial alphasynucleinopathy: Implications for multiple system atrophy. <i>Mov Disord.</i> 2007 Nov 15; 22(15):2196-203.
169	Trojanowski JQ, Revesz T, Neuropathology Working Group on MSA. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. <i>Neuropathol Appl Neurobiol.</i> 2007 Dec; 33(6):615-20.
170	Sinz H, Zamarian L, Benke T, Wenning GK, Delazer M. Impact of ambiguity and risk on decision making in mild Alzheimer's disease. <i>Neuropsychologia.</i> 2008; 46(7):2043-55.
171	Schrag A, Wenning GK, Quinn N, Ben-Shlomo Y. Survival in multiple system atrophy. <i>Mov Disord.</i> 2008 Jan 30; 23(2):294-6.
172	Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. <i>Exp Neurol.</i> 2008 Apr; 210(2):421-7.

173	Quinn N, Barker RA, Wenning GK. Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? <i>Clin Pharmacol Ther. 2008 May; 83(5):663-5.</i>
174	Köllensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, Boesch S, Mueller J, Koukouni V, Quinn N, Pellecchia MT, Barone P, Schimke N, Dodel R, Oertel W, Dupont E, Østergaard K, Daniels C, Deuschl G, Gurevich T, Giladi N, Coelho M, Sampaio C, Nilsson C, Widner H, Sorbo FD, Albanese A, Cardozo A, Tolosa E, Abele M, Klockgether T, Kamm C, Gasser T, Djaldetti R, Colosimo C, Meco G, Schrag A, Poewe W, Wenning GK; European MSA Study Group. Red flags for multiple system atrophy. <i>Mov Disord. 2008 Jun 15; 23(8):1093-9.</i>
175	Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M. Second consensus statement on the diagnosis of multiple system atrophy. <i>Neurology. 2008 Aug 26; 71(9):670-6.</i>
176	Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG. Multiple system atrophy: A primary oligodendroglialopathy. <i>Ann Neurol. 2008 Sep; 64(3): 239-46.</i>
177	Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T; EHDI Study Group, Roos RA. Weight loss in Huntington disease increases with higher CAG repeat number. <i>Neurology. 2008 Nov 4; 71(19):1506-13.</i>
178	Abdo W F, Wenning GK, Bloem BR. Een diagnose in het achterhoofd. <i>Tijdschr Neurol Neurochirurg. 2008; 109(8):343-4.</i>
179	Petzold A, Thompson EJ, Keir G, Quinn N, Holmberg B, Dizdar N, Wenning GK, Rascol O, Tolosa E, Rosengren L. Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy. <i>J Neurol Sci. 2009 Apr 15; 279(1-2):76-9.</i>
180	Diem-Zangerl A, Seppi K, Wenning GK, Trinka E, Ransmayr G, Oberaigner W, Poewe W. Mortality in Parkinson's disease: A 20-year follow-up study. <i>Mov Disord. 2009 Apr 30; 24(6):819-25.</i>
181	Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D, Melchers A, Paudel R, Gibbs JR, Simon-Sanchez J, Paisan-Ruiz C, Bras J, Ding J, Chen H, Traynor BJ, Arepalli S, Zonozi RR, Revesz T, Holton J, Wood N, Lees A, Oertel W, Wüllner U, Goldwurm S, Pellecchia MT, Illig T, Riess O, Fernandez HH, Rodriguez RL, Okun MS, Poewe W, Wenning GK, Hardy JA, Singleton AB, Gasser T. SNCA variants are associated with increased risk for multiple system atrophy. <i>Ann Neurol. 2009 May; 65(5):610-4.</i>
182	Köllensperger M, Stefanova N, Pallua A, Puschban Z, Dechant G, Hainzer M, Reindl M, Poewe W, Nikkhah G, Wenning GK. Striatal transplantation in a rodent model of multiple system atrophy: Effects on L-Dopa response. <i>J Neurosci Res. 2009 May 15; 87(7):1679-85.</i>
183	Lipp A, Sandroni P, Ahlskog JE, Fealey RD, Kimpinski K, Iodice V, Gehrking TL, Weigand SD, Sletten DM, Gehrking JA, Nickander KK, Singer W, Maraganore DM, Gilman S, Wenning GK, Shults CW, Low PA. Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. <i>Arch Neurol. 2009 Jun; 66(6):742-50.</i>

184	Delazer M, Sinz H, Zamarian L, Stockner H, Seppi K, Wenning GK, Benke T, Poewe W. Decision making under risk and under ambiguity in Parkinson's disease. <i>Neuropsychologia</i> . 2009 Jul; 47(8-9):1901-8.
185	Ubhi K, Lee PH, Adame A, Inglis C, Mante M, Rockenstein E, Stefanova N, Wenning GK, Masliah E. Mitochondrial inhibitor 3-nitropropionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. <i>J Neurosci Res</i> . 2009 Sep; 87(12):2728-39.
186	Stefanova N, Hainzer M, Stemberger S, Couillard-Després S, Aigner L, Poewe W, Wenning GK. Striatal transplantation for multiple system atrophy--are grafts affected by alpha-synucleinopathy? <i>Exp Neurol</i> . 2009 Sep; 219(1):368-71.
187	Peralta CM, Frauscher B, Seppi K, Wolf E, Wenning GK, Högl B, Poewe W. Restless legs syndrome in Parkinson's disease. <i>Mov Disord</i> . 2009 Oct 30; 24(14):2076-80.
188	Osaki Y, Ben-Shlomo Y, Lees AJ, Wenning GK, Quinn NP. A validation exercise on the new consensus criteria for multiple system atrophy. <i>Mov Disord</i> . 2009 Nov 15; 24(15):2272-6.
189	Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-Döring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, Köllensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschi G, Böttger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks DJ, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K. Minocycline 1-year therapy in multiplesystem-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSAtrial). <i>Mov Disord</i> . 2010 Jan 15; 25(1):97-107.
190	Wenning GK, Geser F. Erkenntnislehre und Trinitätsspekulation bei Augustinus. <i>Augustinianum</i> . 2010 Jun; 10(1):189-232.
191	Stemberger S, Poewe W, Wenning GK, Stefanova N. Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. <i>Exp Neurol</i> . 2010 Aug; 224(2):459-64.
192	Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Klockgether T, Yekhlef F, Tison F, Daniels C, Deuschi G, Coelho M, Sampaio C, Bozi M, Quinn N, Schrag A, Mathias CJ, Fowler C, Nilsson CF, Widner H, Schimke N, Oertel W, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Colosimo C, Meco G, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Rascol O, Kamm C, Gasser T, Siebert U, Poewe W, Wenning GK; EMSA-SG. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. <i>Mov Disord</i> . 2010 Nov 15; 25(15):2604-12.
193	Stemberger S, Jamnig A, Stefanova N, Lepperdinger G, Reindl M, Wenning GK. Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection. <i>PLoS One</i> . 2011; 6(5):e19808.

194	Moreno-López C, Santamaría J, Salamero M, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Overeem S, Bloem B, Aarden W, Canesi M, Antonini A, Duerr S, Wenning GK, Poewe W, Rubino A, Meco G, Schneider SA, Bhatia KP, Djaldetti R, Coelho M, Sampaio C, Cochen V, Hellriegel H, Deuschl G, Colosimo C, Marsili L, Gasser T, Tolosa E. Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). <i>Arch Neurol.</i> 2011 Feb; 68(2):223-30.
195	Köllensperger M, Krismer F, Pallua A, Stefanova N, Poewe W, Wenning GK. Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. <i>Mov Disord.</i> 2011 Feb 15; 26(3):507-15.
196	Goebel G, Seppi K, Donnemiller E, Warwitz B, Wenning GK, Virgolini I, Poewe W, Scherfler C. A novel computer-assisted image analysis of [ <sup>123</sup> I]-β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. <i>Eur J Nucl Med Mol Imaging.</i> 2011 Apr; 38(4):702-10.
197	Geser F, Malunda JA, Hurtig HI, Duda JE, Wenning GK, Gilman S, Low PA, Lee VM, Trojanowski JQ. TDP-43 pathology occurs infrequently in multiple system atrophy. <i>Neuropathol Appl Neurobiol.</i> 2011 Jun; 37(4):358-65.
198	Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovčová J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nat Genet.</i> 2011 Jun 19; 43(7):699-705.
199	Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK. Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. <i>Am J Pathol.</i> 2011 Aug; 179(2):954-63.
200	Schunk E, Aigner C, Stefanova N, Wenning G, Herzog H, Schwarzer C. Kappa opioid receptor activation blocks progressive neurodegeneration after kainic acid injection. <i>Hippocampus.</i> 2011 Sep; 21(9):1010-20.
201	Saft C, Epplen JT, Wieczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG, Dose M, Tabrizi SJ, Craufurd D; REGISTRY Investigators of the European Huntington's Disease Network, Arning L. NMDA receptor gene variations as modifiers in Huntington disease: a replication study. <i>PLoS Curr.</i> 2011 Oct 4; 3:RRN1247.
202	Onofrj M, Thomas A, Tiraboschi P, Wenning G, Gambi F, Sepede G, Di Giannantonio M, Di Carmine C, Monaco D, Maruotti V, Ciccocioppo F, D'Amico MC, Bonanni L. Updates on Somatoform Disorders (SFMD) in Parkinson's Disease and Dementia with Lewy Bodies and discussion of phenomenology. <i>J Neurol Sci.</i> 2011 Nov 15; 310(12):166-71.
203	Orth M, European Huntington's Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. <i>J Neurol Neurosurg Psychiatry.</i> 2011 Dec; 82(12):1409-12.

204	Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB; European Huntington's Disease Network. Discrepancies in reporting the CAG repeat lengths for Huntington's disease. <i>Eur J Hum Genet.</i> 2012 Jan; 20(1):20-6.
205	Cubo E, González M, del Puerto I, de Yébenes JG, Arconada OF, Gabriel y Galán JM; European Huntington's Disease Initiative Study Group. Placebo effect characteristics

	observed in a single, international, longitudinal study in Huntington's disease. <i>Mov Disord.</i> 2012 Mar; 27(3):439-42.
206	Wenning GK, Granata R, Krismer F, Dürr S, Seppi K, Poewe W, Bleasdale-Barr K, Mathias CJ. Orthostatic hypotension is differentially associated with the cerebellar versus the parkinsonian variant of multiple system atrophy: a comparative study. <i>Cerebellum</i> 2012; 11(1):223-6.
207	Stefanova N, Georgievska B, Eriksson H, Poewe W, Wenning GK. Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model. <i>Neurotox Res.</i> 2012 May; 21(4):393-404.
208	Kaindelstorfer C, García J, Winkler C, Wenning GK, Nikkhah G, Döbrössy MD. Behavioral and histological analysis of a partial double-lesion model of parkinsonian variant multiple system atrophy. <i>J Neurosci Res.</i> 2012 Jun; 90(6):1284-95.
209	Krismer F, Seppi K, Tison F, Sampaio C, Diem-Zangerl A, Peralta C, Yekhlef F, Ghorayeb I, Ory-Magne F, Galitzky M, Bozi M, Scaravilli T, Colosimo C, Geser F, Rascol O, Poewe W, Quinn N, Wenning GK. The unified Multiple System Atrophy rating scale: Intrarater reliability. <i>Movement Disorders</i> 2012; 27(13):1683-1685
210	Frauscher B, Nomura T, Duerr S, Ehrmann L, Gschliesser V, Wenning GK, Wolf E, Inoue Y, Högl B, Poewe W. Investigation of autonomic function in idiopathic REM sleep behavior disorder. <i>J Neurol.</i> 2012 Jun; 259(6):1056-61.
211	Nocker M, Seppi K, Donnemiller E, Virgolini I, Wenning GK, Poewe W, Scherfler C. Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [(123)I]β-CIT SPECT. <i>Eur J Nucl Med Mol Imaging.</i> 2012 Jun; 39(6):1012-20.
212	Stefanova N, Kaufmann WA, Humpel C, Poewe W, Wenning GK. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. <i>Acta Neuropathol.</i> 2012 Jul; 124(1):51-65.
213	Neto SC, Salti A, Puschban Z, Stefanova N, Nat R, Dechant G, Wenning GK. Cell Fate Analysis of Embryonic Ventral Mesencephalic Grafts in the 6-OHDA Model of Parkinson's Disease. <i>PLOS ONE</i> 2012 Nov; 7(11): e50178
214	Scherfler C, Seppi K, Mair KJ, Donnemiller E, Virgolini I, Wenning GK, Poewe W. Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease. <i>Brain</i> 2012; 135(11): 3348-54.
215	Mahlknecht P, Stemberger S, Sprenger F, Rainer J, Hametner E, Kirchmair R, Grabmer C, Scherfler C, Wenning GK, Seppi K, Poewe W, Reindl M. An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. <i>Proteome Science</i> 2012; 10:71.

216	Fuchs P, Wenning GK. Atypischen Parkinsonsyndrome-Neues aus Diagnostik/ Atypical Parkinsonian Disorders – New Aspects in Diagnosis and Therapy. <i>Akt. Neurol</i> 2012; 39:534-545
217	Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn D, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky F, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Shapira A, Schrag A, Seppi K, Taba P, Vidalhet M. EFNS/MDS-ES Recommendations for the diagnosis of Parkinson's Disease. <i>Eur J Neurol</i> 2013 Jan; 20(1): 16-34.
218	Salti A, Nat R, Neto S, Puschban Z, Wenning GK, Dechant G. Expression of early developmental markers predicts the efficiency of embryonic stem cell differentiation into midbrain dopaminergic neurons. <i>Stem Cells Dev</i> . 2013 Feb; 22(3): 397-411
219	Boudes M, Uvin P, Pinto S, Voets T, Fowler CJ, Wenning GK, De Ridder D, Stefanova N. Bladder dysfunction in a transgenic mouse model of multiple system atrophy. <i>Mov. Disord</i> 2013 Mar; 28(3):347-55
220	Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Köllensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, del Sorbo F, Tolosa E, Cardozo A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner WG, Tison F, Poewe W. The Natural History of Multiple System Atrophy: a prospective European cohort study. <i>Lancet Neurology</i> 2013 Mar; 12(3):264-74.
221	Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W, Wenning GK, Stefanova N. Toll-like receptor 4 is required for $\alpha$ -synuclein dependent activation of microglia and astroglia. <i>Glia</i> 2013 Mar; 61(3): 349-60
222	Siri C, Duerr S, Canesi M, Delazer M, Esselink R, Bloem BR, Gurevich T, Balas M, Giladi N, Santacruz P, Marti F, Tolosa E, Rubino A, Meco G, Poewe W, Pezzoli G, Wenning G, Antonini A. A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. <i>J Neural Transm</i> . 2013 Apr; 120(4):613-8
223	Krismer F, Wenning GK, Li Y, Poewe W, Stefanova N. Intact Olfaction in a Mouse Model of Multiple System Atrophy. <i>PLoS ONE</i> 2013 May; 8(5): e64625.
224	Krismer F, Duerr S, Minnerop M, Klockgether T, Stamelou M, Eggert KM, Oertel WH, Schrag A, Poewe W, Wenning GK. MSA-QoL: spezifisches Bewertungsinstrument zur Erfassung der Lebensqualität bei Multisystematrophie. Validierung der deutschsprachigen Übersetzung. <i>Nervenarzt</i> 2013 Jun; 84(6):709-14
225	Kuzdas D, Stemberger S, Gaburro S, Stefanova N, Singewald N, Wenning GK. Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: Experimental evidence. <i>Exp. Neurol.</i> 2013 Sept; 247: 531-536.
226	Wenning GK, Krismer F, Poewe W. Rifampicin for multiple system atrophy. <i>Lancet Neurol</i> 2014 Mar; 13(3): 237-9

227	Stankovic I, Krismer F, Jesic A, Antonini A, Benke T, Brown RG, Burn DJ, Holton JL, Kaufmann H, Ling H, Poewe W, Semnic M, Takeda A, Weintraub D, Wenning GK, on behalf of the Movement Disorders Society MSA (MODIMSA) Study Group. Cognitive impairment in multiple system atrophy. A position statement by the Neuropsychology Task Force of the MDS multiple system atrophy (MODIMSA) Study Group. <i>Mov Disord.</i> 2014 Jun;29(7):857-67
228	Fanciulli A, Strano St, Ndayisaba JP, Goebel G, Gioffre L, Rizzo M, Colosimo C, Caltagirone C, Poewe W, Wenning GK, Pontieri FE. Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. <i>J Neurol.</i> 2014 Jul;261(7):1291-9
229	Gabelia D, Mitterling T, Högl B, Wenning GK, Frauscher B. Do periodic arm movements during sleep exist in healthy subjects? A polysomnographic study. <i>Sleep Med.</i> 2014 Sep;15(9):1150-4.
230	Gatto E, Demey I, Sanguinetti A, Parisi V, Etcheverry JL, Rojas G, Wenning GK. Cognition in a Multiple System Atrophy series of cases from Argentina. <i>Arg Neuropsiquiatr.</i> 2014 Oct;72(10):773-6
231	Fanciulli A, Strano S, Ndayisaba JP, Goebel G, Calcagnini G, Rizzo M, Colosimo C, Caltagirone C, Wenning GK, Pontieri FE. Tilt-table testing predicts pathological

	nocturnal blood pressure profiles in Parkinson's disease and multiple system atrophy. <i>J Neurol.</i> 2014 Jul;261(7):1291-9
232	Poewe W, Seppi K, Fitzer-Attas C, Wenning G, Gilman S, Low P, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. <i>Lancet Neurol</i> 2014 Dec;14:145-52
233	Brugger F, Hepperger C, Hametner EM, Holl AK, Painold A, Schusterschitz C, Bonelli R, Holas C, Wenning GK, Poewe W, Seppi K. Prädiktoren der psychischen und physischen Lebensqualität beim Morbus Huntington. <i>Nervenarzt.</i> 2015 Feb;86(2):167-73
234	Pinter B, Diem-Zangerl A, Wenning GK, Scherfler Ch, Oberaigner W, Seppi K, Poewe W. Mortality in Parkinson's disease: A 38 year follow-up study. <i>Mov Disord.</i> 2015 Feb;30(2):266-9.
235	Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A, Baker M, Finch NC, Yoon H, Kim J, Fujioka S, McLean CA, Ghetti B, Spina S, Cantwell LB, Farlow MR, Grafman J, Huey ED, Ryung Han M, Beecher S, Geller ET, Kretzschmar HA, Roeber S, Gearing M, Juncos JL, Vonsattel JP, Van Deerlin VM, Grossman M, Hurtig HI, Gross RG, Arnold SE, Trojanowski JQ, Lee VM, Wenning GK, White CL, Höglinder GU, Müller U, Devlin B, Golbe LI, Crook J, Parisi JE, Boeve BF, Josephs KA, Wszolek ZK, Uitti RJ, Graff-Radford NR, Litvan I, Younkin SG, Wang LS, Ertekin-Taner N, Rademakers R, Hakonarsen H, Schellenberg GD, Dickson DW. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. <i>Nature Comm</i> 2015 Jun 16;6:7247.
236	Reiter E, Mueller C, Pinter B, Krismer F, Scherfler C, Esterhammer R, Kremser C, Schocke M, Wenning GK, Poewe W, Seppi K. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. <i>Mov Disord.</i> 2015 Jul;30(8):1068-76.

237	Ndayisaba JP, Fanciulli A, Granata R, Duerr S, Hintringer F, Goebel G, Krismer F, Wenning GK. Sex and age effects on cardiovascular autonomic function in healthy adults. <i>Clin Auton Res.</i> 2015 Aug; DOI 10.1007/s10286-015-0310-1
238	Kaindlstorfer C, Sommer P, Georgievska B, Mather RJ, Kugler AR, Poewe W, Wenning GK, Stefanova N. Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications. <i>Neurotox Res.</i> 2015 Oct;28(3):185-94.
239	Ndayisaba JP, Fanciulli A, Granata R, Duerr S, Hintringer F, Goebel G, Krismer F, Wenning GK. Sex and age effects on cardiovascular autonomic function in healthy adults. <i>Clin Auton Res.</i> 2015 Oct;25(5):317-26.
240	Sprenger FS, Stefanova N, Gelpi E, Seppi K, Navarro-Otano J, Offner F, Vilas D, Valldeoriola F, Pont-Sunyer C, Aldecoa I, Gaig C, Gines A, Cuatrecasas M, Högl B, Frauscher B, Iranzo A, Wenning GK, Vogel W, Tolosa E, Poewe W. Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. <i>Neurology.</i> 2015 Nov 17;85(20):1761-8.
241	Kuzdas-Wood D, Irschick R, Theurl M, Malsch P, Mair N, Mantinger C, Wanschitz J, Klimaszewski L, Poewe W, Stefanova N, Wenning GK. Involvement of Peripheral Nerves in the Transgenic PLP-α-Syn Model of Multiple System Atrophy: Extending the Phenotype. <i>PLoS One.</i> 2015 Oct 23;10(10):e0136575
242	Fanciulli A, Goebel G, Metzler B, Sprenger F, Poewe W, Wenning GK, Seppi K. Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease. <i>Mov Disord Clin Pract.</i> 2015 Nov 27;3(2):156-160.

243	Kuzdas-Wood D, Fellner L, Premstaller M, Borm C, Bloem B, Kirik D, Wenning GK, Stefanova N. Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity. <i>BMC Neurosci.</i> 2015 Dec 2;16(1):86.
244	Stefanova N, Kordower JH, Wenning GK. Preface. <i>Mov Disord.</i> 2016 Feb;31(2):151.
245	Scherfler C, Göbel G, Müller C, Nocker M, Wenning GK, Schocke M, Poewe W, Seppi K. Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. <i>Neurology.</i> 2016 Mar 29;86(13):1242-9.
246	Heras-Garvin A, Wenning GK. Is Multiple System Atrophy a New Prion Disorder? <i>Mov Disord.</i> 2016 Mar;31(3):300.
247	Fellner L, Kuzdas-Wood D, Levin J, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N. Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy. <i>Front Neurosci.</i> 2016 Mar 10;10:99.
248	Schafferer S, Khurana R, Refolo V, Venezia S, Sturm E, Piatti P, Hechenberger C, Hackl H, Kessler R, Willi M, Gstir R, Krogsdam A, Lusser A, Poewe W, Wenning GK, Hüttenhofer A, Stefanova N. Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications. <i>PLoS One.</i> 2016 Mar 10;11(3):e0150705.

249	Levin J, Maaß S, Schuberth M, Respondek G, Paul F, Mansmann U, Oertel WH, Lorenzl S, Krismer F, Seppi K, Poewe W, Wenning G; PROMESA study group, Giese A, Bötzl K, Höglinger G. The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. <i>J Neural Transm (Vienna)</i> . 2016 Apr;123(4):439-45.
250	Facciulli A, Göbel G, Ndayisaba JP, Granata R, Duerr S, Strano S, Colosimo C, Poewe W, Pontieri FE, Wenning GK. Supine hypertension in Parkinson's disease and multiple system atrophy. <i>Clin Auton Res</i> . 2016 Apr;26(2):97-105.
251	Ndayisaba JP, Facciulli A, Granata R, Duerr S, Hintringer F, Goebel G, Krismer F, Wenning GK. Erratum to: Sex and age effects on cardiovascular autonomic function in healthy adults. <i>Clin Auton Res</i> . 2016 Apr;26(2):169-70.
252	A. Pavy-Le Traon A, Piedvache A, Perez-Lloret S, Calandra-Buonaura G, Cochen De Cock V, Colosimo C, Cortelli P, Debs R, Duerr S, Facciulli A, Foubert-Samier A, Gerdelaat A, Granata R, Gurevich T, Krismer F, Poewe W, Tison F, Tranchant C, Rascol O, Wenning GK, Meissner G. New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. <i>J Neurol Neurosurg Psychiatry</i> . 2016 May;87(5):554-61.
253	Reiter E, Heim B, Scherfler C, Müller C, Nocker M, Ndayisaba J-P, Loescher W, Seppi K, Lees AJ, Warner T, Poewe W, Wenning GK, Djamshidian A. Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes. <i>Mov disord clin practice</i> , 2016 Jul/Aug;3(4):382-88.
254	Sailer A, Scholz SW, Nalls MA, Schulte C, Federoff M, Price TR, Lees A, Ross OA, Dickson DW, Mok K, Mencacci NE, Schottlaender L, Chelban V, Ling H, O'Sullivan SS, Wood NW, Traynor BJ, Ferrucci L, Federoff HJ, Mhyre TR, Morris HR, Deuschl G, Quinn N, Widner H, Albanese A, Infante J, Bhatia KP, Poewe W, Oertel W, Höglinger GU, Wüllner U, Goldwurm S, Pellecchia MT, Ferreira J, Tolosa E, Bloem BR, Rascol O, Meissner WG, Hardy JA, Revesz T, Holton JL, Gasser T, Wenning GK, Singleton AB, Houlden H; European Multiple System Atrophy Study Group and the UK Multiple System Atrophy Study Group. A genome-wide association study in multiple system atrophy. <i>Neurology</i> . 2016 Oct 11;87(15):1591-1598.
255	Sturm E, Fellner L, Krismer F, Poewe L, Wenning GK, Stefanova N. Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. <i>Neurotherapeutics</i> , 2016 Oct;13(4):871-879.
256	Krismer F, Seppi K, Wenning GK, Abler V, Papapetropoulos S, Poewe W. Minimally clinically important decline in the parkinsonian variant of multiple system atrophy <i>Movement Disorders</i> , 2016 Oct;31(10):1577-1581.
257	Levin J, Maaß S, Schuberth M, Respondek G, Paul F, Mansmann U, Oertel WH, Lorenzl S, Krismer F, Seppi K, Poewe W, Wenning G, Berg D, Claßen J, Ebersbach G, Eggert K, Kassubek J, Lipp A, Löhle M, Mollenhauer B, Münchau A, Südmeyer M, Blankenstein C, Eberhardt C, Ertl-Wagner B, Heise H, Ricard I; PROMESA study group, Giese A, Bötzl K, Höglinger G. Erratum to: The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. <i>J Neural Transm (Vienna)</i> . 2016 Nov;123(11):1357-1358.

258	Nocker M, Seppi K, Boesch S, Donnemiller E, Virgolini I, Wenning GK, Poewe W, Scherfler C. Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy. <i>Mov Disord Clin Pract.</i> 2016 Nov 2;4(3):389-396.
259	Härtner L, Keil TWM, Kreuzer M, Fritz EM, Wenning GK, Stefanova N, Fenzl T. Distinct parameters in the EEG of the PLP α-SYN mouse model for Multiple System Atrophy establish predictive validity for drug screenings. <i>Frontiers in behavioral Neuroscience,</i> 2017 Jan 10;10:252
260	Fiorenzato E, Weis L, Seppi K, Onofrj M, Cortelli P, Zanigni S, Tonon C, Kaufmann H, Shepherd TM, Poewe W, Krismer F, Wenning G, Antonini A, Biundo R; Movement Disorders Society MSA (MODIMSA) Neuropsychology and Imaging Study Groups. Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>J Neural Transm (Vienna).</i> 2017 Mar;124(3):293-302.
261	Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: The movement disordersociety criteria. <i>Mov Disord.</i> 2017 Jun;32(6):853-864.
262	Fanciulli A, Stefanova N, Scherfler C, Moser P, Seppi K, Gizewski E, Boesch S, Poewe W, Wenning GK. Very late-onset pure autonomic failure. <i>Movement disorders,</i> 2017 Jul;32(7):1106-1108
263	Venezia S, Refolo V, Polissidis A, Stefanis L, Wenning GK, Stefanova N. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy. <i>Mol Neurodegener.</i> 2017 Jul 4;12(1):52.
264	Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group. <i>Mov Disord.</i> 2017 Jul;32(7):995-1005.

265	Hensman Moss DJ, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ. Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurol.</i> 2017 Sep;16(9):701-711.
266	Bajaj S, Krismer F, Palma J-A, Wenning GK, Kaufmann H, Poewe W, Seppi K. Diffusion-Weighted MRI discriminates Parkinson's Disease from the Parkinsonian Variant of Multiple System Atrophy: A Meta-analysis. <i>PLoS One</i> 2017 Dec 29;12(12):e0189897

267	Refolo V, Bez F, Polissidis A, Kuzdas-Wood D, Sturm E, Kamaratou M, Poewe W, Stefanis L, Angela Cenci M, Romero-Ramos M, Wenning GK, Stefanova N. Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. <i>Acta Neuropathol Commun.</i> 2018 Jan 3;6(1):2.
268	Wenning G, Trojanowski JQ, Kaufmann H, Wisniewski T, Rocca WA, Low PA. Is multiple system atrophy an infectious disease? <i>Ann Neurol.</i> 2018 Jan; 83(1):10-12.
269	Mangesius S, Hussl A, Krismer F, Mahlknecht P, Reiter E, Tagwercher S, Djamshidian A, Schocke M, Esterhammer R, Wenning G, Müller C, Scherfler C, Gizewski ER, Poewe W, Seppi K. MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. <i>Parkinsonism Relat Disord.</i> 2018 Jan;46:47-55.
270	Pavy-Le Traon A, Piedvache A, Perez-Lloret S, Calandra-Buonaura G, Cochen De Cock V, Colosimo C, Cortelli P, Debs R, Duerr S, Fanciulli A, Gerdelat-Mas A, Gurevich T, Tison F, Tranchant C, Wenning GK, Rascol O, Meissner WG. Delayed orthostatic hypotension: new insights into autonomic failure of Multiple System Atrophy. <i>J Neurol Neurosurg Psychiatry, submitted</i>
271	Kaindlstorfer C, Jellinger KA, Eschlböck S, Stefanova N, Weiss G, Wenning GK. The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint. <i>J Alzheimers Dis.</i> 2018;61(4):1253-1273.
272	Seki M, Seppi K, Mueller C, Potrusil T, Goebel G, Reiter E, Nocker M, Steiger R, Wildauer M, Gizewski ER, Wenning GK, Poewe W, Scherfler C. Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. <i>Parkinsonism Relat Disord.</i> 2018 Apr;49:81-87.
273	Tuovinen N, Seppi K, de Pasquale F, Müller C, Nocker M, Schocke M, Gizewski ER, Kremser C, Wenning GK, Poewe W, Djamshidian A, Scherfler C, Seki M. The reorganization of functional architecture in the early-stages of Parkinson's disease. <i>Parkinsonism Relat Disord.</i> 2018 May;50:61-68.
274	Fellner L, Buchinger E, Brueck D, Irschick R, Wenning GK, Stefanova N. Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived αsynuclein in oligodendroglia: implications for MSA pathogenesis. <i>BMC Neurosci.</i> 2018 May 21;19(1):32.
275	Indelicato E, Fanciulli A, Ndayisaba JP, Nachbauer W, Granata R, Wanschitz J, Wagner M, Gizewski ER, Poewe W, Wenning GK, Boesch S. Autonomic function testing in spinocerebellar ataxia type 2. <i>Clin Auton Res.</i> 2018 Jun;28(3):341-346.
276	Stefani A, Heidbreder A, Brandauer E, Guaita M, Neier LM, Mitterling T, Santamaria J, Iranzo A, Videncovic A, Trenkwalder C, Sixel-Döring F, Wenning GK, Chade A, Poewe W, Gershanik OS, Högl B. Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy. <i>Sleep.</i> 2018 Jun 1;41(6).
277	Struhal W, Thijs RD, Pavy-Le Traon A, Wenning G, Senard JM. In memoriam: Sir Roger Bannister 1929-2018. <i>Clin Auton Res.</i> 2018 Jun;28(3):351.

278	Raccagni C, Gaßner H, Eschlboeck S, Boesch S, Krismer F, Seppi K, Poewe W, Eskofier BM, Winkler J, Wenning G, Klucken J. Sensor-based gait analysis in atypical parkinsonian disorders. <i>Brain Behav.</i> 2018 Jun;8(6):e00977.
-----	---

279	Borm CDJM, Krismer F, Wenning GK, Seppi K, Poewe W, Pellecchia MT, Barone P, Johnsen EL, Østergaard K, Gurevich T, Djaldetti R, Sambati L, Cortelli P, Petrović I, Kostić VS, Brožová H, Růžička E, Marti MJ, Tolosa E, Canesi M, Post B, Nonnekes J, Bloem BR; European MSA Study Group (EMSA-SG). Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism Relat Disord.</i> 2018 Jun 8. pii: S1353-8020(18)30274-8.
280	Kallab M, Herrera-Vaquero M, Johannesson M, Eriksson F, Sigvardson J, Poewe W, Wenning GK, Nordström E, Stefanova N. Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy. <i>Front Neurosci.</i> 2018 Jul 4;12:452.
281	McNulty P, Pilcher R, Ramesh R, Necuiniate R, Hughes A, Farewell D, Holmans P, Jones L; REGISTRY Investigators of the European Huntington's Disease Network. Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study. <i>J Huntingtons Dis.</i> 2018;7(3):209-222.
282	Krismer F, Seppi K, Wenning GK, Papapetropoulos S, Abler V, Goebel G, Schocke M, Poewe W. Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. <i>Parkinsonism Relat Disord.</i> 2018 Aug 7. pii: S1353-8020(18)30334-1.
283	Peball M, Mahlknecht P, Werkmann M, Marini K, Murr F, Herzmann H, Stockner H, de Marzi R, Heim B, Djamshidian A, Willeit P, Willeit J, Kiechl S, Valent D, Krismer F, Wenning GK, Nocker M, Mair K, Poewe W, Seppi K. Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson's Disease: A Cross-Sectional Study. <i>Gerontology.</i> 2018 Sep 10;1-13.
284	Mueller C, Hussl A, Krismer F, Heim B, Mahlknecht P, Nocker M, Scherfler C, Mair K, Esterhammer R, Schocke M, Wenning GK, Poewe W, Seppi K. The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. <i>Parkinsonism Relat Disord.</i> 2018 Sep;54:90-94.
285	Indelicato E, Fanciulli A, Ndayisaba JP, Nachbauer W, Eigentler A, Granata R, Wanschitz J, Poewe W, Wenning GK, Boesch S. Autonomic function testing in Friedreich's ataxia. <i>J Neurol.</i> 2018 Sep;265(9):2015-2022.
286	Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N. Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. <i>Mov Disord.</i> 2018 Nov 19.
287	Oosterloo M, Bijlsma EK, van Kuijk SM, Minkels F, de Die-Smulders CE; REGISTRY Investigators of the European Huntington's Disease Network; Registry Steering committee; Language coordinators; EHDN's associate site in Singapore. Clinical and genetic characteristics of late-onset Huntington's disease. <i>Parkinsonism Relat Disord.</i> 2018 Nov 29. pii: S1353-8020(18)30490-5.
288	Indelicato E, Nachbauer W, Fauth C, Krabichler B, Schossig A, Eigentler A, Dichtl W, Wenning G, Wagner M, Fanciulli A, Janecke A, Boesch S. SYNE1-ataxia: Novel genotypic and phenotypic findings. <i>Parkinsonism Relat Disord.</i> 2018 Dec 11. pii: S1353-8020(18)30535-2. doi: 10.1016/j.parkreldis.2018.12.007.

289	Gaßner H, Raccagni C, Eskofier BM, Klucken J, Wenning GK. The Diagnostic Scope of Sensor-Based Gait Analysis in Atypical Parkinsonism: Further Observations. <i>Front Neurol.</i> 2019 Jan 22;10:5. doi: 10.3389/fneur.2019.00005. eCollection 2019.
290	Krismer F, Seppi K, Göbel G, Steiger R, Zucal I, Boesch S, Gizewski ER, Wenning GK, Poewe W, Scherfler C. Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. <i>Mov Disord.</i> 2019 Jul;34(7):1041-1048. doi: 10.1002/mds.27669. Epub 2019 Mar 28..
291	van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglunger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. <i>Alzheimers Dement (Amst).</i> 2019 Apr 2;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec.
292	Stankovic I, Quinn N, Vignatelli L, Antonini A, Berg D, Coon E, Cortelli P, Fanciulli A, Ferreira JJ, Freeman R, Halliday G, Höglunger GU, Iodice V, Kaufmann H, Klockgether T, Kostic V, Krismer F, Lang A, Levin J, Low P, Mathias C, Meissner WG, Kaufmann LN, Palma JA, Panicker JN, Pellecchia MT, Sakakibara R, Schmahmann J, Scholz SW, Singer W, Stamelou M, Tolosa E, Tsuji S, Seppi K, Poewe W, Wenning GK; Movement Disorder Society Multiple System Atrophy Study Group. A critique of the second consensus criteria for multiple system atrophy. <i>Mov Disord.</i> 2019 Jul;34(7):975-984. doi: 10.1002/mds.27701. Epub 2019 Apr 29.
293	Holzknecht E, Hochleitner M, Wenning GK, Högl B, Stefani A. Gender differences in clinical, laboratory and polysomnographic features of restless legs syndrome. <i>J Sleep Res.</i> 2019 Jun 4:e12875. doi: 10.1111/jsr.12875.
294	Kaindlstorfer C, Stefanova N, Garcia J, Krismer F, Döbrössy M, Göbel G, Jellinger K, Granata R, Wenning GK. L-dopa response pattern in a rat model of mild striatonigral degeneration. <i>PLoS One.</i> 2019 Jun 10;14(6):e0218130. doi: 10.1371/journal.pone.0218130. eCollection 2019.
295	Fanciulli A, Campese N, Wenning GK. The Schellong test: detecting orthostatic blood pressure and heart rate changes in German-speaking countries. <i>Clin Auton Res.</i> 2019 Aug;29(4):363-366. doi: 10.1007/s10286-019-00619-7. Epub 2019 Jul 4.
296	Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Böttzel K, Ertl-Wagner B, Huppertz HJ, Ricard I, Höglunger GU; PROMESA Study Group. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurol.</i> 2019 Aug;18(8):724-735. doi: 10.1016/S1474-4422(19)30141-3. Epub 2019 Jul 2.
297	Herrera-Vaquero M, Bouquio D, Kallab M, Biggs K, Nair G, Ochoa J, Heras-Garvin A, Heid C, Hadrovic I, Poewe W, Wenning GK, Klärner FG, Schrader T, Bitan G, Stefanova N. The molecular tweezer CLR01 reduces aggregated, pathologic, and seedingcompetent α-synuclein in experimental multiple system atrophy. <i>Biochim</i>

	<p><u><a href="#">Biophys Acta Mol Basis Dis. 2019 Nov 1;1865(11):165513. doi: 10.1016/j.bbadi.2019.07.007. Epub 2019 Jul 16.</a></u></p>
298	Seki M, Seppi K, Mueller C, Potrusil T, Goebel G, Reiter E, Nocker M, Kremser C, Wildauer M, Schocke M, Gizewski ER, Wenning GK, Poewe W, Scherfler C. Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. <u><a href="#">J Parkinsons Dis. 2019;9(4):681-691. doi: 10.3233/JPD-181568.</a></u>
299	Respondek G, Grimm MJ, Piot I, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Roeber S, Giese A, Grossman M, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A,
	Rajput A, van Swieten JC, Troakes C, Höglunger GU; Movement Disorder SocietyEndorsed Progressive Supranuclear Palsy Study Group. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. <u><a href="#">Mov Disord. 2020 Jan;35(1):171-176. doi: 10.1002/mds.27872. Epub 2019 Sep 30.</a></u>
300	Raccagni C, Goebel G, Gaßner H, Granata R, Ndayisaba JP, Seebacher B, Schoenherr G, Mitterhuber J, Hendriks P, Kaindlstorfer C, Eschlboeck S, Fanciulli A, Krismer F, Seppi K, Poewe W, Bloem BR, Klucken J, Wenning GK. Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. <u><a href="#">Parkinsonism Relat Disord. 2019 Oct; 67:60-65. doi: 10.1016/j.parkreldis.2019.09.026. Epub 2019 Sep 24.</a></u>
301	Fanciulli A, Goebel G, Lazzeri G, Granata R, Kiss G, Strano S, Colosimo C, Pontieri FE, Kaufmann H, Seppi K, Poewe W, Wenning GK. Urinary retention discriminates multiple system atrophy from Parkinson's disease. <u><a href="#">Mov Disord. 2019 Dec;34(12):1926-1928. doi: 10.1002/mds.27917. Epub 2019 Nov 11.</a></u>
302	Indelicato E, Fanciulli A, Nachbauer W, Eigenthaler A, Amprosi M, Ndayisaba JP, Granata R, Wenning G, Boesch S. Cardiovascular autonomic testing in the work-up of cerebellar ataxia: insight from an observational single center study. <u><a href="#">J Neurol. 2019 Dec 31. doi: 10.1007/s00415-019-09684-4. [Epub ahead of print]</a></u>
303	Stefani A, Ferini-Strambi L, Postuma RB, Iranzo A, Videnovic A, Högl B, Wenning GK. Olfaction in patients with isolated REM sleep behavior disorder who eventually develop multiple system atrophy. <u><a href="#">Sleep. 2020 Jan 10. pii: zsz303. doi: 10.1093/sleep/zsz303. [Epub ahead of print]</a></u>
304	Heras-Garvin A, Refolo V, Reindl M, Wenning GK, Stefanova N. High-salt diet does not boost neuroinflammation and neurodegeneration in a model of α-synucleinopathy. <u><a href="#">J Neuroinflammation. 2020 Jan 24;17(1):35. doi: 10.1186/s12974-020-1714-y.</a></u>
305	Micaela Johanna Glat, Nadia Stefanova, Gregor Karl Wenning, Daniel Offen. Genes to treat excitotoxicity ameliorate the symptoms of the disease in mice models of multiple system atrophy <u><a href="#">J Neural Transm (Vienna) 2020 Feb;127(2):205-212. doi: 10.1007/s00702-020-02158-2. Epub 2020 Feb 17.</a></u>
306	Sabine Eschlböck, Margarete Delazer, Florian Krismer, Thomas Bodner, Alessandra Fanciulli, Beatrice Heim, Antonio Heras Garvin, Christine Kaindlstorfer, Elfriede Karner, Katherina Mair, Christoph Rabensteiner, Cecilia Raccagni, Klaus Seppi, Werner Poewe, Gregor K Wenning Cognition in multiple system atrophy: a single-center cohort study <u><a href="#">Ann Clin Transl Neurol 2020 Feb;7(2):219-228. doi: 10.1002/acn3.50987. Epub 2020 Feb 7.</a></u>

307	Alain Ndayisaba, Gregor K Wenning: Inhibition of the mammalian target of rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophy <u>Clin Auton Res</u> 2020 Feb;30(1):7-8. doi: 10.1007/s10286-019-00662-4. Epub 2020 Jan 9.
308	Bernadette Wimmer, Stephanie Mangesius, Klaus Seppi, Sarah Iglseder, Franziska Di Pauli, Martin Ortler, Elke Gizewski, Werner Poewe, Gregor Karl Wenning. Symptomatic hemiparkinsonism due to extensive middle and posterior fossa arachnoid cyst: case report <u>BMC Neurol</u> 2020 Mar 12;20(1):89 doi: 10.1186/s12883-020-01670-y.
309	Ambra Stefani, Luigi Ferini-Strambi, Ronald B Postuma, Alex Iranzo, Aleksandar Videnovic, Birgit Högl, Gregor K Wenning. Olfaction in patients with isolated REM sleep behavior disorder who eventually develop multiple system atrophy <u>Sleep</u> 2020 Apr 15;43(4): zsz303. doi: 10.1093/sleep/zsz303.
310	Elisabetta Indelicato, Alessandra Fanciulli, Wolfgang Nachbauer, Andreas Eigenthaler, Matthias Amprosi, Jean-Pierre Ndayisaba, Roberta Granata, Gregor Wenning, Sylvia Boesch. Cardiovascular autonomic testing in the work-up of cerebellar ataxia: insight from an observational single center study <u>J Neurol</u> 2020 Apr;267(4):1097-1102. doi: 10.1007/s00415-019-09684-4. Epub 2019 Dec 31.
311	Alessandra Fanciulli, Gregor K Wenning: Which Autonomic Features Distinguish Multiple System Atrophy and When <u>Mov Disord</u> 2020 May;35(5):902-903.doi: 10.1002/mds.28050.
312	Evi Holzknecht, Margarethe Hochleitner, Gregor K Wenning, Birgit Högl, Ambra Stefani Gender differences in clinical, laboratory and polysomnographic features of restless legs syndrome <u>J Sleep Res</u> 2020 Jun;29(3):e12875. doi: 10.1111/jsr.12875. Epub 2019 Jun 4.
313	Fabian Leys, Alessandra Fanciulli, Jean-Pierre Ndayisaba, Roberta Granata, Walter Struhal, Gregor K Wenning: Cardiovascular autonomic function testing in multiple system atrophy and Parkinson's disease: an expert-based blinded evaluation <u>Clin Auton Res</u> 2020 Jun;30(3):255-263. doi: 10.1007/s10286-020-00691-4. Epub 2020 May 15.
314	F Geser, L Fellner, J Haybaeck, G K Wenning. Development of neurodegeneration in amyotrophic lateral sclerosis: from up or down? <u>J Neural Transm (Vienna)</u> 2020 Aug;127(8):1097-1105.
315	Gregor K Wenning; Parkinsonism and dysautonomia: Multiple system atrophy? <u>Parkinsonism Relat Disord</u> 2020 Aug; 77: 150-151.doi: 10.1016/j.parkreldis.2019.08.006. Epub 2019 Aug 19.
316	Cecilia Raccagni, Victoria Sidoroff, Georg Goebel, Roberta Granata, Fabian Leys, Jochen Klucken, Bjoern Eskofier, Robert Richer, Klaus Seppi, Gregor K Wenning, Alessandra Fanciulli: The footprint of orthostatic hypotension in parkinsonian syndromes; <u>Parkinsonism Relat Disord</u> 2020 Aug; 77:107-109. doi: 10.1016/j.parkreldis.2020.06.029. Epub 2020 Jul 2.
317	Wolfgang Mitterer, Lukas Lanser, Margot Fodor, Johannes Weiss, Sonja W Scholz, Gregor K Wenning. Conjugal multiple system atrophy: Rethinking numbers of probability; <u>Parkinsonism Relat Disord</u> 2020 Aug; 77:176-177. doi: 10.1016/j.parkreldis.2020.08.005. Epub 2020 Aug 16.
318	Fabian Leys, Cecilia Raccagni, Victoria Sidoroff, Klaus Seppi, Alessandra Fanciulli, Gregor K Wenning: Effects of self-administered cannabidiol in a patient with multiple system atrophy. <u>Clin Auton Res</u> 2020 Aug;30(4):355-356. doi: 10.1007/s10286-020-00704-2. Epub 2020 Jun 19.

319	Lisa Fellner, Kurt A Jellinger, Gregor K Wenning, Johannes Haybaeck; Commentary: Discriminating $\alpha$ -synuclein strains in parkinson's disease and multiple system atrophy <i>Front Neurosci</i> 2020 Aug 25; 14:802. doi: 10.3389/fnins.2020.00802. eCollection 2020.
320	Stephanie Mangesius, Sara Mariotto, Sergio Ferrari, Sergiy Pereverzyev Jr, Hannes Lerchner, Lukas Haider, Elke R Gizewski, Gregor Wenning, Klaus Seppi, Markus Reindl, Werner Poewe; Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers; <i>Parkinsonism Relat Disord</i> 2020 Aug; 77:57-63. doi: 10.1016/j.parkreldis.2020.05.033. Epub 2020 Jun 22.
321	Alessandra Fanciulli, Katharina Kerer, Fabian Leys, Klaus Seppi, Horacio Kaufmann, Lucy Norcliffe-Kaufmann, Gregor K Wenning; Validation of the Neurogenic Orthostatic Hypotension Ratio with Active Standing; <i>Ann Neurol</i> 2020 Sep;88(3): 643-645.doi: 10.1002/ana.25834. Epub 2020 Jul 14.
322	M Herrera-Vaquero, A Heras-Garvin, F Krismer, R Deleanu, S Boesch, G K Wenning, N Stefanova; Signs of early cellular dysfunction in multiple system atrophy; <i>Neuropathol Appl Neurobiol</i> 2020 Sep 6.doi: 10.1111/nan.12661.
323	Maria Teresa Pellecchia, Iva Stankovic, Alessandra Fanciulli, Florian Krismer, Wassilios G Meissner, Jose-Alberto Palma, Jalesh N Panicker, Klaus Seppi, Gregor K Wenning, Members of the Movement Disorder Society Multiple System Atrophy Study Group; Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group <i>Mov Disord Clin Pract</i> 2020 Sep 3;7(7):750-762. doi: 10.1002/mdc3.13052. eCollection 2020 Oct.
324	Philipp Mahlknecht, Marina Peball, Katherina Mair, Mario Werkmann, Michael Nocker, Elisabeth Wolf, Wilhelm Eisner, Sweta Bajaj, Sebastian Quirbach, Cecilia Peralta, Sabine Eschlböck, Gregor K Wenning, Peter Willeit, Klaus Seppi, Werner Poewe; Has Deep Brain Stimulation Changed the Very Long-Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study; <i>Mov Disord Clin Pract</i> 2020 Sep 21;7(7):782-787. doi: 10.1002/mdc3.13039. eCollection 2020 Oct.
325	Florian Krismer, Vincent Beliveau, Klaus Seppi, Christoph Mueller, Georg Goebel, Elke R Gizewski, Gregor K Wenning, Werner Poewe, Christoph Scherfler. Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease; <i>Mov Disord</i> 2020 Sep 16 doi: 10.1002/mds.28281.
326	Miguel Lemos, Serena Venezia, Violetta Refolo, Antonio Heras-Garvin, Sabine Schmidhuber, Armin Giese, Andrei Leonov, Sergey Ryazanov, Christian Griesinger, Gergana Galabova, Guenther Staffler, Gregor Karl Wenning, Nadia Stefanova; Affiliations expand; Targeting $\alpha$ -synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance <i>Transl Neurodegener</i> 2020 Sep 24;9(1):38. doi: 10.1186/s40035-020-00217-y.
327	Marina Peball, Florian Krismer, Hans-Günther Knaus, Atbin Djamshidian, Mario Werkmann, Federico Carbone, Philipp Ellmerer, Beatrice Heim, Kathrin Marini, Dora Valent, Georg Goebel, Hanno Ulmer, Heike Stockner, Gregor K Wenning, Raphaela Stolz, Kurt Krejcy, Werner Poewe, Klaus Seppi, Collaborators of the Parkinson's Disease Working Group Innsbruck Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone; <i>Ann Neurol</i> 2020 Oct;88(4):712-722. doi: 10.1002/ana.25864. Epub 2020 Aug 31.
328	Alexey A Shadrin, Sören Mucha, David Ellinghaus, Mary B Makarios, Cornelis Blauwendraat, Ashwin A K Sreelatha, Antonio Heras-Garvin, Jinhui Ding, Monia

	Hammer, Alexandra Foubert-Samier, Wassilios G Meissner, Olivier Rascol, Anne Pavy-Le Traon, Oleksandr Frei, Kevin S O'Connell, Shahram Bahrami, Stefan Schreiber, Wolfgang Lieb, Martina Müller-Nurasyid, Ulf Schminke, Georg Homuth, Carsten O Schmidt, Markus M Nöthen, Per Hoffmann, Christian Gieger, Gregor Wenning, European Multiple System Atrophy Study Group; J Raphael Gibbs, Andre Franke, John Hardy, Nadia Stefanova, Thomas Gasser, Andrew Singleton, Henry Houlden, Sonja W Scholz, Ole A Andreassen, Manu Sharma: Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease; <a href="#">Mov Disord 2020 Oct 27</a> .doi: 10.1002/mds.28338.
329	Cecilia Raccagni, Jorik Nonnekes, Bastiaan R Bloem, Marina Peball, Christian Boehme, Klaus Seppi, Gregor K Wenning Gait and postural disorders in parkinsonism: a clinical approach; <a href="#">J Neurol 2020 Nov;267(11):3169-3176</a> . doi: 10.1007/s00415-019-09382-1. Epub 2019 May 22.
330	Alessandra Fanciulli, Nicole Campese, Georg Goebel, Jean Pierre Ndayisaba, Sabine Eschlboeck, Christine Kandlstorfer, Cecilia Raccagni, Roberta Granata, Ubaldo Bonuccelli, Roberto Ceravolo, Klaus Seppi, Werner Poewe, Gregor K Wenning Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease <a href="#">Neurology 2020 Nov 24;95(21):e2854-e2865</a> . doi: 10.1212/WNL.0000000000010749. Epub 2020 Sep 16.
331	Antonio Heras-Garvin, Christoph Danninger, Sabine Eschlböck, Janice L Holton, Gregor K Wenning, Nadia Stefanova: Signs of Chronic Hypoxia Suggest a Novel Pathophysiological Event in α-Synucleinopathies <a href="#">Mov Disord 2020 Dec;35(12):2333-2338</a> . doi: 10.1002/mds.28229. Epub 2020 Sep 3.
332	Victoria Sidoroff, Cecilia Raccagni, Christine Kandlstorfer, Sabine Eschlboeck, Alessandra Fanciulli, Roberta Granata, Björn Eskofier, Klaus Seppi, Werner Poewe, Johann Willeit, Stefan Kiechl, Philipp Mahlknecht, Heike Stockner, Kathrin Marini, Oliver Schorr, Gregorio Rungger, Jochen Klucken, Gregor Wenning, Heiko Gaßner. Characterization of gait variability in multiple system atrophy and Parkinson's disease <a href="#">J Neurol 2020 Dec 31</a> doi: 10.1007/s00415-020-10355-y.
333	William P Cheshire, Roy Freeman, Christopher H Gibbons, Pietro Cortelli, Gregor K Wenning, Max J Hilz, Judith M Spies, Axel Lipp, Paola Sandroni, Naoki Wada, Akiko Mano, Hyun Ah Kim, Kurt Kimpinski, Valeria Iodice, Juan Idiáquez, Pariwat Thaisetthawatkul, Elizabeth A Coon, Phillip A Low, Wolfgang Singer: Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology <a href="#">Clin Neurophysiol 2021 Dec 22; S1388-2457(20)30585-X</a> . doi: 10.1016/j.clinph.2020.11.024.
334	Cheshire WP, Freeman R, Gibbons CH, Cortelli P, Wenning GK, Hilz MJ, Spies JM, Lipp A, Sandroni P, Wada N, Mano A, Ah Kim H, Kimpinski K, Iodice V, Idáquez J, Thaisetthawatkul P, Coon EA, Low PA, Singer W. Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. <a href="#">Clin. Neurophysiol.2021 Feb; 132 (2): 666-682</a> . Doi: 10.1016/j.clinph.2020.11.024. Epub 2020 Dec 22. PMID: 33419664
335	Shadrin AA, Mucha S, Ellinghaus D, Makarrious MB, Blauwendraat C, Sreelatha AAK, Heras Garvin A, Ding J, Hammer M, Foubert-Samier A, Meissner WG, Rascol O, Pavy-Le Traon A, Frei O, O'Connell KS, Bahrami S, Schreiber S, Lieb W, Müller-Nurasyid M, Schminke U, Homuth G, Schmidt CO, Nöthen MM, Hoffmann P, Gieger C, Wenning G;

	European Multiple System Atrophy Study Group, Gibbs JR, Franke A, Hardy J, Stefanova N, Gasser T, Singleton A, Houlden H, Scholz SW, Andreassen OA, Sharma; Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease. <i>Mov Disord.</i> 2021 Feb; 36(2): 449-459. Doi: 10.1002/mds.28338. Epub 2020 Oct 27. PMID: 33107653
336	Heim B, Magnesius S, Krismer F, Wenning GK, Hussl A, Scherfler C, Gizwski ER, Schocke M, Esterhammer R, Quattrone A, Poewe W, Seppi K. Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. <i>Parkinsonism Relat Disord.</i> 2021 Jan; 82: 87-91. Doi 10.1016/j.parkreldis.2020.11.019. Epub 2020 Nov.24. PMID: 33271461
337	Herrera-Vaquero M, Heras-Garvin A, Krismer F, Deleanu R, Boesch S, Wenning GK, Stefanova N. Signs of early cellular dysfunction in multiple system atrophy. <i>Neuropathol Appl Neurobiol.</i> 2021 Feb; 47 (2): 268-282. Doi:10.1111/nan.12661. Epub 2020 Sep 17. PMID: 32892415
338	Sidoroff V, Raccagni C, Kaindlstorfer C, Eschlboeck S, Fanciulli A, Granata R, Eskofier B, Seppi K, Poewe W, Willeit J, Kiechl S, Mahlknecht P, Stockner H, Marini K, Schorr O, Rungger G, Klucken J, Wenning G, Gaßner H. Characterization of gait variability in multiple system atrophy and Parkinson's disease. <i>J Neurol.</i> 2021 May; 268(5): 1770-1779. Doi: 10.1007/s00415-020-10355-y. Epub 2020 Dec 31. PMID: 33382439
339	Krismer F, Beliveau V, Seppi K, Mueller C, Goebel G, Glzewski ER, Wenning GK, Poewe W, Scherfler C. Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. <i>Mov. Disord.</i> 2021 Jan; 36 (1): 241-245. Doi: 10.1002/mds.28281. Epub 2020 Sep 16. PMID: 32935402
340	Geser F, Jellinger KA, Fellner L, Wenning GK, Yilmazer-Hanke D, Haybaeck J.J; Emergent creativity in frontotemporal dementia. <i>J.J. Neural Transm. (Vienna).</i> 2021 Mar; 128 (3): 279-293. Doi: 10.1007/s00702-021-02325-z. Epub 2021 Mar 12. PMID: 33709181
341	Palma JA, Vernetti PM, Perez MA, Krismer F, Seppi K, Fanciulli A, Singer W, Low P, Biaggioni I, Norcliffe-Kaufmann L, Pellechia MT, Marti MJ, Kim HJ, Merello M, Stankovic I, Poewe W, Betensky R, Wenning G, Kaufmann H. Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. <i>Clin Auton Res.</i> 2021 April;31 (2): 157-164. Doi: 10.1007/s10286-021-00782-w. Epub 2021 Feb 7. PMID: 33554315
342	Stankovic I, Fanciulli A, Kostic VS, Krismer F, Meissner WG, Palma JA, Panicker JN, Seppi K, Wenning GK; MoDiMSA Study Group. Laboratory-Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. <i>Mov. Disord Clin Pract.</i> 2021 Mar 10;8 (3): 322-340. Doi: 10.1002/mdc3.13158. eCollection 2021
343	Calandra-Buonaura G, Alfonsi E, Vignatelli L, Benarroch EE, Giannini G, Iranzo A, Low PA, Martinelli P, Provini F, Quinn N, Tolosa E, Wenning GK, Abbruzzese G, Bower P, Antonini A, Bhatia KP, Bonavita J, Pellechia MT, Pizzorni N, Tison F, Ghorayeb I, Meissner WG, Ozawa T, Pachetti C, Pozzi NG, Vicini C, Schindler A, Cortelli P, Kaufmann H. Dysphagia in multiple system atrophy consensus Statement on diagnosis, prognosis and treatment. <i>Parkinsonism Relat Disord.</i> 2021 May; 86: 124-132. doi: 10.1016/j.parkreldis.2021.03.027. Epub 2021 Mar 30. PMID: 33839029
344	Thijs RD, Brignole M, Falup-Pecurariu C, Fanciulli A, Freeman R, Guaraldi P, Jordan J, Habek M, Hilz M, Traon AP, Stankovic I, Struhal W, Sutton R, Wenning G, Van Dijk JG. Recommendations for tilt table testing and other provocative cardiovascular

	autonomic tests in conditions that may cause transient loss of consciousness: consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). <a href="#">Clin Auton Res. 2021 Jun;31 (3): 369-384. doi: 10.1007/s10286-020-00738-6. Epub 2021 Mar 19. PMID: 33740206</a>
345	Grötsch MT, Respondek G, Colosimo C, Compta Y, Corvol JC, Ferreira J, Huber MK, Klietz M, Krey LFM, Levin J, Jecmenica-Lukic M, Macias-Garcia D, Meissner WG, Mir P, Morris H, Nilsson C, Rowe JB, Seppi K, Stamelou M, van Swieten JC, Wenning G, DelSer T, Golbe LI, Höglinder GU; Desripe PSP Study Group, the ProPSP Study Group and the Movement Disorder Society-Endorsed PSP Study Group. A Modified Preogressive Supranuclear Palsy Rating Scale. <a href="#">Mov. Disord. 2021 May; 36 (5): 1203-1215. doi: 10.1002/mds.28470. Epub 2021 Jan 29. PMID: 33513292</a>
346	Heras Garvin A, Refolo V, Schmidt C, Malfertheiner K, Wenning GK, Bradbury M, Stamler D, Stefanova N. ATH434 Reduces a-Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy. <a href="#">Mov. Disord. 2021 Jul 8. doi: 10.1002/mds.28714. Online ahead of print. PMID: 34236731</a>
347	Beatrice Heim, Stephanie Mangesius, Florian Krismer, Gregor K Wenning, Anna Hussl, Christoph Scherfler, Elke R Gizewski, Michael Schocke, Regina Esterhammer, Andrea Quattrone, Werner Poewe, Klaus Seppi; Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism; <a href="#">Parkinsonism Relat Disord 2021 Jan;82:87-91. doi: 10.1016/j.parkreldis.2020.11.019. Epub 2020 Nov 24.</a>
348	Beliveau V, Krismer F, Skalla E, Schocke MM, Gizewski ER, Wenning GK, Poewe W, Seppi K, Scherfler C. Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. <a href="#">Parkinsonism Relat Disord. 2021 Apr;85: 30-36. doi: 10.1016/j.parkreldis. 2021.02.027. Epub 2021 Mar 3. PMID: 33713904</a>
349	Thijs RD, Brignole M, Falup-Pecurariu C, Fanciulli A, Freeman R, Guaraldi P, Jordan J, Habek M, Hilz M, Pavly-LeTraon A, Stankovic I, Struhal W, Sutton R, Wenning G, van Dijk JG. Recommendations for tilt table testing an other provocative cardiovascular autonomic tests in conditions that may cause transiet loss of consciousness: Consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). <a href="#">Auton Neurosci.2021 Jul;233:102792. doi: 10.1016/j. autneu.2021.102792. Epub 2021 Mar 19. PMID: 33752997</a>
350	Van Dijk, Thijs RD; European Federation of Autonomic Societies (EFAS) Task Force on Tilt Table Testing. Rethinking neurological attitudes towards vasovagal syncope: The European Federation of Autonomic Societies (EFAS) recommendations regarding tilt table testing. <a href="#">Eur J Neurol. 2021 Jun 12. doi: 10.1111/ene.14963. Online ahead of print. PMID: 34117676</a>
351	Chesire WP, Freeman R, Gibbons CH, Cortelli P, Wenning GK, Hilz MJ, Spies JM, Lipp A, Sandroni P, Wada N, Mano T, Kim HA, Kimpinski K, Iodice V, Idiáquez J, Thaisetthawatkul P, Coon EA, Low PA, Singer W. Corrigendum to “Electrodiagnostic assessment of the autonomic nervous system: A consenus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology” (Clin. Neurophysiol. 132(2) (2021) 666-682). <a href="#">Clin Neurophysiol. 2021 May; 132 (5): 1194. doi: 10.1016/j.clinph.2021.02.006. Epub 2021 Mar 6. PMID: 33685802</a>
352	Campese N, Goebel G, Leys F, Ndayisaba JP, Eschlboeck S, Eckhardt C, Raccagni C, Granata R, Ceravolo R, Kiechl S, Seppi K, Poewe W, Wenning GK, Fanciulli A.

	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter? <u><a href="#">Mov. Disord.</a></u> 2021 Aug 23. Doi:10.1002/mds.28768. online ahead of print. PMID: 34423874
353	Wenning GK, Riederer P. Kurt Jellinger, Doyen of international neuropathology. <u><a href="#">J Neural Transm (Vienna)</a></u> . 2021 Aug 22. Doi: 10.1007/s00702-021-02397-x. online ahead of print. PMID: 34420118
354	Campese N, Fanciulli A, Stefanova N, Haybaeck J, Kiechl S, Wenning GK, Neuropathology of multiple system atrophy: Kurt Jellinger's legacy. <u><a href="#">J Neural Transm (Vienna)</a></u> . 2021 Jul 28. Doi: 10.1007/s00702-021-02383-3. Online ahead of Print PMID: 34319460
355	Lemos M, Wenning GK, Stefanova N. Current experimental disease-modifying therapeutics for multiple system atrophy. <u><a href="#">J Neural Transm. (Vienna)</a></u> . 2021 Aug 16. Doi: 10.1007/S00702-021-02406-z online ahead of print. PMID: 34398313

Reviews	
1	Wenning GK, Quinn NP. Multiple system atrophy: recent advances in clinical and pathological definition. <u><a href="#">Current Medical Literature</a></u> . 1992 Dec; 8(4):95-8.
2	Quinn N, Wenning G. Multiple system atrophy. <u><a href="#">Br J Hosp Med</a></u> . 1994 May;51(9):492-4.
3	Wenning GK, Quinn N. Multisystematrophie. <u><a href="#">Akt Neurol</a></u> . 1994;21(4):120-6.
4	Wenning GK, Poewe W. Atypische Parkinson-Syndrome. <u><a href="#">Der Mediziner</a></u> . 1995;12:4-11.
5	Volonte M, Wenning GK. The treatment of Parkinson's disease. <u><a href="#">Postgraduate Doctor Middle East</a></u> . 1995;18:4-10.
6	Wenning GK, Poewe W. Die Therapie des Parkinson-Syndroms in Deutschland und den USA. <u><a href="#">Parkinson im Dialog</a></u> . 1995: 3-11.
7	Tison F, Wenning GK, Daniel SE, Quinn NP. Atrophie multisystématisée avec corps de Lewy. <u><a href="#">Rev Neurol (Paris)</a></u> . 1995 Jun-Jul;151(6-7):398-403.
8	Quinn NP, Wenning GK, Marsden CD. The Shy-Drager syndrome. What did Shy and Drager really describe? <u><a href="#">Arch Neurol</a></u> . 1995 Jul;52(7):656-7.
9	Quinn N, Wenning G. Multiple system atrophy. <u><a href="#">Curr Opin Neurol</a></u> . 1995 Aug;8(4):323-6.
10	Tison F, Wenning GK, Daniel SE, Quinn NP. The pathophysiology of parkinsonism in multiple system atrophy. <u><a href="#">Eur J Neurol</a></u> . 1995 Nov;2(5):435-44.
11	Poewe WH, Wenning GK. The natural history of Parkinson's disease. <u><a href="#">Neurology</a></u> . 1996 Dec;47(6 Suppl 3):S146-152.
12	Wenning GK, Pramstaller PP, Ransmayr G, Poewe W. Atypische Parkinson-Syndrome. <u><a href="#">Nervenarzt</a></u> . 1997 Feb;68(2):102-15.
13	Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. <u><a href="#">Mov Disord</a></u> . 1997 Mar;12(2):133-47.
14	Wenning GK, Granata R. Multiple system atrophy: more on the nature of the beast. <u><a href="#">Neurologia</a></u> . 1998 Mar; 13(3):105-10.
15	Poewe W, Wenning GK. Morbus Parkinson – Goldstandard als Therapie. <u><a href="#">Der Hausarzt</a></u> . 1998;18:24-8.

16	Poewe W, Wenning GK. The natural history of Parkinson's disease. <i>Ann Neurol.</i> 1998 Sep;44(3 Suppl 1):S1-9.
17	Gilman S, Low P, Quinn N, Albanese A, Ben-Shlomo Y, Fowler C, Kaufmann H, Klockgether T, Lang A, Lantos P, Litvan I, Mathias C, Oliver E, Robertson D, Schatz I, Wenning G. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. <i>Clin Auton Res.</i> 1998 Dec;8(6):359-62.
18	Gilman S, Low PA, Quinn NP, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK. Consensus statement on the diagnosis of multiple system atrophy. <i>J Auton Nerv Syst.</i> 1998 Dec;74(2-3):189-92.
19	Wenning GK, Granata R, Puschban Z, Scherfler C, Poewe W. Neural transplantation in animal models of multiple system atrophy: a review. <i>J Neural Transm Suppl.</i> 1999;55:103-13.
20	Seppi K, Puschban Z, Wenning GK, Poewe W. Multisystematrophie (MSA). <i>Der Mediziner.</i> 1999;6:29-33.
21	Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK. Consensus statement on the diagnosis of multiple system atrophy. <i>J Neurol Sci.</i> 1999 Feb;163(1):94-8.
22	Wenning GK, Luginger E, Sailer U, Poewe W, Donnemiller E, Riccabona G. Postoperative parkinsonian tremor in a patient with a frontal meningioma. <i>Mov Disord.</i> 1999 Mar;14(2):366-8.
23	Gilman S, Low P, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang A, Lantos P, Litvan I, Mathias C, Oliver E, Robertson D, Schatz I, Wenning GK. Consensus on the diagnosis of multi-system atrophy. <i>Neurologia.</i> 1999 Nov;14(9):425-8.
24	Stefanova N, Seppi K, Scherfler C, Puschban Z, Wenning GK. Depression in alphasynucleinopathies: prevalence, pathophysiology and treatment. <i>J Neural Transm Suppl.</i> 2000;60:335-43.
25	Wenning GK, Puschban Z, Seppi K, Scherfler C. Aktuelle Aspekte zur Diagnostik und Therapie der Multisystematrophie. <i>Schweiz Arch Neurol Psychiatr.</i> 2000;151(4):150-8.
26	Poewe W, Seppi K, Wenning GK. Morbus Parkinson und andere extrapyramidal Bewegungsstörungen bei geriatrischen Patienten. <i>Klinik - Sonderausgabe Geriatrie.</i> 2000;10(1):22
27	Wenning GK, Tison F, Scherfler C, Puschban Z, Waldner R, Granata R, Ghorayeb I, Poewe W. Towards neurotransplantation in multiple system atrophy: clinical rationale, pathophysiological basis, and preliminary experimental evidence. <i>Cell Transplant.</i> 2000 Mar-Apr;9(2):279-88.
28	Poewe W, Wenning GK. Apomorphine: an underutilized therapy for Parkinson's disease. <i>Mov Disord.</i> 2000 Sep;15(5):789-94.
29	Ransmayr G, Wenning GK, Seppi K, Jellinger K, Poewe W. Demenz mit LewyKörperchen. <i>Nervenarzt.</i> 2000 Dec;71(12):929-35.

30	Wenning GK, Seppi K, Scherfler C, Stefanova N, Puschban Z. Multiple system atrophy. <i>Semin Neurol.</i> 2001;21(1):33-40.
31	Wenning GK, Braune S. Multiple system atrophy: pathophysiology and management. <i>CNS Drugs.</i> 2001;15(11):839-52.
32	Luginger E, Wenning GK, Bösch S, Poewe W. Amantadin bessert L-Dopa induzierte Dyskinesien bei Morbus Parkinson. <i>Psycho.</i> 2001;27(7):389-93.
33	Wenning G. Pergolid. <i>Der Mediziner.</i> 2001;5:13.
34	Müller J, Wenning GK, Wissel J, Poewe W. Intrafamilial heterogeneity of facial hyperkinesias: chance association of tics, cranial dystonia, and Huntington's disease? <i>Mov Disord.</i> 2001 Mar;16(2):370-2.
35	Wenning GK. International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration - Clinical Aspects of Multiple System Atrophy. <i>Mov Disord.</i> 2001 Mar;16(2):390.
36	Wenning GK, Seppi K. Diagnostik und Therapie der Multisystematrophie. <i>Schweiz Rundsch Med Prax.</i> 2001 Jun;90(23):1035-40.
37	Wenning GK. Atypische Parkinson-Syndrome – Frühzeitige Verdachtsdiagnose wichtig. <i>Der Neurologe &amp; Psychiater.</i> 2001;11:26-33.
38	Wenning GK, Diem A, Michlmayr S, Schocke M, Seppi K, Poewe W. Atypische Parkinsonsyndrome. <i>Akt Neurol.</i> 2001 Dez;28(Sonderheft 3):S242-5.
39	Wenning GK, Michlmayr S, Braune S, Brücke T, Fogel W, Gerster P, Schulz JB, Volkmann J. Empfehlungen zur Differentialdiagnose von Parkinson-Syndromen. <i>Akt Neurol.</i> 2001 Dez;28(Sonderheft 3):S256-60.
40	Wenning G, Seppi K. Management der Parkinson-Krankheit. <i>Total Quality Management.</i> 2002 Jan:1-4.
41	Poewe W, Wenning G. The differential diagnosis of Parkinson's disease. <i>Eur J Neurol.</i> 2002 Nov;9(Suppl 3):23-30.
42	Wenning GK, Poewe W, Seppi K. M. Parkinson – Klinik und Therapie. <i>Ärztemagazin.</i> 2002 Dez;Sonderheft:14-16.
43	Wenning GK, Geser F. Multiple system atrophy. <i>Rev Neurol (Paris).</i> 2003 May;159(5 Pt 2):S31-8.
44	Wenning GK, Geser F, Stampfer-Kountchev M, Tison F. Multiple system atrophy: an update. <i>Mov Disord.</i> 2003 Sep;18(Suppl 6):S34-42.
45	Wenning G, Geser F. Diagnosis and Treatment of Multiple System Atrophy: an Update. <i>Adv Clin Neurosci Rehabil.</i> 2004 Jan/Feb;3(6):5-10.
46	Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. <i>Lancet Neurol.</i> 2004 Feb;3(2):93-103. Erratum in: <i>Lancet Neurol.</i> 2004 Mar;3(3):137.
47	Bonelli RM, Wenning GK, Kapfhammer HP. Huntington's disease: present treatments and future therapeutic modalities. <i>Int Clin Psychopharmacol.</i> 2004 Mar;19(2):51-62.
48	Wenning GK, Poewe W. Where are we after 30 years of clinical experience with levodopa? <i>Focus on Parkinson's Disease.</i> 2004 Oct;16(Supp A):A13-8.
49	Wenning G. Bei „malignen“ Parkinson-Symptomen an MSA denken. <i>Jahres Neurologie &amp; Psychiatrie.</i> 2004 Nov; 12(7):44-5.

50	Geser F, Wenning GK. Klinik und Therapie der Multisystematrophie. <i>J Neurol Neurochir Psychiatr.</i> 2004;5(2):56-62.
51	Geser F, Wenning G. Zur Differentialdiagnose von Parkinson-Syndromen. <i>Nervenheilkunde.</i> 2005;24(1):14-20.
52	Geser F, Wenning GK. Klinik und Therapie der Multisystematrophie und progressive supranukleären Paralyse. <i>Psychopharmakotherapie.</i> 2005;12(2):40-50.
53	Wenning GK, Jellinger K. The role of alpha-synuclein in the pathogenesis of multiple system atrophy. <i>Acta Neuropathol (Berl).</i> 2005 Feb;109(2):129-40.
54	Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy bodies: state of the art. <i>Mov Disord.</i> 2005 Aug;20(Suppl 12):S11-20.
55	Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. <i>Mov Disord.</i> 2005 Aug;20(Suppl 12):S67-76.
56	Wenning GK, Jellinger K. The role of alpha-synuclein and tau in neurodegenerative movement disorders. <i>Curr Opin Neurol.</i> 2005 Aug;18(4):357-62.
57	Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK. Animal models of multiple system atrophy. <i>Trends Neurosci.</i> 2005 Sep;28(9):501-6.
58	Berciano J, Wenning GK. The Lewis family revisited: no evidence for autosomal dominant multiple system atrophy. <i>Parkinsonism Relat Disord.</i> 2005 Sep;11(6):363-5.
59	Mueller J, Wenning GK, Poewe W, Kemmler G. Re: Patient-based outcomes of cervical dystonia: a review of rating scales. <i>Mov Disord.</i> 2005 Sep; 20(9):1230.
60	Seppi K, Schocke MF, Wenning GK, Poewe W. How to diagnose MSA early: the role of magnetic resonance imaging. <i>J Neural Transm.</i> 2005 Dec;112(12):1625-34.
61	Geser F, Seppi K, Stampfer-Kountchev M, Kollensperger M, Diem A, Ndayisaba JP, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Dodel R, Klockgether T, Ghorayeb I, Yekhlef F, Tison F, Daniels C, Koppler F, Deuschl G, Coelho M, Ferreira J, Rosa MM, Sampaio C, Bozi M, Schrag A, Hooker J, Kim H, Scaravilli T, Mathias CJ, Fowler C, Wood N, Quinn N, Widner H, Nilsson CF, Lindvall O, Schimke N, Eggert KM, Oertel W, del Sorbo F, Carella F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Meco G, Colosimo C, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Ory F, Rascol O, Kamm C, Buerk K, Maass S, Gasser T, Poewe W, Wenning GK; EMSASG. The European Multiple System Atrophy-Study Group (EMSA-SG). <i>J Neural Transm.</i> 2005 Dec;112(12):1677-86.
62	Colosimo C, Tiple D, Wenning GK. Management of multiple system atrophy: state of the art. <i>J Neural Transm.</i> 2005 Dec;112(12):1695-704.
63	Tolosa E, Wenning GK, Poewe W. The diagnosis of Parkinson's disease. <i>Lancet Neurol.</i> 2006 Jan;5(1):75-86.
64	Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. <i>Curr Pharm Des.</i> 2006;12(21):2701-20.
65	Geser F, Wenning GK. Multiple System Atrophy: An Update. <i>Geriatr Aging.</i> 2006 Apr;9(4):281-9.

66	Auff E, Poewe W, Asenbaum-Hanke S, Bancher C, Berek K, Bösch S, Brücke T, Gerschlager W, Grossmann J, Hochschorner G, Katzenschlager R, Koppi S, Ott E, Pinter M, Pirker W, Ransmayr G, Reisecker F, Schautzer F, Schmidbauer M, Schnider P, Soukop W, Volc D, Weber J, Wenning G, Zifko U. Consensus – Morbus Parkinson – Wearing-OFF – Früherkennung & optimal Therapie. <i>Österr Ärztezeitung. 2006 Apr; Suppl.3-12.</i>
67	Auff E, Poewe W, Asenbaum-Hanke S, Bancher C, Berek K, Bösch S, Brücke T, Gerschlager W, Grossmann J, Hochschorner G, Katzenschlager R, Koppi S, Ott E, Pinter M, Pirker W, Ransmayr G, Reisecker F, Schautzer F, Schmidbauer M, Schnider P, Soukop W, Volc D, Weber J, Wenning G, Zifko U. ÖPG-Konsensusstatement "WearingOff": Früherkennung & optimal Therapie. <i>P-aktuell. 2006; 2:1-11.</i>
68	Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Seminar on choreas. <i>Lancet Neurol. 2006 Jul;5(7):589-602.</i>

69	Berciano J, Boesch S, Perez-Ramos JM, Wenning GK. Olivopontocerebellar atrophy: toward a better nosological definition. <i>Mov Disord. 2006 Oct;21(10):1607-13.</i>
70	Stampfer-Kountchev M, Wenning G. M. Parkinson IV – Autonome Funktionsstörungen sind nicht selten. <i>CliniCum psy. 2006;6:54-5.</i>
71	Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Chorea-tische Syndrome. <i>Paktuell. 2006;4:1-8.</i>
72	Wenning G, Köllensperger M. Der Stellenwert von TOLCAPON im Therapiemanagement motorischer Komplikationen bei M. Parkinson. <i>P-aktuell. 2007;1:3-6.</i>
73	Ransmayr G, Katzenschlager R, Dal-Bianco P, Wenning G, Bancher C, Jellinger K, Schmidt R, Poewe W. Lewy-Körper-Demenz und ihre differentialdiagnostische Abgrenzung von Alzheimer'scher Erkrankung: Ein gemeinsames Konsensus-Statement der Österreichischen Alzheimer Gesellschaft (ÖAG) und der Österreichischen Parkinson Gesellschaft (ÖPG). <i>Neuropsychiatr. 2007; 21(2):63-74.</i>
74	Ransmayr G, Katzenschlager R, Dal-Bianco P, Wenning G, Bancher C, Jellinger K, Schmidt R, Poewe W. Lewy-Körper-Demenz und ihre differentialdiagnostische Abgrenzung von Alzheimer'scher Erkrankung. <i>P-aktuell. 2007; 2:1-14.</i>
75	Poewe W, Katzenschlager R, Wenning G, Ransmayr G. Konsensusstatement der Österreichischen Parkinson Gesellschaft: Einsatz von COMT-Hemmern in der Parkinson-Therapie – Aktueller Stellenwert von Tolcapon. <i>P-aktuell. 2007; 4:1-12.</i>
76	Wenning GK, Dürr S. Erkrankungen des autonomen Nervensystems – eine Einführung. <i>Neurologisch. 2008;3:76-9.</i>
77	Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG. Multiple system atrophy: a primary oligodendroglialopathy. <i>Ann Neurol. 2008 Sep;64(3):239-46.</i>
78	Pirker W, Katzenschlager R, Wenning G, Poewe W. Klinik und Therapie der ParkinsonPsychose – State of the Art-Review. <i>P-aktuell. 2009;1:1-7.</i>
79	Dürr S, Wenning GK. Multisystematrophie und andere atypische Parkinsonsyndrome. <i>P-aktuell. 2009;2:1-8.</i>
80	Köllensperger M, Wenning GK. Assessing disease progression with MRI in atypical parkinsonian disorders. <i>Mov Disord. 2009;24 (Suppl 2):S699-702.</i>

81	Tiefenthaler W, Wenning GK, Gruber H, Benzer A. Sonographic diagnosis of catheter malposition in a patient with postoperative plexus lesion after right internal jugular vein catheterization - case report. <i>Middle East J Anesthesiol.</i> 2009 Oct;20(3):443-5.
82	Wenning GK, Stefanova N. Recent developments in multiple system atrophy. <i>J Neurol.</i> 2009 Nov;256(11):1791-808.
83	Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. <i>Lancet Neurol.</i> 2009 Dec;8(12):1172-8.
84	Stampfer-Kountchev M, Wenning GK. Autonome Störungen in der Neurologie – Die Bedeutung der Anamnese. <i>Neurologisch.</i> 2009;3:14-5.
85	Wenning GK, Dürr S, Granata R, Hödl S, Struhal W, Lahrmann H. Therapieoptionen bei autonomen Störungen in der Neurologie – eine Übersicht. <i>Neurologisch.</i> 2009;3:22-4.
86	Wenning GK, Dürr S. Autonomes Versagen bei M. Parkinson und MSA. <i>Neurologisch.</i> 2009;3:36-7.
87	Wenning GK, Dürr S, Granata R, Pittl S, Sojer M, Stampfer-Kountchv M. Dynamik und Prädiktoren von kipptischinduzierten Synkopen. <i>Neurologisch.</i> 2009;4:90-1.
88	Wenning GK. Neues zur Therapie des M. Parkinson und der Multisystematrophie. <i>NeuroGer.</i> 2009;6(2):68-9.
89	Finke C, Siebert E, Plotkin M, Wenning GK, Reuter U. Multiple system atrophy masking multiple sclerosis. <i>Clin Neurol Neurosurg.</i> 2010 Jan;112(1):59-61.

90	Kuzdas D, Stefanova N, Wenning GK. Multisystematrophie – Tiermodelle und neue Therapieansätze. <i>Neurologisch.</i> 2010;2:70-2.
91	Dürr S, Wenning GK. Autonomes Versagen bei Parkinsonsyndromen. <i>Jahres Neurologie &amp; Psychiatrie.</i> 2010 Mai; 18(3):20-2.
92	Wenning G, Krismer F, Dürr S. Weltweit größtes MSA-Register (EMSA-R) zeigt Mängel in der Patientenversorgung auf. <i>Neurologisch.</i> 2010;4:100.
93	Wenning GK, Colosimo C. Diagnostic criteria for multiple system atrophy and progressive supranuclear palsy. <i>Rev Neurol (Paris).</i> 2010 Oct;166(10):829-33.
94	Krismer F, Wenning G, Struhal W, Mismas A. Erythropoientin in der Behandlung der Multisystematrophie. <i>Neurologisch.</i> 2011;1:64-5.
95	Dürr S, Wenning G. Morbus Parkinson – nicht immer leicht zu diagnostizieren. <i>Neurologisch.</i> 2011;2:14-9.
96	Dürr S, Granata R, Wenning G. Droxidopa zur Therapie der symptomatischen neurogenen orthostatischen Hypotension – ein Überblick. <i>Neurologisch.</i> 2011;2:82-4.
97	Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary Parkinsonisms. <i>Mov Disord.</i> 2011 May;26(6):1083-95.
98	Stemberger S, Wenning GK. Modelling progressive autonomic failure in MSA: where are we now? <i>J Neural Transm.</i> 2011 May;118(5):841-7.
99	Fellner L, Jellinger KA, Wenning GK, Stefanova N. Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. <i>Acta Neuropathol.</i> 2011 Jun;121(6):67593.
100	Wenning GK, Krismer F, Poewe W. New insights into atypical parkinsonism. <i>Curr Opin Neurol.</i> 2011 Aug;24(4):331-8.

101	Pavy-Le Traon A, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Shaftman SR, Tison F, Wenning GK, Goetz CG, Poewe W, Sampaio C, Schrag A, Stebbins GT, Rascol O. The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. <i>Mov Disord.</i> 2011 Sep;26(11):1985-92.
102	Krismer F, Wenning GK, Stefanova N. Intakte Olfaktion als Schlüsselmerkmal der Multisystematrophie vom Parkinson-Typ: experimentelle Evidenz. <i>Neurologisch.</i> 2011;4:96-7.
103	Stemberger S, Scholz SW, Singleton AB, Wenning GK. Genetic players in multiple system atrophy: unfolding the nature of the beast. <i>Neurobiol Aging.</i> 2011 Oct;32(10):1924.e5-14.
104	Kuzdas D, Krismer F, Stefanova N, Wenning GK. Aktuelle Laborforschung zur Parkinsondemenz. <i>Jatros Neurologie &amp; Psychiatrie.</i> 2011 Nov;19(7):9-11.
105	Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK. Premotor signs and symptoms of multiple system atrophy. <i>Lancet Neurol.</i> 2012 Apr;11(4):361-8.
106	Duerr S, Wenning GK, Seppi K, Poewe W. Atypische Parkinson-Syndrome - Aktuelles aus Diagnostik und Therapie. <i>Fortschr Neurol Psychiatr.</i> 2012 Sep;80(9): 492-500.
107	Wenning GK. Impfung gegen Parkinson – Hoffen auf alpha-Synuclein-Antikörper. <i>Deutsche Apotheker Zeitung.</i> 2012 Aug;31:36-7.
108	Kaindelstorfer C, Granata R, Wenning GK. Tremor in Multiple System Atrophy – a review. <i>Tremor Other Hyperkinet Mov</i> 2013 Sept; 07:36:11
109	Metzler M, Duerr S, Granata R, Krismer F, Robertson D, Wenning GK: Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. <i>J Neurol</i> 2013 Sept; 260(9): 2212-9

110	Kuzdas-Wood D, Stefanova N, Jellinger KA, Seppi K, Schlossmacher MG, Poewe W, Wenning GK. Towards translational therapies for multiple system atrophy. <i>Progress in Neurobiology.</i> 2014 Jul;118(2014):19-35.
111	Krismer F, Jellinger KA, Scholz SW, Seppi K, Stefanova N, Antonini A, Poewe W, Wenning GK. Multiple System Atrophy as Emerging Template for Accelerated Drug Discovery in α-Synucleinopathies. <i>Parkinsonism Relat Disord.</i> 2014 Aug;20(8):793-9
112	Cirolli L, Krismer F, Nicoletti F, Wenning GK. An Update on the cerebellar subtype of multiple system atrophy. <i>Cerebellum and Ataxias.</i> 2014 Oct 10;1:14.
113	Stefanova N, Wenning GK. Animal models of multiple system atrophy. <i>Clin Auton Res.</i> 2015 Feb;25(1):9-17.
114	Facciulli A, Wenning GK. Multiple-system atrophy. <i>N Engl J Med</i> 2015 Jan; 372:249263
115	Laurens B, Constantinescu R, Freeman R, Gerhard A, Jellinger K, Jeromin A, Krismer F, Mollenhauer B, Schlossmacher MG, Shaw LM, Verbeek MM, Wenning GK, Winge K, Zhang J, Meissner WG. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. <i>Neurobiol Dis.</i> 2015 Aug;80:29-41.
116	Indelicato E, Facciulli A, Poewe W, Antonini A, Pontieri FE, Wenning GK. Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. <i>Parkinsonism Relat Disord.</i> 2015 Dec;21(12):1393-7.

117	Eschlöck S, Krismer F, Wenning GK. Interventional trials in atypical parkinsonism. <i>Parkinsonism Relat Disord.</i> 2016 Jan;22 Suppl 1:S82-92.
118	Brück D, Wenning GK, Stefanova N, Fellner L. Glia and alpha-synuclein in neurodegeneration: A complex interaction. <i>Neurobiol Dis</i> 2016 Jan;85:262-74.
119	Stefanova N, Wenning GK. Multiple system atrophy: emerging targets for interventional therapies. <i>Neuropathol Appl Neurobiol.</i> 2016 Feb;42(1):20-32.
120	Krismer F, Seppi K, Stefanova N, Wenning GK. Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. <i>Mov Disord.</i> 2016 Feb;31(2):235-40.
121	Jellinger KA, Wenning GK. Multiple system atrophy: pathogenic mechanisms and biomarkers. <i>J Neural Transm (Vienna).</i> 2016 Jun;123(6):555-72.
122	Fiorenzato E, Weis L, Seppi K, Onofrj M, Cortelli P, Zanigni S, Tonon C, Kaufmann H, Shepherd TM, Poewe W, Krismer F, Wenning GK, Antonini A, Biundo R. Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>J Neural Transm.</i> 2016 Okt; 123 (12): 1-10.
123	Krismer F, Wenning GK. Multiple system atrophy: insights into a rare and debilitating movement disorder. <i>Nat Rev Neurol.</i> 2017 Apr;13(4):232-243.
124	Fiorenzato E, Antonini A, Wenning G, Biundo R. Cognitive impairment in multiple system atrophy. <i>Mov Disord.</i> 2017 Sep;32(9):1338-1339.
125	Castro Caldas A, Levin J, Djaldetti R, Rascol O, Wenning G, Ferreira JJ; Movement Disorders Society MSA Study Group. Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. <i>Mov Disord.</i> 2017 Oct;32(10):1356-1364.
126	Eschlöck S, Wenning G, Fanciulli A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. <i>J Neural Transm (Vienna).</i> 2017 Dec;124(12):1567-1605.
127	Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenbach J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinder GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P,
128	Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology.</i> 2018 Jan 9;90(2):74-82.
129	Overk C, Rockenstein E, Valera E, Stefanova N, Wenning G, Masliah E. Multiple system atrophy: experimental models and reality. <i>Acta Neuropathol.</i> 2018 Jan;135(1):33-47.
130	Eschlöck S, Wenning G, Fanciulli A. Correction to: Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. <i>J Neural Transm (Vienna).</i> 2018 Feb;125(2):273-274.

131	Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P, Eschlboeck S, Grassi G, Hilz MJ, Kaufmann H, Lahrmann H, Mancia G, Mayer G, NorcliffeKaufmann L, Pavly-Le Traon A, Raj SR, Robertson D, Rocha I, Struhal W, Thijs R, Tsiofis KP, van Dijk JG, Wenning GK. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS) Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). <i>Clin Auton Res.</i> 2018 May 15.
132	Pavy-Le Traon A, Cotterill N, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Tison F, Wenning GK, Goetz CG, Poewe W, Sampaio C, Schrag A, Rascol O, Martinez-Martin P, Stebbins GT; Members of the MDS Committee on Rating Scales Development. Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. <i>Mov Disord Clin Pract.</i> 2018 Oct 25;5(5):479-491.
133	Ndayisaba A, Jellinger K, Berger T, Wenning GK. TNF $\alpha$ inhibitors as targets for protective therapies in MSA: a viewpoint. <i>J Neuroinflammation.</i> 2019 Apr 11;16(1):80.
134	Raccagni C, Nonnikes J, Bloem BR, Peball M, Boehme C, Seppi K, Wenning GK. Gait and postural disorders in parkinsonism: a clinical approach. <i>J Neurol.</i> 2019 May 22. doi: 10.1007/s00415-019-09382-1. [Epub ahead of print].
135	Ndayisaba A, Herrera-Vaquero M, Wenning GK, Stefanova N. Induced pluripotent stem cells in multiple system atrophy: recent developments and scientific challenges. <i>Clin Auton Res.</i> 2019 Aug;29(4):385-395. doi: 10.1007/s10286-019-00614-y. Epub 2019 Jun 11.
136	Cortelli P, Calandra-Buonaura G, Benarroch EE, Giannini G, Iranzo A, Low PA, Martinelli P, Provini F, Quinn N, Tolosa E, Wenning GK, Abbruzzese G, Bower P, Alfonsi E, Ghorayeb I, Ozawa T, Pacchetti C, Pozzi NG, Vicini C, Antonini A, Bhatia KP, Bonavita J, Kaufmann H, Pellecchia MT, Pizzorni N, Schindler A, Tison F, Vignatelli L, Meissner WG. Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. <i>Neurology.</i> 2019 Oct 1;93(14):630-639. doi: 10.1212/WNL.0000000000008208.
137	Fanciulli A, Stankovic I, Krismer F, Seppi K, Levin J, Wenning GK. Multiple system atrophy. <i>Int Rev Neurobiol.</i> 2019; 149:137-192. doi: 10.1016/bs.irn.2019.10.004. Epub 2019 Nov 21.
138	Ndayisaba A, Wenning GK. Inhibition of the mammalian target of rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophy. <i>Clin Auton Res.</i> 2020 Jan 9. doi: 10.1007/s10286-019-00662-4. [Epub ahead of print] No abstract available.
139	F Geser, L Fellner, J Haybaeck, G K Wenning Affiliations expand Development of neurodegeneration in amyotrophic lateral sclerosis: from up or down? <i>J Neural Transm (Vienna)</i> 2020 Aug;127(8):1097-1105. doi: 10.1007/s00702-020-02213-y. Epub 2020 Jun 4.
140	Maria Teresa Pellecchia, Iva Stankovic, Alessandra Fanciulli, Florian Krismer, Wassilios G Meissner, Jose-Alberto Palma, Jalesh N Panicker, Klaus Seppi, Gregor K Wenning, Members of the Movement Disorder Society Multiple System Atrophy Study Group Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group <i>Mov Disord Clin Pract</i> 2020 Sep 3;7(7):750-762. doi: 10.1002/mdc3.13052. eCollection 2020 Oct.

141	Cecilia Raccagni, Jorik Nonnekes, Bastiaan R Bloem, Marina Peball, Christian Boehme, Klaus Seppi, Gregor K Wenning; Gait and postural disorders in parkinsonism: a clinical approach; <i>J Neurol</i> 2020 Nov;267(11):3169-3176. doi: 10.1007/s00415-019-09382-1. Epub 2019 May 22.
142	William P Cheshire, Roy Freeman, Christopher H Gibbons, Pietro Cortelli, Gregor K Wenning, Max J Hilz, Judith M Spies, Axel Lipp, Paola Sandroni, Naoki Wada, Akiko Mano, Hyun Ah Kim, Kurt Kimpinski, Valeria Iodice, Juan Idiáquez, Pariwat Thaisetthawatkul, Elizabeth A Coon, Phillip A Low, Wolfgang Singer Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology; <i>Clin Neurophysiol</i> 2020 Dec 22; S1388-2457(20)30585-X.doi: 10.1016/j.clinph.2020.11.024.
143	Geser F Jellinger KA, Fellner L, Wenning GK, Yilmazer-Hanke D, Haybaeck J. Emergent creativity in frontotemporal dementia. <i>J Neural Transm (Vienna)</i> . 2021 Mar;128(3):279-293. Doi 10.1007/S00702-021-02325-z. Epub 2021 Mar 12.PMID: 33709181
144	Palma JA, Vernetti PM, Perez MA, Krismer F, Seppi K, Fancuilli A, Singer W, Low P, Biaggioni I, Norcliffe Kaufmann L, Pellechia MT, Marti MJ, Kim HJ, Merello M, Stankovic I, Poewe W, Betensky R, Wenning GK, Kaufmann H. Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. <i>Clin Auton Res</i> . 2021 Feb 7:1-8. Doi: 10.1007/s10286-021-00782-w. Online ahead of print. PMID: 33554315
145	Stankovic I, Fancuilli A, Kostic VS, Krismer F, Meissner WG, Palma JA, Panicker JN, Seppi K, Wenning GK; Laboratory-Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. <i>Mov. Disord Clin Pract</i> .2021 Mar 10; 8 (3): 322-340. Doi: 10.1002/mdc3.13158. eCollection 2021 Apr.PMID: 33816659
146	Thiis RD, Brignole M, Falup-Pecurariu C, Fancuilli A, Freeman R, Guaraldi P, Jordan J, Habek M, Hilz M, Traon AP, Stankovic I, Struhal W, Sutton R, Wenning GK, Van Dijk JG. Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of Consciousness: Consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). <i>Clin Auton Res</i> . 2021 Mar 19. Doi: 10.1007/s10286-020-00738-6. Online ahead of print. PMID: 33740206

#### Letters to the Editor, Editorials, Comments

1	Wenning GK, Quinn NP, Daniel SE. How accurate is death certification of multiple system atrophy? <i>Lancet</i> . 1992 Dec; 340(8833):1481-2.
2	Wenning GK, Wagner S, Daniel S, Quinn NP. Multiple system atrophy: sporadic or familial? <i>Lancet</i> . 1993 Sep; 342(8872):681.
3	Davie CA, Wenning GK, Barker GJ, Brennan A, Quinn N, Miller MD. MRS to differentiate multiple system atrophy from idiopathic Parkinson's disease. <i>Lancet</i> . 1993 Sep; 342(8872):681-2.

4	Wenning G, Quinn N. Are Lewy bodies non-specific epiphenomena of nigral damage? <i>Mov Disord.</i> 1994 May; 9(3):378-9.
5	Ben-Shlomo Y, Wenning G. Incidental Lewy body disease. <i>Lancet.</i> 1994 Nov; 344(8935):1503.
6	Tison F, Wenning GK, Quinn NP, Smith SJ. REM sleep behaviour disorder as the presenting symptom of multiple system atrophy. <i>J Neurol Neurosurg Psychiatry.</i> 1995 Mar; 58(3):379-80.
7	Bandmann O, Wenning GK, Quinn NP, Harding AE. Arg296 to Cys296 polymorphism in exon 6 of cytochrome P-450-2D6 (CYP2D6) is not associated with multiple system atrophy. <i>J Neurol Neurosurg Psychiatry.</i> 1995 Nov; 59(5):557.
8	Wenning GK, Quinn NP, Daniel SE, Garratt H, Marsden CD. Facial dystonia in pathologically proven multiple system atrophy: a video report. <i>Mov Disord.</i> 1996 Jan; 11(1):107-9.
9	Litvan I, McKee A, Jellinger K, Jankovic J, Wenning GK; for the PSP Study Group. What are the Obstacles for an Accurate Clinical Diagnosis of Pick's disease? <i>Neurology.</i> 1998 Apr; 50(4):1192-1193.
10	Wenning GK, Litvan I, Verny M, Chaudhuri KR, Granata R, Poewe W, Jellinger K. Is EEG useful in the differential diagnosis of parkinsonism? <i>Parkinsonism Relat Disord.</i> 1998 Aug, 4(2):79-80.
11	Wenning GK, Poewe W. Journal Club 1038 (Barone et al. Pergolidmonotherapy im Frühstadium des Morbus Parkinson: eine randomisierte, kontrollierte Studie). <i>InFo Neurologie &amp; Psychiatrie</i> 2000; 2(2):1
12	Kofler M, Wenning GK, Poewe W, Jellinger K, Maier H. Cortical and brain stem hyperexcitability in a pathologically confirmed case of multiple system atrophy. <i>Mov Disord.</i> 2000 Mar; 15(2):362-3.
13	Jellinger KA, Wenning GK. An early description of striatonigral degeneration. <i>J Neurol.</i> 2000 Apr; 247(4):309-10.
14	Wenning GK, Poewe W. Journal Club 2193 (Freed et al. Transplantation embryonaler dopaminerger Neurone bei fortgeschrittener Parkinson-Krankheit). <i>InFo Neurologie &amp; Psychiatrie</i> 2001; 3(6):1-2.
15	Seppi K, Puschban Z, Stefanova N, Scherfler C, Mueller J, Poewe W, Wenning GK. Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome. <i>Nat Med.</i> 2001 Feb; 7(2):132.
16	Wenning GK, Diem A. Is peripheral neuropathy a feature of multiple system atrophy? <i>Clin Auton Res.</i> 2001 Apr; 11(2):63.
17	Abbruzzese G, Agid Y, Albanese A, ... Wenning GK et al. An open letter to the Committee on The Novel Prize in Medicine. <i>Parkinsonism Relat Disord.</i> 2001 Apr; 7(2):149-55
18	Bauer I, Gencik M, Laccone F, Peters H, Weber BH, Feder EH, Weirich H, MorrisRosendahl DJ, Rolfs A, Gencikova A, Bauer P, Wenning GK, Epplen JT, Holmes SE, Margolis RL, Ross CA, Riess O. Trinucleotide repeat expansions in the junctophilin-3

	gene are not found in Caucasian patients with a Huntington's disease-like phenotype. <i>Ann Neurol.</i> 2002 May; 51(5):662.
19	Jellinger KA, Seppi K, Wenning GK. Lewy bodies in patients presenting clinically with Alzheimer disease. <i>J Alzheimers Dis.</i> 2002 Aug; 4(4):327-8.
20	Jellinger KA, Seppi K, Wenning GK. Accuracy of diagnosis in dementia with Lewy bodies. <i>Arch Neurol.</i> 2003 Mar; 60(3):452.
21	Jellinger KA, Seppi K, Wenning GK. Neuropathologic changes in Parkinson disease with late onset of dementia. <i>Arch Neurol.</i> 2003 Mar; 60(3):452-3; author reply 453-4.
22	Jellinger KA, Seppi K, Wenning GK. Clinical and neuropathological correlates of Lewy body disease. <i>Acta Neuropathol (Berl).</i> 2003 Aug; 106(2):188-9; author reply 190.
23	Wenning GK, Geser F, Poewe W. The 'risus sardonicus' of multiple system atrophy. <i>Mov Disord.</i> 2003 Oct; 18(10):1211.
24	Diguet E, Gross CE, Bezard E, Tison F, Stefanova N, Wenning GK. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. <i>Neurology.</i> 2004 Jan; 62(1):158; author reply 158-9.
25	Wenning G. Journal Club (Burton EJ et al. Cerebrale Atrophie-Muster bei M. Parkinson mit und ohne Demenz: ein Vergleich mit Alzheimer Demenz und Demenz mit LewyKörperchen) <i>P-aktuell.</i> 2004; 1:7.
26	Wenning G. (Gasser T et al. LRRK2/PARK8 in Parkinson-Familien) <i>P-aktuell.</i> 2005; 2:1112.
27	Wenning G. (Mark MH et al. Langzeitwirksamkeit von Istradefyllin bei Patienten mit idiopathischem Parkinson-Syndrom) <i>P-aktuell.</i> 2005; 2:12.
28	Wenning G. (Wenning GK et al. Die Prävalenz von Bewegungsstörungen in der Allgemeinbevölkerung) <i>P-aktuell.</i> 2005; 2:12-13.
29	Colosimo C, Gilman S, Quinn N, Wenning GK. Preface - Special issue: Multiple system atrophy. <i>J Neural Transm.</i> 2005 Dec; 112(12):1601-3.
30	Wenning GK. Chorea-tische Syndrome. <i>P-aktuell.</i> 2006; 4:1.
31	Wenning GK. Hauswirths Konzept der vegetativen Konstitutionstherapie: Relevanz im Zeitalter der Evidenz-basierten Medizin. <i>Arzt und Praxis.</i> 2007; 61(928):20.
32	Wenning GK, Katzenschlager R. Aktuelles zur Rolle von DUODOPA und TOLCAPON in der Parkinson-Therapie. <i>P-aktuell.</i> 2007; 1:1.
33	Wenning GK, Katzenschlager R. Demenz mit „Lewy-Körperchen“. <i>P-aktuell.</i> 2007; 2:1.
34	Geser F, Wenning GK. Disproportionate antecollis: a warning sign for multiple system atrophy. <i>Mov Disord.</i> 2007 Oct 15; 22(13):1986; author reply 1986-7.
35	Mizuno Y, Wenning GK. Preface. <i>Mov Disord.</i> 2007 Dec 14; 22(S17):S325-S326.
36	Wenning G, Katzenschlager R. Die tiefe Gehirnstimulation als Therapieoption bei Dystonie. <i>P-aktuell.</i> 2008; 1:1.
37	Wenning G, Katzenschlager R. Essentieller Tremor – ein Update. <i>P-aktuell.</i> 2008; 2:1.
38	Wenning G, Katzenschlager R. Fibrotische Herzklappenveränderung unter der Therapie mit Dopamin-Agonisten. <i>P-aktuell.</i> 2008; 3:1.
39	Wenning G, Katzenschlager R. Klinik und Therapie der Parkinson-Psychose. <i>P-aktuell.</i> 2009; 1:1.

40	Wenning GK, Brown R. Dementia in multiple system atrophy: does it exist? <i>Eur J Neurol.</i> 2009 May; 16(5):551-2.
41	Lim SY, Wadia P, Wenning GK, Lang AE. Clinically probable multiple system atrophy with predominant parkinsonism associated with myotonic dystrophy type 2. <i>Mov Disord.</i> 2009 Jul; 24(9):1407-9.
42	Wenning GK. Invasive Parkinson-Therapie. <i>P-aktuell.</i> 2009;3:1.
43	Löscher WN, Wenning GK. No need to droop your head in Parkinson's disease? <i>Parkinsonism Relat Disord.</i> 2009 Nov; 15(9):620.
44	Wenning G, Katzenschlager R. Hereditäre degenerative Kleinhirnerkrankungen – Neues zu Diagnostik und Therapie. <i>P-aktuell.</i> 2009;4:1.
45	Srulijeska K, Hauser AK, Guella I, Asseltac R, Brockmann K, Schultea C, Sold G, Ciliad R, Maetzler W, Scholsa L, Wenning GK, Poewe W, Baroneg P, Wullner U, Oerteli W, Berga D, Goldwurm S, Gasser T. No association of GBA mutations and multiple system atrophy. <i>Eur J Neurol.</i> 2013; 20:e61-e62
46	Foki T, Steininger S, Kasprian G, Wenning GK, Fertl E, Pirker W. An exceptional case of MSA-P. <i>J Neurol.</i> 2013 Apr; 260(4):1171-3.
47	Sharma M, Wenning G, Krüger R; European Multiple-System Atrophy Study Group (EMSA-SG). Mutant COQ2 in multiple-system atrophy. <i>N Engl J Med.</i> 2014 Jul 3;371(1):80-1.
48	Krismer F, Wenning GK. Autonomic failure in CANVAS syndrome. <i>Brain.</i> 2014 Oct;137(Pt 10):2625-6
49	Fanciulli A & Wenning GK. Multiple-system atrophy. <i>NEJM</i> 2015 Apr 2;372(14):1375-6.
50	Krismer F, Wenning GK. Multiple system atrophy in the USA: another piece in the jigsaw. <i>Lancet Neurol.</i> 2015 Jul;14(7):672-4.
51	Stefanova N, Kordower JH, Wenning GK. Preface. <i>Mov Disord.</i> 2016 Feb;31(2):151.
52	Heras-Garvin A, Wenning GK. Is Multiple System Atrophy a New Prion Disorder? <i>Mov Disord.</i> 2016 Mar;31(3):300.
53	Ndayisaba JP, Fanciulli A, Granata R, Duerr S, Hintringer F, Goebel G, Krismer F, Wenning GK. Erratum to: Sex and age effects on cardiovascular autonomic function in healthy adults. <i>Clin Auton Res.</i> 2016 Apr;26(2):169-170.
54	Jellinger KA, Wenning GK. Overlaps between multiple system atrophy and multiple sclerosis: a novel perspective. <i>Mov Disord.</i> 2016 Dec;31(12):1767-1771.
55	Krismer F, Wenning GK. Diagnosis and treating multiple system atrophy. <i>Nature review Neurology,</i> in press
56	Wenning GK. Parkinsonism and dysautonomia: Multiple system atrophy? <i>Parkinsonism Relat Disord.</i> 2019 Aug 19. pii: S1353-8020(19)30362-1. doi: 10.1016/j.parkreldis.2019.08.006. [Epub ahead of print]
57	Fellner L, Wenning GK. Multiple system atrophy - Are cerebrospinal fluid cytokines reliable potential diagnostic marker? <i>Parkinsonism Relat Disord.</i> 2019 Aug; 65:1-2. doi: 10.1016/j.parkreldis.2019.09.019. Epub 2019 Sep 17.

## Books and Book Chapters

1	Wenning GK, Quinn NP. Multiple system atrophy: recent advances in clinical and pathological definition. In: Harkness W, Hayward RD, Meierkord H, Quinn NP, Scadding JW, Shorvon SD, Wade JPH. Peer selected Citations '93. Neurology & Neurosurgery. <i>Current Medical Literature, 1993, London, pp 60-3.</i>
2	Quinn NP, Wenning GK. Multiple system atrophy. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (Eds.). Advances in Neurology. Volume 69. Parkinson's Disease. <i>Lippincott-Raven, 1996, Philadelphia, pp 413-9.</i>
3	Wenning GK, Quinn NP. Multiple system atrophy. In: Quinn NP (Ed.). Bailliere's Clinical Neurology. Parkinsonism. <i>Bailliere Tindall, 1997, London, pp 187-204.</i>
4	Poewe W, Wenning GK. Chorea and ballism. In: Tolosa E, Koller WC, Gershanik OS (Eds.). Differential diagnosis and treatment of movement disorders. <i>ButterworthHeinemann, 1998, Oxford, pp 77-88.</i>
5	Poewe W, Wenning GK. Levodopa in Parkinson's disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E (Eds.). Parkinson's disease and movement disorders. 3 <sup>rd</sup> Edition. <i>Lippincott Williams &amp; Wilkins, 1998, Baltimore, pp 177-90.</i>
6	Poewe W, Wenning GK, Gerlach M, Riederer P. Nicht-idiopathische ParkinsonSyndrome. In: Hopf HC, Deuschl G, Diener HC, Reichmann H (Hrsg.). Neurologie in Praxis und Klinik. Band II. 3. Auflage. <i>Thieme, 1999, Stuttgart, pp 69-77.</i>
7	Wenning GK, Bösch S, Luginger E, Wagner M, Poewe W. Effects of Long-term, Continuous Subcutaneous Apomorphine Infusions on Motor Complications in Advanced Parkinson's Disease. In: Stern GM (Ed.). Advances in Neurology. Volume 80. Parkinson's Disease. <i>Lippincott Williams &amp; Wilkins, 1999, Philadelphia, pp 545-8.</i>
8	Wenning GK, Poewe W. Exkurs: Progressive supranukleäre Blickparese. In: Riederer P, Laux G, Pöldinger W (Hrsg.). Neuro-Psychopharmaka. Ein Therapiehandbuch. Band 5: Parkinsonmittel und Antidementiva. 2. Auflage. <i>Springer, 1999, Wien, pp 410-5.</i>
9	Wenning GK, Poewe W. Exkurs: Multisystematrophie. In: Riederer P, Laux G, Pöldinger W (Hrsg.). Neuro-Psychopharmaka. Ein Therapiehandbuch. Band 5: Parkinsonmittel und Antidementiva. 2. Auflage. <i>Springer, 1999, Wien, pp 416-21.</i>
10	Poewe W, Wenning GK. Nuevos agonistas dopaminergicos. Es alguno realmente diferente? In: Merello M, Lees AJ (Eds.). Tratamiento de la enfermedad de Parkinson. <i>Talleres Graficos de "La ley" S.A.E., 1999, Buenos Aires, pp. 125-147.</i>
11	Poewe W, Wenning GK. Sicher therapieren mit Parkinsonmitteln. 2. Auflage. <i>pmVerlag, 2000, Kössen.</i>
12	Scherfler C, Seppi K, Puschban Z, Weiler B, Granbichler H, Poewe W, Wenning GK. Nigral degeneration in animal models of multiple system atrophy. In: Storch A, Collins MA (Eds.). Neurotoxic Factors in Parkinson's Disease and Related Disorders. <i>Kluwer Academic/Plenum Publishers, 2000, New York, pp 65-8.</i>
13	Poewe W, Wenning GK. The natural history of Parkinson's disease. In: <i>Wells Medical Ltd., 2001, Tunbridge Wells.</i>
14	Poewe W, Wenning GK. Levodopa in Parkinson's disease: mechanisms of action and pathophysiology of late failure. In: Jankovic JJ, Tolosa E (Eds.). Parkinson's disease and movement disorders. 4 <sup>th</sup> Edition. <i>Lippincott Williams &amp; Wilkins, 2002, Philadelphia, pp 104-15.</i>

15	Poewe W, Wenning GK. Morbus Parkinson. <i>Arcis, 2002, München.</i>
16	Poewe W, Wenning GK. Morbus Parkinson, Teil 2 "Spätphase". In: Conrad B, CeballosBaumann A (Hrsg.). Bewegungsstörungen in der Neurologie. Richtig erkennen und behandeln. <i>Thieme, 2002, Stuttgart.</i>
17	Wenning GK, Seppi K, Jellinger K. Diagnostic Accuracy in Lewy Body Dementia. In: Tolosa E, Schulz JB, McKeith IG, Ferrer I (Eds.). Neurodegenerative Disorders Associated with $\alpha$ -Synuclein Pathology. <i>Ars Medica, 2002, Barcelona, pp 111-6.</i>
18	Poewe W, Wenning GK. Atypische Parkinson-Syndrome. In: Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. 4. Auflage. <i>Kohlhammer, 2003, Stuttgart, pp 964-82.</i>
19	Poewe W, Wenning GK. Atypical parkinsonism. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (Eds.). Neurological Disorders. Course and Treatment. 2 <sup>nd</sup> Edition. <i>Academic Press, 2003, San Diego, pp 1081-98.</i>
20	Wenning GK, Stampfer M. Dementia with Lewy bodies. In: Robertson D, Biaggioni I, Burnstock G, Low PA (Eds.). Primer on the Autonomic Nervous System. 2 <sup>nd</sup> Edition. <i>Elsevier Academic Press, 2004, San Diego, pp 293-4.</i>
21	Rosenow F, Werhahn KJ, Wenning GK. Myoklonien. In: Sitzer M, von Stuckrad-Barre S, Schmutzhard E (Hrsg.). Neurologische Notfall- und Intensivmedizin. <i>Elsevier Urban &amp; Fischer, 2004, München, pp 154-9.</i>
22	Geser F, Wenning GK. Multiple System Atrophy. In: Litvan I (Ed.). Atypical Parkinsonian Disorders. Clinical And Research Aspects. <i>Humana Press, 2005, Totowa, pp 335-60.</i>
23	Wenning GK, Geser F, Poewe W. Diagnosis and treatment of multiple system atrophy: an update. In: Galvez-Jimenez N (Ed.). Scientific Basis for the Treatment of Parkinson's Disease. 2 <sup>nd</sup> Edition. <i>Taylor &amp; Francis, 2005, Abingdon, pp 291-8.</i>
24	Geser F, Colosimo C, Wenning GK. Multiple system atrophy. In: Beal MF, Lang AE, Ludolph AC (Eds.). Neurodegenerative Diseases. Neurobiology, Pathogenesis and Therapeutics. <i>Cambridge University Press, 2005, Cambridge, pp 623-62.</i>
25	Colosimo C, Geser F, Wenning GK. Clinical Spectrum and Pathological Features of Multiple System Atrophy. In: Le-Doux M (Ed.). Animal models of movement disorders. <i>Elsevier, 2005, Burlington, pp 541-70.</i>
26	Ghorayeb I, Stefanova N, Fernagut PO, Wenning GK, Tison F. Double-lesion animal models of multiple system atrophy. In: Le-Doux M (Ed.). Animal models of movement disorders. <i>Elsevier, 2005, Burlington, pp 571-83.</i>
27	Poewe W, Wenning GK. Klinik und Therapie des fortgeschrittenen idiopathischen Parkinson-Syndroms. In: Ceballos-Baumann A, Conrad B (Hrsg.). Bewegungsstörungen. 2. Auflage. <i>Thieme, 2005, Stuttgart, pp 71-85.</i>
28	Wenning G. Multiple System Atrophy. <i>Butterworth-Heinemann, 2005, Oxford.</i>
29	Wenning GK, Geser F. Multiple system atrophy. In: Jankovic J, Tolosa E (Eds.). Parkinson's disease and movement disorders. 5 <sup>th</sup> Edition. <i>Lippincott Williams and Wilkins, 2007, Baltimore, pp 175-85.</i>
30	Colosimo C, Geser F, Benarroche EE, Wenning GK. Multiple system atrophy. In: Gilman S. (Ed.). Neurobiology of disease. <i>Elsevier, 2007, Burlington, pp 83-93.</i>

31	Stefanova N, Granata R, Wenning GK. Morbus Parkinson und andere extrapyramidale Bewegungsstörungen. In: Berger T, Brezinka C, Luef G (Hrsg.). Neurologische Erkrankungen in der Schwangerschaft. <i>Springer, 2007, Wien, pp 211-29.</i>
32	Geser F, Globas C, Schöls L, Wenning GK. Multiple System Atrophy. In: Brice A, Pulst SM (Eds.). Spinocerebellar Degenerations: The Ataxias and Spastic Paraplegias. Blue Books of Neurology. <i>Butterworth Heinemann, 2007, Philadelphia, pp 78-112.</i>
33	Geser F, Scholz SW, Wenning GK. Progressive supranuclear palsy and corticobasal degeneration. In: Youdim MBH, Riederer P, Mandel SA, Battistin L, Lajtha A (Eds.). Handbook of Neurochemistry and Molecular Neurobiology. Degenerative Diseases of the Nervous System. 3 <sup>rd</sup> Edition. <i>Springer, 2007, Berlin, pp 123-37.</i>
34	Wenning GK, Stefanova N. Inwieweit spiegeln Tiermodelle die menschlichen Erkrankungen Parkinson-Krankheit und Multisystematrophie wieder? <i>Roche Pharma Symposiumband, 2007.</i>
35	Poewe W, Wenning GK. Atypische Parkinson-Syndrome. In: Brandt T, Dichgans J, Diener HC (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen. 5. Auflage. <i>Kohlhammer, 2007, Stuttgart, pp 1008-26.</i>
36	Geser F, Wenning GK. Primary autonomic failure. In: Schapira AHV (Ed.). Neurology and clinical neuroscience. <i>Mosby Elsevier, 2007, Philadelphia, pp 372-93.</i>
37	Poewe W, Wenning GK. Parkinson Plus Disorders. In: Schapira AHV (Ed.). Neurology and clinical neuroscience. <i>Mosby Elsevier, 2007, Philadelphia, pp 961-82.</i>

38	Stampfer-Kountschev M, Wenning GK. Autonomic failure in dementia with Lewy bodies. In: Jiritsu-Shinkei-Gaku (des.). Autonomic Neuroscience (Japanese translation: Primer on the Autonomic Nervous System. Robertson D, Biaggioni I, Burnstock, G, and Low PA (eds.). 2 <sup>nd</sup> English edition, 2004). <i>Elsevier, 2007, Tokyo.</i>
39	Geser F, Egger KE, Wenning GK. A face to remember .... In: Reich SG (Ed.). Movement Disorders: 100 Instructive Cases. <i>Informa Healthcare, 2008, London, pp 135-8.</i>
40	Köllensperger M, Wenning GK. Parkinson-Plus Disorders. In: Hallett M, Poewe W (Eds.). Therapeutics of Parkinson's Disease and Other Movement Disorders. <i>John Wiley &amp; Sons Ltd., 2008, Chichester, pp 157-75.</i>
41	Geser F, Jellinger K, Köllensperger M, Stefanova N, Wenning GK. Multiple system atrophy: Etiology, pathology and pathogenesis. In: Schapira AHV, Lang AET, Fahn S (Eds.). Movement Disorders 4. Blue Books of Neurology. <i>Saunders Elsevier, 2010, Philadelphia, pp 321-39.</i>
42	Kuzdas D, Wenning G. Combination lesion models of MSA. In: Lane EL, Dunnett SB (Eds.). Animal Models of Movement Disorders. Volume II. Neuromethods. Volume 62. <i>Humana Press, 2011, New York, pp 37-54.</i>
43	Stemberger S, Wenning GK. Multiple System Atrophy. In: Gálvez-Jiménez N, Tuite P, Bhatia K (Eds.). Uncommon Causes of Movement Disorders. <i>Cambridge University Press, 2011, Cambridge, pp 1-15.</i>
44	Colosimo C, Riley DE, Wenning GK. Handbook of Atypical Parkinsonism. <i>Cambridge University Press, 2011, Cambridge</i>

45	Granata R, Wenning GK. Multiple System Atrophy. In: Colosimo C, Riley DE, Wenning GK (Eds.). <i>Handbook of Atypical Parkinsonism</i> . Cambridge University Press, 2011, Cambridge, pp 27-57.
46	Wenning GK, Granata R. Multisystematrophie (MSA). In: Oertel WH, Deuschl G, Poewe W (Hrsg.). <i>Parkinson-Syndrome und andere Bewegungsstörungen</i> . Thieme, 2011, Stuttgart, pp 125-37.
47	Poewe W, Wenning G, Bürk K. Skalen zur Beurteilung von Schweregrad und Beeinträchtigung bei Bewegungsstörungen. In: Oertel WH, Deuschl G, Poewe W (Hrsg.). <i>Parkinson-Syndrome und andere Bewegungsstörungen</i> . Thieme, 2011, Stuttgart, pp 587-601.
48	Stemberger S, Stampfer M, Wenning GK. Dementia with Lewy Bodies. In: Robertson D, Biaggioni I, Burnstock G, Low PA, Paton JFR (Eds.). <i>Primer on the Autonomic Nervous System</i> . 3 <sup>rd</sup> Edition. Academic Press, 2012, San Diego, pp 463-6.
49	Wenning GK, Krismer F, Gilman S. Multiple System Atrophy (MSA). In: <i>Handbook of the Cerebellum and Cerebellar Disorders. Volume 3</i> . Springer Science+Business Media, Dordrecht, 2012, pp 2119-41.
50	Münchau A, Wenning GK. Atypische Parkinson-Syndrome. In: Brandt T, Diener HC, Gerloff C (Hrsg.). <i>Therapie und Verlauf neurologischer Erkrankungen</i> . 6. Auflage. Kohlhammer, 2012, Stuttgart, pp 989-1005.
51	Wenning G, Krismer F, Stefanova N. Multiple system atrophy. Springer, 2012, Wien
52	Stefanova N, Wenning GK. Experimental models to define multiple system atrophy and autonomic failure. In: <i>Autonomic Failure. A Textbook of Clinical Disorders of the Autonomic Nervous System</i> . 5 <sup>th</sup> Edition. Oxford University Press, 2013, Oxford, pp 523530.
53	Wenning GK, Krismer F. Multiple System Atrophy (MSA). In: <i>Oxford Textbook of Movement Disorders</i> . Oxford university press, England, 2013, Oxford, pp 129-138
54	Seppi K, Mueller C, Wenning GK, Schocke M. Magnetic Resonance Imaging of Multiple System Atrophy. In: <i>Magnetic Resonance Imaging in Movement Disorders. A Guide for Clinicians and Scientists</i> . Cambridge University Press, 2013, Cambridge, pp 167-203
55	Wenning GK, Krismer F. Multiple System Atrophy. In: <i>Handbook of Clinical Neurology. Autonomic Nervous System</i> (edited by Buijs, Swaab). Elsevier, 2013, Amsterdam, pp 229-241
56	Wenning GK, Facciulli A. Multiple System Atrophy. Springer-Verlag, Wien, 2013
57	Facciulli A, Wenning GK. Historical Review. In: <i>Multiple System Atrophy</i> . Springer, Wien, 2013, pp 1-9
58	Krismer F, Wenning GK. Epidemiology. In: <i>Multiple System Atrophy</i> . Springer, Wien, 2013, pp 11-15
59	Facciulli A, Wenning GK. Clinical Presentation. In: <i>Multiple System Atrophy</i> . Springer, Wien, 2013, pp 97-119
60	Facciulli A, Wenning GK. Clinical Diagnostic Criteria. In: <i>Multiple System Atrophy</i> . Springer, Wien, 2013, pp 121-132
61	Facciulli A, Wenning GK. Natural History. In: <i>Multiple System Atrophy</i> . Springer, Wien, 2013, pp 133-142

62	Fanciulli A, Wenning GK. Investigations. In: Multiple System Atrophy. <i>Springer, Wien, 2013, pp 143-168</i>
63	Fanciulli A, Wenning GK. Treatment. In: Multiple System Atrophy. <i>Springer, Wien, 2013, pp 169-194</i>
64	Fellner L, Wenning GK, Stefanova N. Models of multiple system atrophy. In: Current Topics in Behavioral Neurosciences. <i>Springer, Berlin 2013, 22:369-93.</i>
66	Wenning GK, Fanciulli A. Dysautonomia in Movement Disorders. In: Movement Disorders in Neurologic and Systemic Disease. <i>Cambridge University Press, 2014, pp 363-382.</i>
67	Krismer F, Kuzdas D, Colosimo C, Stefanova N, Wenning GK. Animal models of multiple system atrophy. In: Movement Disorders, 2 <sup>nd</sup> Edition (edited by Mark LeDoux), <i>Academic Press, 2014, pp 887-898.</i>
68	Stankovic I, Wenning GK. Neuropsychiatric Manifestations in Atypical Parkinsonian Disorders. In: Neuropsychiatric Symptoms of Movement Disorders (edited by Dr. Reichmann). <i>Springer, 2015, pp 141-170.</i>
69	Struhal W, Lahrmann H, Wenning GK, Fanciulli A. Bedside Approach to Autonomic Disorders. A Clinical Tutorial. <i>Springer, 2017.</i>
70	Wenning GK, Dr. Krismer F, IARPD Textbook of Movement Disorders; Cambridge University Press, Shaftesbury Road, Cambridge, CB2 8BS, UK
71	Poewe W, Seppi K, Wenning GK, Granata R, Eschlböck S; Synukleinopathien; in: Deuschl G, Oertel WH, Poewe W (Hsg); Parkinson Syndrome und andere Bewegungsstörungen; Georg Thieme Verlag KG; 2. Auflage 2020, S 68-197; ISBN 978-3-13-241550-8
72	Seppi K, Scherfler C, Stockner H, Wenning GK, Fanciulli A, Poewe W, Mahlknecht P, Buerk K; Diagnostische Verfahren bei Bewegungsstörungen; in: Deuschl G, Oertel WH, Poewe W (Hsg); Parkinson Syndrome und andere Bewegungsstörungen; Georg Thieme Verlag KG; 2. Auflage 2020, S742-792, ISBN 978-3-13-241550-8.